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Delivery of protein therapeutics is restricted to intravenous infusions due to 
protein-dependent problems including low solubilities, high viscosities, and physical 
instabilities. The ability to inject high concentrations of proteins via subcutaneous 
injections would increase accessibility and compliance. Large particles of a protein in a 
non-aqueous solvent can decrease the viscosity over a solution of equally concentrated 
individual protein molecules. The lower viscosity of a particle suspension is due to 
decreased surface area resulting in reduced electroviscous effects, solvation and 
deviations of the particle shape from a spherical geometry. 
Additional studies show that aqueous-based dispersions of antibody nanoclusters 
can be formed by increasing the attractive interactions between protein molecules using 
the excluded volume effects of extrinsic crowding agents. These novel, equilibrium, 
nanoclusters are maintained by a balance of highly attractive interactions and weak 
electrostatic repulsive interactions near the protein’s pI. These protein nanoclusters are 
 vi 
ideal for subcutaneous delivery as they have low interactions between the colloids, are 
reversible in nature, and dissolve rapidly upon dilution in a buffer media. Through in vivo 
mouse studies, the bioavailability of a monoclonal antibody in the dispersion is prolonged 
and higher doses can be administered versus a solution. Overall, these studies with high 
concentration, low viscosity subcutaneous injections of protein therapeutics open new 
opportunities in biotechnology. 
For oral delivery of itraconzole, controlled flocculation of individual 
polymerically-stabilized nanoparticles is used to increase supersaturation. Flocculation of 
these nanoparticles is achieved by desolvating the polymer by changing the pH. The 
flocculated dispersions can then be easily filtered. The final amorphous powder maintains 
high supersaturation with simulated stomach and small intestine conditions and improves 
bioavailability of itraconazole, over the commercial product, Sporanox®. 
Solutions of monoclonal antibodies are unstable for proper storage times, thus 
frozen storage stability of a monoclonal antibody is necessary.  To create a representative 
small-scale model of freezing in a commercial tank, understanding of the effects of 
freezing rate, freeze-concentration, and exposure of the protein to interfaces on protein 
aggregation is essential. Studies of frozen storage stability at various freezing rates were 
conducted under different storage conditions for up to 1 year.
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Chapter 1:  Introduction 
Proteins for use as therapeutics have received much attention due to advances in 
recombinant DNA technology and synthetic techniques to manufacture them.1-3 In 
addition, they are viewed to be less toxic and behave more predictably in vivo therefore 
expanding and improving patient treatment.4, 5 Lagging behind however is the ability to 
effectively deliver these large macromolecules.1 Proteins are readily denatured by a 
variety of stresses including heating, agitation, freezing, pH changes and exposure to 
interfaces and denaturants.3, 6 In addition, proteins can be chemically modified by 
reactions such as hydrolysis and deamidation.2, 6 Once denatured, the protein can 
aggregate to form soluble or insoluble, non-covalent or covalent, and reversible or 
irreversible aggregates.3 On top of the effect of environmental conditions around the 
protein, the structure of the protein, both primary and secondary structures, may play a 
role in the ability and the degree of protein aggregation.7, 8 Monoclonal antibodies (MAb) 
are of particular interest as therapeutics because they can successfully target distinct 
antigens and can potentially be used in the treatment of many diseases such as cancer, 
allergic diseases, asthma and other inflammatory diseases, cardiovascular, respiratory and 
infectious diseases.9, 10 As a result, it is estimated that as of 2003 >20% of all 
biopharmaceuticals being evaluated in clinical trials were mAbs.9 
To overcome the instabilities proteins encounter in solution, dry protein powders 
can be produced to improve shelf life of proteins at ambient temperatures.11-13 
Lyophilization has been a common method used to produce stable dry protein powders.13, 
14 During lyophilization, the liquid protein solution is slowly cooled until frozen and then 
water is removed by sublimation under vacuum (Figure 1.1).11 The low  
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specific surface area powder produced by lyophilization is typically reconstituted to a 
solution and delivered by an intravenous infusion.16, 17 Formulation of protein 
therapeutics in general has often been limited to low concentration (<50 mg/mL) due to 
the chemical and physical instabilities of the active therapeutic.4, 5, 9, 10, 18, 19 As a result, 
delivery of protein therapeutics has been typically limited to high volume intravenous 
injections (more than 2 mL) because a typical therapeutic dose is 100-1000 mg 
corresponding to several mg/kg dosing.5, 9, 10 The primary focus of this dissertation is on 
the formation of highly concentrated, low viscosity suspensions of proteins suitable for 
subcutaneous delivery. Additional sections on increased supersaturation of amorphous 
poorly-water soluble drug particles, the formation of flocculated amorphous nanoparticles 
for oral delivery of itraconazole and on the relationship between freezing conditions and 
the stability of a monoclonal antibody over extended frozen storage follow. 
1.1 CONCENTRATED PROTEIN SUSPENSIONS FOR SUBCUTANEOUS DELIVERY 
To take full advantage of protein therapeutics, delivery techniques must be 
expanded to include some that are more readily accessible allowing for outpatient 
administration and home use, lowering the cost of treatment.5, 9, 10, 19 Especially for mAbs 
(~150 kDa), large proteins are very unlikely candidates for non-invasive delivery routes 
including oral and pulmonary since membrane permeability and resulting bioavailability 
from these types of delivery is very low and has only barely been successful with small 
peptides.10, 20, 21 Therefore, an alternative is to formulate a subcutaneous injection, similar 
to a relatively painless injection of insulin. However, for subcutaneous delivery, the 
maximum volume that can be administered is 1.5 mL, giving a necessary protein 
concentration greater than 100mg/mL for doses on the order of a few mg/kg.5, 9, 10, 20, 22 
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Currently, solution formulations have been explored to obtain a formulation with the 
necessary concentration range, however the increase in viscosity and the decrease in 
stability of the mAb are serious drawbacks to this approach.5, 9, 18, 19, 23-26 MAbs 
reconstituted from a lyophilized powder or concentrated by techniques such as tangential 
flow filtration exhibit rapidly increasing viscosities at a concentration of approximately 
125 mg/mL due to short-range attractive protein interactions, electrostatic effects, and 
excluded volume effects.10, 22 Chemical reactions and physical interactions resulting in 
chemical modifications of the protein or physical aggregation of the protein have a linear 
or higher dependence on the concentration.27 Thus, high concentrations of protein can 
increase the rates of physical aggregation and chemical modification of proteins.27 
A novel approach is to create a low-viscosity suspension of the protein. 
Suspensions leave the mAb in the solid state and increase the stability of the protein by 
avoiding irreversible protein unfolding by decreasing protein flexibility, which is 
hypothesized to increase resistance to thermal denaturation and chemical degredation.28 
An increase in enzyme catalytic activity in nearly anhydrous organic solvents also attests 
to the stability of a protein in an organic solvent.29, 30 In addition, suspensions of protein 
C and a proprietary mAb, in a polymer gel formulation and benzyl benzoate 31, 32 and 
factor IX, a therapeutic protein, in perfluorodecalin and perfluorotributylamine23 have 
shown physical stability of the protein over an extended time of exposure to the organic 
solvents. 
1.2 ISOLATION OF NANOPARTICLES OF A POORLY WATER SOLUBLE DRUG 
A secondary objective of this dissertation is to improve oral drug delivery of a 
small molecule, poorly-water soluble drug, Itraconazole. It has been estimated 40% of 
drugs currently in development have poor water solubility, which leads to low 
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bioavailability of these therapeutic agents.33, 34 For these poorly water soluble drugs, 
absorption into the blood stream from oral delivery is limited by low solubility in the GI 
tract.35 Dissolution rates can be enhanced by increasing the surface area for adsorption, 
A, by reducing the particle size, as predicted by the Noyes-Whitney equation36 
 (1.1) 
where M is the mass of undissolved drug, t is time, D is the average diffusion coefficient, 
and ΔC is the different between the equilibrium concentration of the drug adjacent to the 
particle surface and the concentration in the bulk. In addition, solutions of poorly water 
soluble drugs can be supersaturated by using the amorphous form.37, 38 However, 
common techniques to form nanoparticles including mechanical milling39 and high 
pressure homogenization40 often require long processing times, risk contamination with 
impurities, and offer little control over the morphology of the final product.41 Controlled, 
antisolvent precipitation (AP) to form polymerically stabilized nanoparticles of poorly 
water soluble drugs, offers more control over the production of amorphous particles with 
high drug loading with high process yields.42-44 During AP, high surface area particles are 
produced by generating high levels of drug supersaturation to induce rapid nucleation in 
the presence of amphiphilic polymer stabilizers (Figure 1.2).43, 44 The polymer stabilizer 
partitions to the interface introduced by the newly created drug surface to arrest particle 
growth and orients itself to increase steric stabilization.44  
Polymerically stabilized aqueous nanoparticle dispersions of poorly water soluble 
drug may be isolated into a dry powder by a variety of methods. Spray drying has been 
used to isolate poorly water soluble drugs such as ketoconazole, itraconazole and 
ibuprofen particles.45 However, the elevated temperatures (~90ºC), can result in 
crystallization of the therapeutic as the temperature approaches the glass transition 
temperature.46 In addition, ultrafiltration with submicron polycarbonate membrane has  
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been used to isolate small microparticles of budesonide.47 However, long processing 
times allow for possible agglomeration of the individual nanoparticles.  
A third option is to rapidly flocculate polymer stabilized drug nanoparticle 
dispersions. The large flocs formed can be rapidly filtered to maintain the amorphous 
morphology of the drug.8, 46 A critical flocculation temperature, corresponding to the  
cloud point temperature, may be observed for the stabilizing polymer in the aqueous 
nanoparticle dispersion.48 This temperature can be decreased by the addition of inorganic 
salts, such as sodium sulfate.49 Rapid flocculation of the nanoparticle dispersion with a 
constant overall volume fraction of solids results in the formation of open fractal flocs 
with a low fractal dimension (Figure 1.3).46 In contrast, the particle volume fraction and 
the temperature increase during spray drying producing much denser flocs.46 The 
differences in pathways in particle volume fraction and solvent conditions, as a function 
of temperature and salinity, is shown to have a profound effect on the particle size upon 
redispersion, and ultimately, the level of supersaturation as the particles dissolve.46 
However, in some cases the increase in salinity is not sufficient to reach the cloud point 
of the polymer at a reduced temperature; therefore there is a need to explore other 
methods to rapidly flocculate these amorphous nanoparticles. For example, the cloud 
point temperature can be readily accessible near room temperature for polymers where a 
change in dissociation with pH influences solvation. 
1.3 OBJECTIVES 
The primary goal for the first section of this dissertation is to improve the 
subcuanteous delivery of protein therapeutics, especially monoclonal antibodies, by 
 8 
forming highly concentrated, non-aqueous and aqueous suspensions of model and 
therapeutic proteins. In the second section, the goal is to improve the oral delivery of the  
 
 
Figure 1.3 Floc structure as a function of polymer solvation and φ. Polymer solvency 
diminishes with increase in salinity or temperature.46 
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poorly water soluble drug, itraconazole, by using amorphous dry powders formed by 
antisolvent precipitation, flocculated, filtered and dried at room temperature. The final 
objective of this dissertation is to improve long term frozen storage of a monoclonal 
antibody therapeutic by analyzing the impact of freezing rate and freeze concentration on 
the stability of a monoclonal antibody over a time period of 2 months to a year. 
To improve delivery of proteins by subcutaneous injections, the first objective is 
to form highly concentrated non-aqueous suspensions of the model protein lysozyme 
with apparent viscosities below 50 cP. Milled particles, smaller than 37 µm, of lyosyzme, 
were suspended in the non-aqueous solvent benzyl benzoate or a 50/50 volume mixture 
of safflower oil and benzyl benzoate at concentrations up to nearly 400 mg/ml. These 
highly concentrated suspensions produced apparent viscosities below 50cP due to their 
low intrinsic viscosity. The intrinsic viscosity, regressed from the Krieger-Dougherty 
model, is only slightly above the Einstein value of 2.5, indicating the increase in viscosity 
relative to that of the solvent was caused primarily by excluded volume. Thus, increases 
in viscosity from electrical double layer interactions, solvation of the particles, or 
deviations of the particle shape from a spherical geometry are minimal, and much smaller 
than typically observed for soluble protein aqueous solutions. 
A second objective to improve delivery of proteins by subcutaneous injections is 
the formation of highly concentrated aqueous nanoclusters of an antibody. Here, we 
assemble a protein (sheep IgG) into translucent dispersions of 80-250nm nanoclusters at 
high concentrations, while simultaneously preserving the native folded state due to self-
crowding. The design of slightly charged protein colloids at the isoelectric point is the 
opposite of the normal approach, where the protein is highly charged at a pH away from 
the isoelectric point to solubilize the protein monomer. The dispersions were formed by 
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gently stirring a mixture of lyophilized powder, with a mass ratio of protein/trehalose of 
1/1 with a buffer solution, and in some cases, additional crowders. The size of the 
nanoclusters for an overall volume fraction, φ, up to 0.21 (275 mg/ml IgG) was varied by 
tuning the depletion attraction by varying the volume fraction of extrinsic crowder, φE, 
with trehalose as a single crowder, or with mixed crowders. At constant φ, the 
hydrodynamic diameters were equivalent at a given φE, upon changing φE along various 
pathways, upwards and downwards, suggesting an approach to thermodynamic 
equilibrium. Thus, concentrated equilibrium nanoclusters may be formed at the 
isoelectric point, where the short range attractive forces are strong enough to balance the 
repulsion from the small charge on the protein. Universality of the mechanism is shown 
by utilizing a second, potentially therapeutic monoclonal antibody, mAb1B7. Similar 
nanoclusters dispersions to those formed with the sheep IgG are formed. Additional in 
vitro stability of the mAb1B7 shows that the formation of nanoclusters does not impact 
the binding of mAb1B7 to Pertussis toxin. Further in vivo studies resulted in a favorable 
pharmacokinetic profile with a reduced burst phase, as compared to intravenous or 
subcutaneous injection of an antibody solution at the same concentration. Many people 
contributed to the completion of these chapters including Ameya Borwankar, Brian 
Wilson, Aileen Dinin, Tarik Khan, Kevin Kaczorowski, Jamie Sutherland, and Jamye 
O’Neal. In addition to running many of the experiments used in this study, Brian Wilson 
contributed significantly in the discovery and tunability of the translucent dispersions. 
Ameya Borwankar with the help of Thomas Truskett created the model for predicting 
cluster size and contributed significant time and effort to obtaining many of the dynamic 
light scattering results obtained. In vivo studies were conducted with the help of Tarik 
Khan and Jamye O’Neal. 
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To improve oral delivery of the poorly water soluble drug, itraconazole, the 
primary objective is to investigate an alternate recovery method for antisolvent 
precipitated nanoparticles using flocculation by changing the pH. Amorphous 
nanoparticle dispersions stabilized with a pH sensitive polymer, Eudragit®L100-55, are 
flocculated by the reduction of pH to 2.5 where the polymer is no longer charged. The 
rapid change in pH desolvates the polymeric stabilizer resulting in strong attractive forces 
between the nanoparticles to form open flocs. The particles are flocculated under constant 
volume of particles, without removing water. After flocculation, the flocs are rapidly 
filtered using high porosity filter paper and air drying to remove residual water. The 
particles remain amorphous throughout flocculation, filtration and drying with high 
yields. Previously, salt flocculation has been demonstrated with antisolvent precipitation 
of naproxen8 and itraconazole46, 50. This dissertation extends the study of flocculation to 
form amorphous particles, by demonstrating the high sustained supersaturation and in 
vivo bioavailability of a powder formed by pH flocculation. The original salt flocculation 
process was the work of Michal Matteucci. The in vivo studies were conducted by James 
DiNunzio. In addition, the theory of the excess heat capacity leading to increased 
supersaturation is analyzed in depth for antisolvent precipitated nanoparticles of 
itraconazole. This work was originated and many of the calculations initially run by 
Michal Matteucci. 
1.4 DISSERTATION OUTLINE 
Chapter 2 presents apparent viscosities below 50 cP are reported for suspensions 
of milled lysozyme microparticles up to nearly 400 mg/ml in benzyl benzoate or benzyl 
benzoate mixtures with safflower oils through a syringe with a 25 to 27-gauge needle at 
room temperature. These apparent viscosities were confirmed using a cone-and-plate 
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rheometer. The intrinsic viscosity regressed from the Kreiger-Dougherty model was only 
slightly above the Einstein value of 2.5, indicating the increase in viscosity relative to that 
of the solvent was caused primarily by the excluded volume. Thus, the increases in 
viscosity from electrical double layer interactions (electroviscous effects), solvation of 
the particles, or deviations of the particle shape from a spherical geometry were minimal, 
and much smaller than typically observed for proteins dissolved in aqueous solutions. 
The small electroviscous effects are expected given the negligible zeta potential and thin 
double layers in the low dielectric constant organic solvent. The suspensions were 
resuspendable after a year, with essentially constant particle size after two months as 
measured by static light scattering. The lower apparent viscosities for highly concentrated 
protein suspensions relative to protein solutions, coupled with these favorable 
characteristics upon resuspension, may offer novel opportunities for subcutaneous 
injection of therapeutic proteins. 
Chapter 3 shows how highly concentrated, polyclonal sheep IgG is crowded by 
extrinsic molecular crowders, into 80-250nm clusters to form aqueous dispersions. These 
dispersions allow protein self-crowding within the cluster to preserve the native folded 
state. These novel, equilibrium clusters are formed by balancing attraction from the 
extrinsic molecular crowders and the inherent specific short-range protein interactions 
against very weak electrostatic charging of the protein near the isoelectric point. Equally 
sized nanoclusters were formed by multiple techniques including dispersing a lyophilized 
protein powder to an aqueous solution containing additional molecular crowders and 
adding and removing crowders from a protein solution. A universal curve, based on the 
total φ of crowders in the dispersion but independent of the type of crowder used, can be 
formed from individual and multiple crowders, including trehalose, PEG300 and NMP. 
Since the φ of the protein within the nanoclusters is estimated to be at least 0.3, protein 
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self-crowding within the cluster is anticipated to prevent protein unfolding. The 
consistent, equilibrium size of the cluster allows the interactions to be viewed from the 
standpoint of a protein or the cluster as an individual entity. Thus, by changing the 
colloid size from a protein monomer (~1-15nm) to a submicron nanocluster (80-250nm), 
specific short-range attractive interactions on the protein, whose influence is important to 
~1nm from the surface, and excluded volume effects from the extrinsic molecular 
crowders can be minimized. The decreased effect of specific short-range attractive 
interactions results in decreased viscosity of the nanocluster dispersion when compared to 
a protein solution.  
In Chapter 4, the concept of forming highly concentrated, aqueous dispersions of 
mAbs is expanded to a therapeutic mAb1B7 to show universality of Chapter 3. 
Dispersions of antibody particles were created by rapid freezing and lyophilization, 
followed by particle suspension in a buffer that limits antibody dissolution.  By changing 
the colloid size from a protein monomer (~10 nm) to a submicron cluster (~200 nm), the 
effects of specific short-range attractive interactions are minimized, resulting in 
decreased viscosity and increased colloidal and protein stability. This procedure provided 
antibody dispersions in high yield, with no detectable alteration of tertiary structure and 
full retention of biological activity in vitro. Subcutaneous administration of amorphous 
antibody dispersions resulted in a favorable pharmacokinetic profile with a reduced burst 
phase, as compared to intravenous or subcutaneous injection of an antibody solution at 
the same concentration. Moreover, antibody present in the serum retained full activity as 
measured by in vitro binding and cellular neutralization assays.  
Chapter 5 presents the rapid flocculation of nanoparticle dispersions of a poorly 
water soluble drug, itraconazole (Itz). Rapid flocculation was utilized to produce 
amorphous powders with desirable dissolution properties for high bioavailability in rats. 
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Antisolvent precipitation (AP) was utilized to form Itz nanodispersions with high drug 
loadings stabilized with hydroxypropylmethylcellulose (HPMC) or the pH-sensitive 
Eudragit® L100-55 (EL10055). The HPMC dispersions were flocculated by desolvating 
the polymer through the addition of a divalent salt, and the enteric EL10055 by reducing 
the pH. The formation of open flocs by essentially diffusion limited aggregation, 
facilitated redispersion of the flocs at pH 6.8. Upon redispersion of the flocculated 
nanoparticles at pH 6.8, the particle size was modestly larger than the original size, on the 
order of 1 µm. High in vitro supersaturation (AUC) of the flocculated nanoparticle 
dispersions was observed in micellar media at pH 6.8, after 2 hours initial exposure at pH 
1.2 to simulate the stomach, relative to the AUC for a commercially available solid 
dispersion Itz formulation, Sporanox. Greater in vivo bioavailability in rats was correlated 
directly to the higher in vitro AUC at pH 6.8 with micelles during the pH shift 
experiment for the flocculated nanoparticle dispersions relative to Sporanox. The ability 
to generate and sustain high supersaturation in micellar media at pH 6.8, as shown with 
the in vitro pH shift dissolution test, is beneficial for increasing bioavailability of Itz by 
oral delivery. 
In Chapter 6, dissolution of pure solid itraconazole in metastable amorphous 
states was used to produce high supersaturation in low pH media. For a pre-wet 
dispersion of particles on the order of 1 µm produced by antisolvent precipitation, an 
experimental supersaturation of 63 times the crystalline solubility was achieved. This 
experimental value approached the calculated value of 95 from the configurational free 
energy, Gconf, which was determined from modulated differential scanning calorimetry 
measurements. A high fragility, quantitatively determined by the fragility parameter, γcp, 
is dependent on the configurational heat capacity, Cpconf, favoring a high Gconf and thus 
high supersaturation. However, high fragility also increases the driving force for 
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crystallization of the solid during dissolution. The relatively fragile pre-wet dispersions 
dissolved rapidly and produced high supersaturation without crystallizing, in contrast 
with much lower supersaturation values for slowly dissolving particles with low wet 
surface areas formed by spray drying or lyophilization of aqueous dispersions. 
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Chapter 2:  Low Viscosity Highly Concentrated Injectable Non-
Aqueous Suspensions of Lyosyzme Microparticles 
Subcutaneous injection of concentrated protein and peptide solutions, in the range 
of 100 to 400 mg/ml, is often not possible with a 25 to 27-gauge needle, as the viscosity 
can be well above 50 cP. Apparent viscosities below this limit are reported for 
suspensions of milled lysozyme microparticles up to nearly 400 mg/ml in benzyl 
benzoate or benzyl benzoate mixtures with safflower oils through a syringe with a 25 to 
27-gauge needle at room temperature. These apparent viscosities were confirmed using a 
cone-and-plate rheometer. The intrinsic viscosity regressed from the Kreiger-Dougherty 
model was only slightly above the Einstein value of 2.5, indicating the increase in 
viscosity relative to that of the solvent was caused primarily by the excluded volume. 
Thus, the increases in viscosity from electrical double layer interactions (electroviscous 
effects), solvation of the particles, or deviations of the particle shape from a spherical 
geometry were minimal, and much smaller than typically observed for proteins dissolved 
in aqueous solutions. The small electroviscous effects are expected given the negligible 
zeta potential and thin double layers in the low dielectric constant organic solvent. The 
suspensions were resuspendable after a year, with essentially constant particle size after 
two months as measured by static light scattering. The lower apparent viscosities for 
highly concentrated protein suspensions relative to protein solutions, coupled with these 
favorable characteristics upon resuspension, may offer novel opportunities for 
subcutaneous injection of therapeutic proteins. 
2.1 INTRODUCTION 
Proteins and other polypetides therapeutics are on the rise in recent years given 
their lower toxicity and more predictable and selective behavior in vivo than for other 
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classes of drugs not naturally found in the body.1,2 Delivery of high dosages (100-
1000mg) of protein therapeutics has been limited primarily to dilute large volume 
intravenous injections. The high dilution helps prevent physical and chemical instabilities 
of proteins that would be encountered at high concentrations.1-7 A potentially less 
invasive method of administration is a subcutaneous injection. Since the injection volume 
is limited to ~1.5 ml, the concentration of the protein therapeutic is often substantially 
above 100 mg/ml, where loss in stability can become a major issue.2,3,5-8 In addition, the 
viscosity of a highly concentrated solution often increases markedly, typically well above 
50 cP for proteins with non-spherical shapes, electrical double layer interactions, and 
hydration of the protein molecule in water, severely limiting the feasibility of 
subcutaneous injection.5,7-11 Various electrostatic interactions due to the distortion of the 
double layer by shear and intramolecular and intermolecular double layer interactions, 
collectively called the electroviscous effects, can increase the viscosity markedly.12,13 In 
some cases, the viscosity increase from electroviscous effects can be mitigated by adding 
sodium chloride to increase the ionic strength of the solution or by varying the buffer 
species and pH to reduce the surface charge on the protein.2,5,7,14 Another limitation is 
that large excipient concentrations, often up to 20:1 excipient to protein by mass15, are 
often needed to protect against denaturation and aggregation; however, the excipients 
occupy space in solution otherwise available to the protein.3,5,8 An alternative to solutions 
is to form suspensions of an insoluble protein in a non-aqueous solvent. In some cases, 
smaller excipient levels are needed to stabilize the protein in the solid state relative to in 
solution and the storage time can be increased to that appropriate for pharmaceutical 
products.3,16 
To date, relatively few examples of suspensions of proteins in non-aqueous media 
have been reported for medicinal purposes as the focus has been on aqueous protein 
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solutions. Highly viscous suspensions of bovine somatotropin, marketed to increase milk 
production in dairy cows, and a bovine growth hormone releasing factor analog, used to 
release somatotropin from the cow’s pituitary gland, have been formulated in sesame oil 
and Miglyol oil, respectively.4,17,18 These viscous suspensions require a large 14-16 gauge 
needle for injection, whereas the preferred needle size for humans is ~ 25 - 27 gauge. In 
addition, a few non-aqueous extended release formulations for the peptide insulin and for 
very stable proteins such as protein C and a proprietary monoclonal antibody have been 
produced with the aid of viscosity enhancers and gel forming polymers in the presence of 
diluents such as benzyl benzoate or benzyl alcohol.4,19-21 However, injection of these 
suspensions with a larger 21-gauge needle causes significant pain leading to non-
compliance. In addition, the high levels of excipients needed to stabilize the protein 
particles and form the gel reduce the overall concentration of the protein in the 
formulation.19,21-23 Another option is to crystallize the protein or monoclonal antibody 
and to suspend the crystals in aqueous media.3,4,24 However, crystallization of high 
molecular weight proteins can be very difficult due to the high degree of segmental 
flexibility, and is more feasible for small peptides that have a much lower degree of 
flexibility.3,4 
The objective of this study was to produce highly-concentrated (up to 400 mg/ml) 
protein suspensions with viscosities below ~ 50 cp, the limit for a subcutaneous injection 
via a 25- to 27-gauge syringe, and to describe theoretically the reasons for the low 
viscosities. Suspensions of particles smaller than 37 μm of the model protein, lysozyme, 
with concentrations from 50 to 370 mg/ml were formulated with benzyl benzoate as the 
pure non-aqueous solvent or a 50/50 volume mixture of the pharmaceutically acceptable 
solvents safflower oil and benzyl benzoate. The organic solvents offer various advantages 
over aqueous solvents including low protein solubility and reduced electrostatic 
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interactions (electroviscous effects) due to the low dielectric constants of the solvent. The 
experimental apparent viscosities are correlated with the Krieger-Dougherty equation to 
determine the intrinsic viscosity. The regressed intrinsic viscosity will be shown to be 
near the Einstein value of 2.5 indicating primarily an excluded volume effect. Thus, the 
increases in viscosity from the effects of protein shape, solvation, and electroviscous 
effects are small. In contrast, increases in viscosities from these additional effects can be 
pronounced for aqueous protein solutions.5,7 In addition, for successful delivery with 
concentrated suspensions, the particle size and suspension uniformity must  be controlled 
in order to administer an accurate and uniform dose.4 The uniform aliquots measured 
from the suspensions, as well as the slow settling rates, are shown to be sufficient to favor 
uniform doses. Colloidal stability of the particles is shown by consistent static light 
scattering measurements of particle size over months. 
2.2 MATERIALS AND METHODS 
2.2.1 Materials 
Lysozyme in lyophilized powder form (L6876) was purchased from Sigma 
Chemical Company (St. Louis, MO). Bovine serum albumin (BSA) in lyophilized 
powder form (BP671), ACS grade acetonitrile and USP grade ethanol were used as 
received from Fisher Chemicals (Fairlawn, NJ). Food grade olive oil and safflower oil 
were used while benzyl benzoate was obtained from Acros Organics (New Jersey) and 
N.F. grade ethyl oleate from Spectrum Chemical Corp. (Gardena, CA). 
2.2.2 Suspension Formation  
Lysozyme powder as received was dry milled with a porcelain mortar and pestle 
for several minutes. The milled powder was then sieved through a number 400 mesh and 
particles smaller than 37 μm were collected. Samples of the particles were then weighed 
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and added to the measured amount of benzyl benzoate or a premixed 50/50 volume 
mixture of benzyl benzoate and safflower oil to give 50 to 400 mg/ml concentration of 
particles in the solvent. Each vial was then shaken by hand to disperse the powder evenly 
through the suspension without the need for sonication. 
2.2.3 Particle Size Analysis 
Particle size was measured by multiangle static laser light scattering using a 
Malvern Mastersizer-S (Malvern Instruments, Ltd., Worcestershire, UK). The size of the 
milled and sieved powder was measured upon suspension in acetonitrile in a large 
recirculation cell (~500ml) and also immediately after being added to ethanol in a small 
batch cell (Malvern, Worcestershire, UK, ~15ml). In each case the obscuration during the 
measurement was between 10-15%. After storing the suspensions for 2 months at room 
temperature, the particle size was measured again immediately after shaking and diluting 
the sample in ethanol in the small batch cell. 
2.2.4 Viscosity Measurement 
The viscosity was measured as the time to draw 1 ml of the sample into a 1ml BD 
tuberculin slip tip syringe with a 25 g 5/8” long or 27 g 1/2” long needle at room 
temperature. Each measurement was made at least 3 times and averaged, while 
maintaining the suction force by holding the end of the plunger at the 1ml mark each 
time. Liu et al. found this measurement time to be correlated linearly to viscosity.5-7 
Using known viscosities of each pure liquid, benzyl benzoate, ethanol, ethyl oleate and 
olive oil, the correlation between the time to draw 1 ml of solution and the viscosity was 
found for each needle size to give an r2 value greater than 0.999 as expected from the 
Hagen-Poiseuille equation (Eq. 1 below). The apparent viscosity of the suspensions in 
each pure solvent was calculated from these correlations and the values for the two 
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separate needle sizes were averaged to give a final average apparent viscosity of each 
sample. Additional samples of the solvent mixture of benzyl benzoate and safflower oil 
were made from 10 to 90 percent benzyl benzoate by volume and the viscosity was 
calculated as described above. 
2.2.5 Rheology Measurement 
The change in viscosity at various shear stresses was measured using an AR 
2000ex cone-and-plate rheometer (TA Instruments, New Castle, Delaware) for two of the 
pure benzyl benzoate suspensions (200 and 400 mg/ml particles). Approximately 1 ml of 
the suspension was placed on the peltier plate and the 40 mm 2° HAL aluminum cone 
was lowered to a final truncation gap of 55 μm. The excess suspension was removed 
prior to performing a measurement. 25 measurements between the shear stress of 5 and 
100Pa were taken after the equipment equilibrated at room temperature (23ºC). The shear 
rate was measured up to 103 s-1 where inertial and edge effects began to introduce error. 
However the applied torque was within instrument specifications, giving a maximum 2-
3% error in the viscosity measurement. 
2.2.6 Average Settling Rate and Maximum Volume Fraction Measurement 
The settling rate of the particles in the solvents was measured by shaking the 
suspension in a test tube 13 mm in diameter. Pictures were taken with a standard digital 
camera after 10 to 1440 minutes as the height of the sediment-supernatant interface 
decreased. To measure the final settling volume of the samples, the vials containing the 
suspensions were left undisturbed for 4 months and images of the settled suspension were 
taken. All images were analyzed using ImageJ software to determine the distance from 
the meniscus to the settling front. This approach has been used previously to measure the 
average settling rate of a concentrated suspension.25 The maximum volume fraction for 
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the settled suspension was defined by dividing the volume fraction of particles in the 
overall suspension by the ratio of the volume containing particles after settling for 4 
months to the overall volume. 
2.2.7 Quantification of Protein Concentration 
The concentration of lysozyme in an aqueous solution was measured following 
the protocols for the Micro BCA Protein Assay (Pierce, Rockford, IL). Each sample was 
measured in triplicate with relative standard deviations (%RSD) less than 2% in a 
General Assay 96 well plate. The absorbance was measured at 562 nm in a 
spectrophotometer (μQuant Model MQX200; Biotek Instruments Inc., Winooski, VT). A 
standard curve of untreated lysosyme was prepared at concentrations between 2 and 30 
μg/ml. 
2.2.8 Rate of Lysozyme Partitioning to Aqueous Phase 
Partitioning and dissolution of lysozyme from the concentrated suspension was 
measured in pH 7.4 potassium phosphate buffer. The USP paddle method was used with 
a VanKel VK6010 Dissolution Tester with a Vanderkamp VK650A heater/circulator. 900 
ml of dissolution media was preheated in large 1L capacity dissolution vessels (Varian 
Inc., Cary, NC) to 37°C. A sample of the concentrated suspension giving a total of 18 mg 
of lysozyme was added. At time increments of 2 to 240 minutes, 1 ml samples were taken 
and analyzed using the Micro BCA protein analysis mentioned earlier. 
2.2.9 Optical Density Measurement 
The lysozyme in suspension was dissolved in water, and the optical density was 
measured to determine whether large aggregates were present. 0.1 ml of the concentrated 
lysozyme suspension was added to a test tube with 4 ml of DI water. This mixture was 
then gently mixed and left for 3 days for the protein to partition to the water phase. The 
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water phase was then separated and a sample was diluted and tested for concentration 
using the Micro BCA Protein Assay as mentioned above. On the basis of the 
concentrations measured, the remaining aqueous solution was diluted to 1 mg/ml. This 
solution was tested for optical density using at least 3 200μl aliquots in a 96-well plate 
and analyzed using the μQuant spectrophotometer at 350 nm. A standard lysozyme 
aqueous solution was made at 1 mg/ml concentration and exposed to the pure benzyl 
benzoate solvent and the benzyl benzoate and safflower oil solvent mixture for 3 days 
and measured as the standard for oil-water interface induced aggregation of the protein. 
An aqueous solution never exposed to any organic solvent was also measured 
immediately after it was made and used as a standard for absorbance measurements. 
2.2.10 Suspension Uniformity Measurement 
Three separate 0.1 ml aliquots of the resuspended concentrated lysozyme 
suspensions were added to test tubes with 8 ml of DI water. These mixtures were then 
gently mixed and left for 1 day for the protein to partition to the water phase. The 
aqueous phase was then separated and diluted to a theoretical concentration of 20 μg/ml 
if 100% of the protein partitioned. The actual concentration was then analyzed using the 
Micro BCA protein assay mentioned above. 
2.2.11 Karl Fischer Moisture Analysis 
After being stored for four months, a sample of 0.1 ml of the redispersed 
concentrated suspension was inserted using a 19-gauge needle through the septum of the 
titration cell of an Aquatest 8 Karl-Fischer Titrator (Photovolt Instruments, Indianapolis, 
IN). Each suspension, pure benzyl benzoate and the benzyl benzoate and safflower oil 
solvent mixture was measured in triplicate and averaged. 
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2.2.12 Polarity Determination 
An aliquot of the suspension was diluted with the solvent until individual particles 
were visible on a slide through an optical microscope (Bausch & Lomb, 10x 
magnification). Microelectrophoresis was used to determine if a charge was present on 
the particles. The diluted particle dispersion was placed between two parallel wire 
electrodes (0.01-in. diameter stainless steel 304 wire, California Fine Wire) spaced 1 mm 
apart. The electrodes were secured to a glass microscope slide and observed by optical 
microscopy. A potential of 10–100 V was applied with the polarity of the electrodes 
switched every 15–60 sec. 
2.3 RESULTS 
2.3.1 Formation of Suspensions 
Prior to adding the milled and sieved lysozyme particles to the suspending media, 
the lysozyme mass percentage was determined to be 91.5% by weight of the particles, 
consistent with the manufacturers specifications, according to the micro BCA assay. The 
average particle size found to be approximately 20 μm, according to static light scattering 
measurements (Figure 2.1). For the average particle size measurement, a minor secondary 
submicron peak was also visible in all measurements. However since the 15 ml small 
batch cell is only calibrated for particle sizes down to 500 nm, this peak was not included 
in the analysis. Upon adding the suspending media, a uniform suspension was formed by 
shaking by hand as shown in Figure 2.2b. Thereafter, the particles settled slowly enough 
to remain partially suspended even after 24 hours (Figure 2.2c) and took up a significant 




Figure 2.1 Volume % of particles versus size measured for the original lysozyme (LYS) 
milled particles in acetonitrile (○) and ethanol (◊) and after 2 months of 
storage for the suspensions in pure benzyl benzoate(BB) (□) and a mixture 
of benzyl benzoate and oil (BB/oil) (▲) both measured immediately after 
being diluted in ethanol to 10-15% obscuration by light scattering 
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Figure 2.2 Pictures of the 300mg/mL suspension of lysozyme particles in 50/50 Benzyl 
Benzoate and Safflower Oil A) in vial after being left for 2 months B) after 
being shaken and resuspended in a test tube C) after being allowed to settle 
for 24 hours 
A. B. C. 
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2.3.2 Apparent Viscosity of Solvent Mixture and Suspensions 
Using the known viscosities of pure solvents, a correlation between the time to 
draw 1 ml of the sample and viscosity was generated. This type of correlation has been 
described by Shire and coworkers on the basis of the Hagen-Poiseuille equation, 
















where υ is the velocity, R is the inner radius of the needle, η is the viscosity, and ∆P/L is 
the average pressure drop over the length of the needle. To ensure that the entrance 
pressure drop was negligible, the entry distance was calculated. The resulting value of 
0.0001 cm was significantly less than the 1.27cm or 1.58cm length of the needle (see 
supplemental information for calculation). Ensuring that the average pressure drop over 
the length of the needle remains constant for each sample by maintaining the same 
suction pressure inside the syringe, the inverse of the velocity of the fluid multiplied by 
the cross-sectional area gives the time to draw up a specified volume of liquid, in this 
case 1 ml. This time is proportional to the viscosity as shown by the Hagen-Poiseuille 
equation, and has been very accurately correlated by Shire et al. to the viscosity.5,7 Using 






γ =  (2.2) 
where Q is the volumetric flow rate and R is the radius of the needle, the shear at the wall 
over the length of the capillary for both needle sizes was calculated to be on the order of 
103 s-1. In this shear rate range for two of the suspensions formulated, the apparent 
viscosity was approximately that measured using a cone-and-plate rheometer at the 
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appropriate shear rate (Figure 2.5). Because only this high shear rate range is relevant to 
subcutaneous injection, additional samples were measured with the syringe method alone. 
The measured viscosities of the solvent mixtures of benzyl benzoate and 
safflower oil at room temperature are shown in Figure 2.3. In this case, since the 
minimum and maximum values are the for the pure solvents, the generalized mixing rule 
should follow the form 
( ) ( )Li
i
iLm fxf ηη ∑=  (2.3) 
where ηm is the viscosity of the mixture, i is the number of components, xi is the 
liquid volume, weight, or mole fraction, and ηi is the viscosity of the ith component. 
( )Lf η  can be ηL, ln (ηL), 1/ ηL etc.26 For our data, the best correlations were obtained 
with ( )Lf η  =  ln (ηL). This theoretical result is shown by the dotted line in Figure 2.3, 
assuming no water was present in the system. As will be discussed below, the small 
amount of residual moisture below 100 μg/ml in the solvent may be expected to change 
the viscosity by less than 1%. 
The apparent viscosities of the suspensions with increasing concentration were 
measured for both the pure benzyl benzoate system and the solvent mixture of 50/50 
benzyl benzoate and safflower oil. Figure 2.4 presents the resulting apparent viscosities, 
averaged from the measurements using two syringe sizes (left y-axis), and the average 
time to draw 1 ml from the 25-gauge syringe (right y-axis) as a function of the 
concentration of lysozyme particles. For subcutaneous delivery, 50 cP is an appropriate 
maximum viscosity where it will take approximately 20 seconds for 1 ml of the 
suspension to be expelled via a 26-gauge syringe.3 From Figure 2.4, the highest apparent 
viscosity measured was approximately 50 cP, where it took approximately 55 seconds to 
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Figure 2.3 Viscosity of a solution of benzyl benzoate and safflower oil at room 
temperature at varying concentrations measured experimentally and 




Figure 2.4 The apparent viscosity as a function of concentration of particle in suspensions 
of the non-aqueous solvents, benzyl benzoate (BB) (■) and 50/50 benzyl 
benzoate and safflower oil (BB/oil) (▲) with there correlations based on the 
Kreiger-Dougherty equation (eq. 2.4) and the theoretical viscosity of an 
aqueous lysozyme (LYS) solution, calculated using the hard quasisphere 
model (eq. 2.8) (solid line) 
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smaller suction force that can be applied to draw the volume into the syringe relative to 
the larger force available to expel the solution from the syringe. 
The correlation of the apparent viscosity with the free solvent volume fraction, 1 – 

























where η is the apparent viscosity of the dispersion, ηo the solution viscosity, φ the volume 
fraction of particles, φmax the maximum packing fraction, and [η] the intrinsic viscosity 
(Table 2.1). φmax was approximated experimentally after gravitational settling of the 
particles over 4 months. It was approximately 0.50 for the pure benzyl benzoate solvent 
solution and 0.52 for the benzyl benzoate and safflower oil solvent for low shear rates. 
Using these values, the intrinsic viscosity of the suspension, [η], was determined to be 2.7 
for the pure benzyl benzoate suspensions and 2.3 for the benzyl benzoate and safflower 
oil suspensions. Since the exponent, -[η]φmax was used to determine [η], uncertainty in 
the approximation of φmax of about 20% can introduced a similar uncertainty in [η]. 
However, this uncertainty is small when compared with changes in [η] of more than an 
order of magnitude for proteins with strong interactions in solutions. 
2.3.3 Particle Stability of the Suspension 
The stability of the particles in suspension was measured by numerous different 
techniques. First the average settling rate was measured and compared to the calculated 












Table 2.1 Comparison of the two solvent systems used for highly concentrated 
suspensions for the exponents for the Krieger-Dougherty equation, the 
experimental or assumed (*) maximum packing fraction, and intrinsic 
viscosity average plus or minus the standard deviation 









Benzyl benzoate suspension -1.36 ± 0.09 0.50 2.7 ± 0.18 
50/50 Safflower Oil and 
Benzyl Benzoate suspension 




where Δρ is the difference in densities between the solvent and the particles, and g is 
acceleration due to gravity. For a high concentration of particles, the particle crowding 
will reduce the settling rate to yield 
( ) 55.61 φ−= sUU  (2.6) 
This modified average Stokes settling rate and the experimentally measured values were 
found to be within a factor of two for most concentrations lower than 300 mg/ml as 
shown in Table 2.2. However, for a concentration of 400 mg/ml the experimental values 
was an order of magnitude lower than the predicted rate (Table 2.2). At this high 
concentration, the increase in apparent viscosity at the very low shear rates found in 
settling (~10-5 s-1)27 is much more pronounced, leading to an increased settling time 
(Figure 2.5). Shear thinning is expected in concentrated suspensions, as high shear will 
overcome interparticle forces and rearrange the particles to a more ordered 
configuration.27-29 
Three aliquots were taken of an organic suspension to determine the uniformity of 
the protein within the suspension. The organic suspension was added to an aqueous phase 
to form a two-phase system as described in the experimental section. The system was 
equilibrated for 1 day, to be conservative; as it appeared that the partitioning reached 
equilibrium in 60 minutes. The aqueous phase was then diluted approximately 1000 
times, and the concentration of protein was measured. For 8 ml of aqueous phase 
equilibrated with 0.1 ml of the concentrated non-aqueous suspension, at least 80% of the 
protein partitions into the aqueous phase in 24 hours (Table 2.3). The %RSD for the 
amount of extracted protein were typically below 5% indicating reasonable uniformity of 
the protein particles in the redispersed suspension. The %RSD was slightly larger for the 
highly concentrated 300 mg/ml sample in the mixed solvent.  
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Table 2.2 Comparison of experimental settling rates and settling rates quantified by the 
modified Stokes settling equation accounting for particle interactions (eq. 
2.5,2.6) 
Safflower oil concentration 
(% of solvent) 













50 46  0.03515 1.85 0.85 
50 92  0.0703 1.32 0.67 
50 183 0.1406 0.32 0.40 
50 275 0.2109 0.043 0.23 
0 46  0.03515 3.91 2.24 
0 92  0.0703 1.64 1.76 
0 183  0.1406 0.52 1.05 
0 366  0.2812 0.031 0.32 
 
Table 2.3 Percent of sample recovered in aqueous phase and % relative standard 
deviation (%RSD) of 3 samples for suspensions formed in benzyl benzoate 
with and without safflower oil 
Safflower oil concentration  
(% of solvent) 





aqueous % RSD 
50 50 84.4% 2.21% 
50 100 85.8% 6.61% 
50 200 93.8% 3.20% 
50 300 83.3% 9.45% 
0 50 93.1% 1.52% 
0 100 100% 3.46% 
0 200 100% 3.65% 




The particles in suspension were stored for extended time periods to determine 
whether the particle size changed due to aggregation or other processes including 
Ostwald ripening. The original particle size was measured via static light scattering 
immediately after the particles were sieved and resuspended in both acetonitrile, where 
lysozyme is very insoluble, and ethanol, where lysozyme is slightly soluble.30 The 
uniformity of the two measurements ensures that the time scale of the measurement is 
much quicker then the time scale of growth of the particles in ethanol (Figure 2.1). 
Following 2 months of storage, the samples were diluted in ethanol and immediately 
tested. The particle size was found to be essentially constant during storage (Figure 2.1). 
The visual inspection of one formulated suspension after storage for a year and 
redispersion by shaking confirms that the particles could be redispersed. 
The potential effect of electrostatic interactions on the particle stability was tested. 
However the lysozyme particles did not display organized movement when the current 
was reversed for voltages from 10 to 100 V for two electrodes spaced 1 mm apart in the 
benzyl benzoate solvent.  Thus the charge on the particles was small as expected given 
the low dielectric constant of the solvent. 
2.3.4 Protein Stability in the Suspension by Optical Density 
Protein aggregation was investigated by measuring the optical density on sample 
aliquots that partitioned from the organic to the water phase. The protein was diluted to a 
concentration of 1 mg/ml, confirmed by dilution of an aliquot to 20 μg/ml with the micro 
BCA assay. Additional lysozyme samples in an aqueous solution at the same 
concentration were exposed to the solvent to measure the effect of the oil-water interface 
on aggregation. All these solutions were checked for large protein aggregates by 
comparison with a fresh lysozyme solution at the same concentration. The absorbance at 
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350 nm of the standard solution, without exposure to the non-aqueous solvent (0.047 ± 
0.005), was approximately the same as that for the particles in the pure benzyl benzoate 
solvent (0.051) and the mixed benzyl benzoate/safflower oil solvent (0.052). As this is 
within the error of the experiment, it suggests that the particles did not undergo 
significant formation of large aggregates over the four to five month month time period 
tested. Since lysozyme is a very stable model protein, additional protein denaturation and 
aggregation studies were not conducted. 
Quantification of the moisture content may be used to determine the free and 
bound water in the suspension. The moisture content was measured for each suspension 
after being exposed to atmospheric conditions for 2 months. The linear correlations found 
between the moisture content and suspension concentration indicates that the moisture is 
directly associated with the protein (Figure 2.6). The benzyl benzoate solvent contains an 
average of 20 μg of water per 0.1 ml of solution or approximately 0.02% by weight. The 
safflower oil and benzyl benzoate mixture contains approximately 74 ug of water in the 
same volume sample or approximately 0.074%. The sample with the highest 
concentration of protein in benzyl benzoate, 400 mg/mL, contained the most moisture, an 
average of 4450 µg of water per 0.1 ml of suspension giving an absolute maximum 
concentration of 4.5% by weight of the suspension after being stored for 2 months. 
2.4 DISCUSSION 
2.4.1 Colloidal Stability of the Protein in Suspension 
A key concern for an injectable suspension is the ability to redisperse the particles 
after settling with gentle agitation.4 For the various aliquots of the protein in water 
extracted from the redispersed suspensions, the relatively constant protein concentrations 
indicate that the suspensions were uniform after gentle shaking. The lack of particle  
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Figure 2.6 Karl Fisher moisture content analysis of the non-aqueous suspension in benzyl 















aggregation as measured by static light scattering (Figure 2.1) and lack of caking of the 
suspended particles demonstrate significant storage stability. The lack of sintering of the 
particles is favored by the fact that the hydrophobic poor solvent does not soften the 
protein chains. The lack of particle growth from Ostwald ripening is not surprising since 
the protein is almost completely insoluble in these non-aqueous solvents30 and will 
therefore undergo little diffusion. Furthermore, the lack of particle aggregation is favored 
by the weak hydrophobic interactions between the protein particles in a low dielectric 
constant organic solvent. 
The average particle size of ~10 μm is optimal to balance the need for sufficiently 
small particles to flow through the needle versus large particles to minimize the particle 
surface area. Milled nanoparticles (~300 nm diameter) were found to produce a highly 
viscous paste. The high surface area led to stronger interactions between the particles, 
which increased the viscosity (results not shown).31 In addition, particles not milled 
through the 37μm sieve caused clogging of the syringe (results not shown). Therefore, an 
aspect ratio compared to the needle of ~ 0.1 provided the proper balance of low particle 
surface area for weak particle interactions (low [η]) and small enough particles to prevent 
mechanical clogging of the needle. 
The concept of protein particle engineering for the formation of low viscosity 
suspensions may be generalized beyond the milling technique in this study. For example, 
micron-sized protein particles may be formed by lyophilization or spray drying. In 
addition they may be encapsulated in polymer microspheres18,24 for controlled delivery. 
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2.4.2 Effects of excluded volume, shape, solvation and electroviscous effects on 
viscosities of proteins in solution versus protein suspensions 
In the Einstein model for the viscosity of a dilute colloidal dispersion of solid 
spheres (φ<0.03) 27,32, the slope of the viscosity ratio of the suspension over the solvent 
versus φ is 2.5. This slope signifies the excluded volume increment of viscosity due to the 
addition of dispersed particles, the intrinsic viscosity, [η]. The [η] of concentrated protein 
colloids and protein suspensions may be regressed from the Kreiger-Doughety equation 
to give an indication of the effects of excluded volume and other interparticle forces 
(Equation 3).27,28 The [η] can increase from the Einstein value of 2.5 depending on the 
effects of solvation, particle shape, and electrical double layer forces (electroviscous 
effects), as well as the shear rate.1,27 The values near 2.5 for the benzyl benzoate and the 
benzyl benzoate and safflower oil mixture suspensions in Table 2.1 indicate that the 
viscosity increase is governed primarily by the excluded volume effect. The value of 2.3 
for the 50/50 benzyl benzoate and safflower oil mixture is slightly below the minimum 
Einstein 2.5 limit due to experimental uncertainty. 
































solvated  (2.7) 
where m1,b is the mass of the bound solvent, m2 is the mass of the particle, ρ2 is the 
density of the particle and ρ1 is the density of the solvent.27 In the case of the Krieger-
Dougherty equation, this solvation is manifested as an increase in [η].13,27 For the organic 
solvents in the present study, the increase in φ may be expected to be much smaller than 
in the case of water, which is a much stronger solvent for solvating proteins. 
Since the solvated volume fraction is often unknown, the analysis of protein 
solutions is typically done using mass concentrations (g/ml) rather than volume fractions, 
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leading to values of the intrinsic viscosity in units of cm3/g and different higher order 
relationships derived from the virial expansion.5,33 For example, a hard quasi-spherical 

























where c is the mass protein concentration, k is a crowding factor and υ is the Simha 
parameter accounting for the change in shape from a sphere. For various proteins in 
solution, [η] varies from 2.7 for lysozyme to over 200cm3/g.33 Even for lysozyme, a 
protein with a small axial ratio of 1.533, this model shows a dramatic increase in viscosity 
around a concentration of 300mg/ml (Figure 2.4). For glass fibers with axial ratios, 7, 14 
and 21, the intrinsic viscosity increases from 3.8 to 5.03 to 6.0, respectively.28 Our lower 
values of [η] are consistent aspect ratios close to 1, as expected for particles formed by 
milling. 
The electroviscous effect caused by the charge on a protein surface and the 
associated double layer interactions often produces a marked increase the viscosity of a 
protein aqueous solution as a function of pH and salinity. The electroviscous effects are: 
primary, from distortion to the diffuse double layer surrounding the protein molecule, 
secondary, from interparticle double-layer interactions, and tertiary, from changes in 
intramolecular double layer interactions that affect the geometry of the system.12-14,27 The 
primary electroviscous effect on the intrinsic viscosity, for the case of small zeta 
potentials (<25 mV) and large distortions of the double layer is given by 




















η  (2.9) 
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where εr is the relative permittivity, ε0 is the permittivity of free space, ζ is the zeta 
potential, k is the specific conductivity of the continuous phase, Rs is the radius of the 
colloid, and Pe is the Peclet number.12,27 For aqueous protein colloids, assuming low 
ionic strength, an increase in ζ as the pH moves away from the pI, will raise [η].14 For a 
protein in a lower dielectric solvent, as has been shown for a polymer in methanol35, the 
primary electroviscous effect, as shown in equation 2.9, has a reduced impact on [η]. In 
addition, the [η] has been shown previously to approach the Einstein value of 2.5 upon 
screening the surface charges on nanoparticles with ligands that adsorb on the charged 
sites.36 In our case of non-aqueous protein suspension in low dielectric solvents, the 
negligible ζ observed experimentally, as a consequence of the low ε, leads to an 
insignificant increase in [η] from this electroviscous effect. Furthermore, secondary and 
tertiary electroviscous effects may also be ameliorated by lowering the dielectric constant 
thus lowering the surface charge and decreasing the thickness of the double layer. 
The negligible elecroviscous effects and increase in φ from solvation for organic 
solvents can be attractive for achieving low [η], thereby increasing the achievable 
volume fraction of particles for a viscosity below 50 cP. These lower apparent viscosities 
in benzyl benzoate suspensions have also been seen for other milled proteins including 
bovine serum albumin (Figure 2.4). Benzyl benzoate and safflower oil are known 
solvents for parenteral delivery.37,38 These solvents have been found in formulations 
including a testosterone propionate solution and a hydroxyprogesterone benzoate 
preparation for intramuscular delivery, but are much less common than water.38 Benzyl 
Benzoate has been found to be completely nontoxic in a formulation with 50% or less 
benzyl benzoate in a fixed (nonvolatile) oil and non-irritating to the skin when injected at 
10% benzyl benzoate in oil.39,40 FDA approval of the use of benzyl benzoate as a pure 
solvent for subcutaneous delivery awaits further testing. 
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2.4.3 Destabilization of Protein Molecules in Suspension 
It is challenging to prevent denaturation and aggregation of peptides and proteins 
at high concentrations, whether in solution or suspension form.17,41-43 Oxidation due to 
the oil has been visible for Factor IX in soybean oil whereas miglyol oil has been used as 
the solvent to suspend a bovine growth hormone releasing factor analog for 10 weeks 
with no reported loss in stability measured by reverse-phase HPLC and FTIR.17,41 In 
addition, at high concentrations (up to 300 mg/ml) the stability of bovine somatotropin in 
sesame oil was confirmed by fluorescence, Raman and FTIR spectroscopy.42 In benzyl 
benzoate, insulin, protein C, and a proprietary monoclonal antibody are stable in 
sustained release polymer formulations.19-21 
For the suspensions in this study, insoluble protein aggregates were not visible by 
optical density for lysozyme at any concentration after 2 months of storage at ambient 
conditions. Thus, the protein particles redissolved after being in suspension. As the 
optical density test was conducted in water, this also indicates that the exposure of the 
protein to the oil-water interface generated between the non-aqueous solvents and an 
aqueous environment, as will occur upon injection, did not produce insoluble aggregates. 
Additional characterization of the stability of lysoyzme was not performed, since 
lysozyme is very stable. Thus lysozyme would not be a good indicator of the stability of 
more fragile proteins, both with regard to denaturation and the formation of irreversible 
protein soluble and insoluble aggregates.41,42,44-46 However, the moisture content in the 
suspension was examined, as it is an important factor that influences protein stability. 
The moisture controls protein hydration in the solid state, which is known to have a large 
effect on protein stability. For example, the reduced stability of Factor IX in another non-
aqueous solvent, methoxyflurane, was attributed to water mediated reaction and 
conformational changes.41 On the opposite end, studies of enzymatic activity in organic 
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solvents at low hydration levels have shown increased activity when the protein was only 
partially hydrated. The increase in activity has been attributed to reduced protein 
unfolding at low water levels.47,48 For the suspensions studied, the values measured by 
Karl Fischer titration indicate that the water incorporated within the suspension tracked 
the concentration of the protein, therefore the slope describes the hydration of the protein 
in the solvent. In pure benzyl benzoate solvent, slightly less sorption of water was 
observed (~ 100 μg water/mg of protein), versus 140 μg water/mg of protein for benzyl 
benzoate/safflower oil after 4 months of storage at room temperature (~23°C) with no 
control over the humidity. Both of these values are above that needed for full hydration of 
the lysozyme protein molecules(~ 20 μg water/mg of protein).47 
To achieve the optimum partially hydrated conditions for increased protein 
stability using the present suspensions, storage of proteins suspensions at lower 
temperatures and/or low humidities may maximize the stability of a protein in these 
organic solvents. At these low levels of protein hydration, the sorption of water from 
organic solvents has been found to be similar to that for solid protein particles exposed to 
air.47,49 Since lysozyme and many other proteins have been shown to be stable in the solid 
phase with the proper excipients and storage conditions, the stability of the protein in the 
non-aqueous suspension may also be favorable.44-46 
2.5 CONCLUSIONS 
The viscosities of concentrated suspensions up to 300-400 mg/ml of ~10 μm 
milled particles of the model protein, lysozyme, were below 50 cp, the limit for 
subcutaneous injection through a 25 to 27-gauge needle. The apparent viscosity was 
correlated with volume fraction at all conditions according to the Krieger-Dougherty 
equation with an intrinsic viscosity close to 2.5, indicating weak interparticle interactions. 
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The various factors that produce large increases in viscosity for proteins in aqueous 
solution, including electroviscous effects from double layer interactions, an increase in φ 
from solvation, and deviations of the particle shape from a spherical geometry, have 
almost negligible effects for the non-aqueous protein suspensions in this study. The small 
electroviscous effects are a consequence of the small zeta potential and thin double layers 
in the low dielectric constant organic solvent. An average particle size of ~10 μm with an 
aspect ratio compared to the needle of ~ 0.1 provided the proper balance of low particle 
surface area for weak particle interactions (low [η]) and small enough particles to prevent 
mechanical clogging of the needle. Static light scattering of the suspensions demonstrated 
that the protein particle size did not vary for at least 2 months when stored at atmospheric 
conditions. The low settling rate of the particles (< 2 cm/hr) contributed to the excellent 
dose uniformity of 0.1 ml aliquots. The demonstration of injectable low viscosity 
supsensions with good collidal stability and dose uniformity is an important advancement 
for the ultimate goal of subcutaneous delivery of therapeutic proteins. 
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 Chapter 3:  Weakly interacting, equilibrium nanoclusters of stable 
protein at high concentration 
Highly concentrated, polyclonal sheep IgG is crowded by extrinsic molecular 
crowders, into 80-250nm clusters to form dispersions, while the protein self-crowding 
within the cluster preserves the native folded state. These novel, equilibrium clusters are 
formed by balancing attraction from the extrinsic molecular crowders and the inherent 
specific short-range protein interactions against very weak electrostatic charging of the 
protein near the isoelectric point. Equally sized nanoclusters were formed by multiple 
techniques including dispersing a lyophilized protein powder to an aqueous solution 
containing additional molecular crowders and adding and removing crowders from a 
protein solution. A universal curve, based on the total φ of crowders in the dispersion but 
independent of the type of crowder used, can be formed from individual and multiple 
crowders, including trehalose, PEG300 and NMP. Since the φ of the protein within the 
nanoclusters is estimated to be ~0.3, protein self-crowding within the cluster is 
anticipated to prevent protein unfolding. The consistent, equilibrium size of the cluster 
allows the interactions to be viewed from the standpoint of a protein or the cluster as an 
individual entity. Thus, by changing the colloid size from a protein monomer (~1-15nm) 
to a submicron nanocluster (80-250nm), specific short-range attractive interactions on the 
protein, whose influence is important to ~1nm from the surface, and excluded volume 
effects from the extrinsic molecular crowders can be minimized. The decreased effect of 
specific short-range attractive interactions results in decreased viscosity of the 
nanocluster dispersion when compared to a protein solution. While this concept is 
demonstrated for a particular antibody, the formation of nanocluster dispersions by 
increasing the total attractions between protein molecules, close to the isoelectric point, to 
increase protein stability and decrease protein viscosity is applicable to any protein. 
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3.1 INTRODUCTION 
Concentrated proteins in aqueous media (100 to 500 mg/ml) are of widespread 
interest in colloid and biophysical chemistry1, biochemistry2, cellular processes3, protein 
crystallization4, 5, protein processing and storage6, drug delivery by subcutaneous 
injection and other routes7, 8, and medicine9, 10. At these concentrations where the average 
spacing between protein molecules is ~5 nm,  hydrophobic,11 hydrogen bonding, and 
fluctuating charge dipole12 attractive interactions (~3kT) with a range of  ~1nm limit 
solubilities markedly.2, 13 Even when the proteins are soluble, these specific short range 
interactions often produce protein aggregates3, 14, or viscous gels15, as described with 
colloidal phase diagrams.5, 13, 16-19 Extensive protein specific studies have addressed these 
problems by manipulating the sequence of amino acids.20, 21 A complimentary alternative 
would be to utilize concepts in colloid chemistry to form dispersions of insoluble protein 
particles, as reported recently in organic solvents.22 In principle this approach may be 
applicable to large classes of proteins, including therapeutic antibodies, if the protein 
remains folded within the particles. 
Even though proteins have complex structures and short-range interactions, 
colloidal phase diagrams are similar for proteins and simple spherical particles with 
short-range attraction.5, 13, 19 For uncharged spherical polymer colloids with a diameter σ, 
of 560nm, the strength and range (∆σ < 100 nm) of the short range attraction have been 
adjusted independently to map transitions from individual particles to polydipserse 
clusters and ultimately equilibrium phase separation to form gels.1, 23, 24 In the case of 
very slightly charged spherical polymer particles (~10-3 charges/particle) in a low 
dielectric constant organic solvent, distinct equilibrium clusters of 103 particles23, 25 were 
formed by balancing of short range attraction and repulsion, from self-charging within 
the cluster. To our knowledge these types of large equilibrium clusters have rarely been 
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reported in aqueous media, with recent examples of charge-screened biodegradable gold 
clusters26 and sugar27 of unknown charge. For concentrated solutions (φ = 0.2) of highly 
charged lysozyme at pH 7.0 (isoelectric point, pI= 11), dilute dynamic clusters about 2.5 
times larger than the monomer, or ~15 nm have been observed by neutron spin echo and 
small angle neutron scattering28, 29 and dynamic light scattering (DLS)30. To form much 
larger protein clusters, the charge on the protein would have to be smaller to reduce 
electrostatic repulsion. However, the attractive interactions between the clusters must also 
be sufficiently weak and balanced by electrostatic repulsion to avoid aggregation of 
nanoclusters resulting in viscous gels. The ability to design the proper balance of 
colloidal interactions for the formation of stable nanoclusters of proteins at high 
concentrations would provide an alternative to solutions of individual protein molecules. 
The folded state of dilute proteins is stabilized by excluded volume (depletion) 
effects with the addition of crowding agents, for example sugars and polysaccharides, 
relative to the larger unfolded state.31-33 In cells, the high total volume34, 35 fraction of 
these extrinsic crowders, φE, enhances the folded state.3 The excluded volume 
interactions or likewise depletion attraction between two particles is driven by the gain in 
entropy as a cosolute (often called crowder3) is excluded from the depletion zones 
(overlap region) between two solutes. Thus, the depletion force compresses the protein to 
assume the more compact folded state, with the smaller depletion zone.31, 32, 34-36 Recent 
in vitro experiments have related the force for unfolding a dilute globular protein 
ubiquitin to the concentration of the extrinisic crowder, dextran, up to φΕ = 0.4 with 
atomic force microscopy.37, 38 Depletion attraction from self-crowding of proteins (in 
contrast with extrinsic crowders) may be expected to stabilize the folded state, as 
demonstrated by simulation and theory, at ultra high protein concentrations (φ>0.15).11, 39 
However, the limited solubility of proteins in solution has prevented verification of these 
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predictions experimentally. If protein nanoclusters with controlled size could be formed, 
and self-crowding within the nanoclusters prevented unfolding, highly concentrated 
dispersions could be designed as an alternative to protein solutions. 
Here, we assemble a protein (sheep IgG) into translucent dispersions of 80-250nm 
nanoclusters at high concentrations, while simultaneously preserving the native folded 
state due to self-crowding. Equilibrium nanoclusters are formed near the pI, where the 
short range attractive forces are strong enough to balance the repulsion from the small 
charge on the protein. This novel concept is the opposite of the typical approach to 
solubilize highly charged protein in the monomer state away from the pI. The dispersions 
were formed by gently stirring a mixture of lyophilized powder, with a mass ratio of 
protein/trehalose of 1/1 with a buffer solution near the pI, in some cases with additional 
crowers including polyethyelene glycol (Mw = 300) (PEG300) and n-methyl-2-
pyrrolidone (NMP). The hydrodynamic diameter of the clusters, Dh, was measured by 
dynamic light scattering at 160 or 165o to minimize multiple scattering. At constant φI, 
the values of Dh were equivalent at a given φE or upon changing φE along various 
pathways, upwards and downwards, suggesting an approach to thermodynamic 
equilibrium. For an overall φΙ up to 0.21 (275 mg/ml IgG), Dh was tuned from 85 to 
260nm by varying the depletion attraction via the volume fraction of extrinsic crowder, 
φE. In another type of experiment, the protein was diluted at constant crowder 
concentration, to determine the φΙ where the protein became monomer. We define this 
value as the “DLS solubility” of the protein. The lack of formation of aggregates of the 
nanoclusters is demonstrated in situ with DLS and SEM micrographs, as well as a 
repulsive osmotic second virial coefficient for the intercluster interaction from static light 
scattering (SLS). The weak intercluster interactions limit viscosities for the nanocluster 
dispersion to ~50 cp even with protein concentrations up to 275 mg/ml where φΙ = 0.21. 
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The self-crowding (depletion attraction) of the proteins within the clusters 
prevented protein unfolding, as demonstrated by tryptophan (TRP) fluorescence in the 
concentrated dispersions. As predicted by theory,11, 39 the concentrations of protein in the 
clusters, around 0.29 for various cluster sizes from 85 to 258nm respectively, as 
characterized by static light scattering,  were sufficiently high to provide self-crowding. 
Furthermore, after dilution in buffer, the protein remained stable according to an enzyme-
linked immunorsorbent assay (ELISA), and the presence of only a sharp monomer peak 
by DLS, in addition to TRP fluorescence. 
The mechanism of cluster formation and stability is explained in terms of a 
hierarchy of attractive intracluster and repulsive intercluster colloidal interactions, along 
with a new free energy model. The predictions of the cluster size with the free energy 
model are in semi-quantitative agreement with the experimental data. The electrostatic 
repulsion is shown to be relatively weak for the weakly charged protein monomer, but 
simultaneously strong between the clusters, given their much larger charge. 
Simultaneously, the depletion and specific short range attractive interactions are strong 
enough at the protein molecule scale to hold the clusters together (intracluster), yet very 
weak at the intercluster scale. This hierarchy of electrostatic and attractive interactions 
provides two key goals: (1) formation of equilibrium nanoclusters of protein monomer 
and (2) weak interactions between the nanoclusters for stable dispersions with low 
viscosities. The range of the specific short range and depletion interactions, ~1 nm, is 
essentially independent of protein particle size. Thus, these intercluster attractive 
interactions are much weaker for 100 nm clusters where the average spacing is 50 nm at 
φΙ = 0.2, relative to 5 nm for 10 nm protein molecules.  The design of these concentrated 
dispersions of equilibrium stable protein nanoclusters is based on universal colloid 
scaling concepts for hierarchical short-ranged interactions balanced by electrostatic 
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repulsion, and thus may be expected to be applicable to wide classes of proteins. The low 
viscosity (<50 cp) and high molecular stability are of great interest in subcutaneous 
injection of protein therapeutics with a 25-28 gauge needle, where high dosages of 
greater than 100 mg/ml are desired in an injection volume of only 1-1.5 ml.6 
3.2 MATERIALS AND METHODS 
3.2.1 Materials 
Polyclonal sheep IgG (Product No. I5131) was purchased from Sigma-Aldrich, 
Inc.(St. Louis, MO) and further purified by size-exclusion, fast protein liquid 
chromatography (FPLC) (details in Appendix 1.2). α-α trehalose, polyethylene glycol 
with an average molecular weight of 300 (PEG 300), n-methyl 2-pyrrolidone (NMP), and 
all other chemicals were purchased from Fisher Chemicals (Fairlawn, NJ). 
3.2.2 Powder and dispersion formation 
The pI of the protein was determined to be 6.4 from the zeta potential in 20mM 
histidine buffer at a pH of 5.5, 6.4 and 7.4 and confirmed by isoelectric focusing gel 
electrophoresis (Figure A1.2.1) (see Appendix 1.2 for procedure). The IgG solution, 
purified by FPLC, (see Appendix 1.2 for details), at an initial concentration of 20 mg/ml 
in histidine buffer, pH 5.5, with 1:1 wt ratio of α-α trehalose, was slowly frozen over 6 
hours in 8 ml vials on a pre-cooled lyophilizer tray at -40°C (VirTis Advantage Plus 
Benchtop Freeze Dryer). The sample was then lyophilized to form a dry powder at 
100mTorr with 12 hours of primary drying at-40°C followed by a 6 hour ramp to 25°C 
and an additional 6 hours of secondary drying at 25°C. Scanning electron microscopy 
images of the powders formed upon lyophilization are included in the supplementary 
section (Figure A1.2.2). Between 0.039 and 0.08g ± 0.0005g of powder were compacted 
with a spatula into a 0.1ml conical vial (Wheaton Science Products No. 986211). 100 + 1 
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µl of an aqueous-based buffer were added to the conical vial with a 20-200 µl micropipet 
to yield a total dispersion volume of ~0.1ml. NaCl was added to 50 mM pH 6.4 
phosphate buffer (the pI of sheep IgG40) to yield a total ionic strength of 154mM. The 
mixture of powder and buffer was stirred gently, at low shear, with the tip of the 25g 
needle to remove air pockets and form a translucent dispersion without the appearance of 
any visible inhomogeneities (Figure 3.1) using the naked eye. It was assumed that the 
highly soluble trehalose in the powder dissolved and became an extrinsic crowding agent 
in the dispersion. In certain experiments, the aqueous buffer contained a known volume 
of PEG300 as an additional crowder, or mixture of PEG300 and NMP. The total volumes 
of the various components in the concentrated dispersions are given in Table A1.2.1, 
based on known masses and densities (from partial molar volumes) of IgG and trehalose 
and known added volumes of the other (liquid) components. The volume fractions of the 
components (φ, I for IgG, T for trehalose, P for PEG300, and N for NMP) are given in 
Table 3.1. This basic procedure was also used to determine volume fractions throughout 
the study. 
3.2.3 Characterization of the dispersions 
Hydrodynamic diameters, Dh, of nanoclusters and/or protein monomer in the 
aqueous crowder solutions were measured by dynamic light scattering (DLS) at various 
concentrations on a custom-built (Brookhaven) apparatus with a 632.8 nm laser, a fiber 
optic detector and an avalanche photodiode41 at various scattering angles and a 





Figure 3.1 Digital image of translucent dispersion. A) 157 mg/ml – 0.08 φP/0.16 φN B) 
275 mg/ml. All dispersions in Table 3.1 looked very similar.  
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Table 3.1. Hydrodynamic diameter of clusters, protein monomer solubility by DLS dilution, and viscosities in pH 6.4 50mM 
phosphate buffer. The volume fractions were calculated assuming ideal mixing; actual masses in the dispersions 
are given in Table A1.2.1. 
 
























214 0.16 0.13 0 0 0.13 85 ±25 31-50 37 1.5 17 
275 0.21 0.17 0 0 0.17 88 ± 9 31-50 63 2.1 14 
157 0.12 0.09 0.16 0 0.25 111 ± 10 ND 51 ± 7 3.4 20 
162 0.12 0.10 0.24 0 0.34 111 ± 10 <1 48 ± 1 3.5 19 
157 0.12 0.10 0.08 0.16 0.33 258 ± 24 1.25-2.5 25 ± 5 4.3 13 
204 0.15 0.12 0.07 0.14 0.34 ND 1.25-2.5 102 5.6 16 
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from 0.12 to 0.21 were made at 160-165° scattering angle to minimize multiple 
scattering42 with a specialized ~60 µl sample cell (Beckman Coulter Part # A54094) to 
minimize the amount of protein required. To ensure that multiple scattering was 
minimized for the concentrated dispersion, additional measurements at a second 
scattering angle of 135° were conducted and found to give a Dh within 10% of the  
measurement at 160°. Data analysis was performed with CONTIN using a digital 
autocorrelator (Brookhaven BI-9000AT). DLS measurements in Table 3.1 were 
performed in triplicate. Reported average diameters corresponded to the DV50, or diameter 
at which the cumulative sample volume was under 50%. All samples contained one peak 
with a narrow distribution resulting in a relative standard deviation in peak width of less 
than 20% (see supplemental table A1.2.2 for detailed analysis). The particular samples 
containing PEG300 without NMP (lines 3 and 4 in Table 3.1) were measured in the same 
cell, but with a Delsa Nano Particle Size Analyzer (Beckman Coulter, Fullerton, CA) at a 
scattering angle of 165º. The technique was validated with a polystyrene standard (φ = 
0.3) as shown in Figure A1.2.3. A variety of experiments were performed with much 
lower concentrations of protein (1 mg/ml) in 2 ml ampoules (Wheaton Scientific product 
#176776) at a scattering angle from 30° to 90° as previously reported.26 In addition, the 
average count rate for the larger volume, low concentration dispersions was recorded as 
the measured intensity for static light scattering (SLS) to determine the porosity and 
second osmotic virial coefficient. 
To further characterize particle morphology by scanning electron microscopy 
(SEM) and scanning transmission electron microscopy (STEM) the aqueous dispersions 
were diluted to 40 mg/ml and lyophilized as described in the supplemental section. The 
degree of folding of the IgG within the concentrated dispersed particles was monitored 
from the λmax in fluorescence of the tryptophan residues in the fully unfolded protein 
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(350nm) versus the folded protein (336nm).43 A standard curve of the sheep IgG 
unfolding versus the concentration of a denaturant, urea, is included in the supplemental 
(Figure A1.2.4). The protein activity was characterized by a polyclonal capture enzyme-
linked immunosorbent assay (ELISA), after 10 μl of the dispersion was diluted to 1 
mg/ml in a phosphate buffer, as described in detail in the supplemental section. These 
samples were also measured by DLS at 30º to characterize the protein monomer peak and 
to identify the presence of any irreversible aggregates. The monomeric peak obtained by 
DLS was also verified by size exclusion chromatography (SEC), described in the 
Appendix A1.2 and Table A1.2.3. 
3.2.4 Viscosity measurement 
The apparent viscosity of the IgG nanocluster dispersions was measured in 
triplicate with 10% relative standard deviation using a 25 gauge (ID = 0.1mm) 1.5” long 
needle attached to a 1ml tuberculin slip tip syringe, according to the Hagen-Pouiselle 
equation. The velocity through the needle was determined with a video camera (Image J 
software) on the basis of the time to draw the dispersion from a height 0.4” from the 
bottom of the cone to a height 0.1” (~50 µl). The time was measured to within 0.05 
seconds at least 3 times and averaged, while maintaining a nearly constant suction force 
by holding the end of the plunger at the 1ml mark. A maximum volume of 10% of the 
cavity in the syringe was filled with dispersion to minimize variation in the pressure drop. 
A linear correlation between the time to draw 0.05 ml from the conical vial and the 
viscosity of various calibration fluids is shown in Figure A1.2.5.21, 22 The mixed aqueous-
based solvent mixture viscosity (without protein) was measured using a Cannon-Fenske 




3.3.1 Formation of highly concentrated nanocluster dispersions 
A translucent dispersion was formed upon gentle stirring of high concentrations 
of the lyophilized IgG:trehalose (1:1) particles in aqueous pH 6.4 phosphate buffer 
(Figure 3.1). This translucent appearance is a consequence of the unusually low 
difference in refractive indices between the protein (~1.42) and the aqueous solvent 
(~1.33-1.37), despite the high protein concentration, ci, of 150-275 mg/ml. The low 
turbidity enables visual observation that macroscopic particles were not present in all 
cases, which would be an important heuristic for the use of these dispersions for 
parenteral therapy. 
The DLS results are first presented for the highly concentrated dispersions in 
Table 3.1, followed by more specialized studies to determine the “DLS solubility” of the 
IgG and to vary pathways to prove that the clusters reached equilibrium. At a scattering 
angle of 160o, the Dh of the protein nanoclusters was approximately an order of 
magnitude larger than the value of 10nm for individual IgG molecules44 (Table 3.1). For 
the simplest cases in the first two rows with trehalose as the only extrinsic crowder, Dh 
~85-88 nm for ci and trehalose concentrations of 214 and 275 mg/ml (Figure 3.2A and 
Table 3.1). The ability to accurately measure Dh at a scattering angle of 160° with a 
concentrated dispersion was determined by additional measurements at angles of 145° 
and 135° confirming the average particle size within 10%. In addition, a polystyrene 
standard with φ of 0.3 was used to confirm that the accuracy of the particle size to within 
15%. In Figure 3.2A for one representative DLS run at each crowder condition, no larger 
aggregates are observed in the size distribution and the peak width had a relative standard 
deviation of less than 10%. All Dh values reported in Table 3.1 are the average and 




Figure 3.2. DLS hydrodynamic diameters of protein nanoclusters. A) Trehalose is only 
extrinsic crowder. (At 142 mg/ml IgG, φT = 0.09) B) 157 mg/ml IgG dispersion with φP = 
0.16 or 0.24. Additional sample information in Table 3.1. 
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A1.2.2). For a lower concentration of trehalose as a crowder and a ci of 142 mg/ml (φT = 
0.09), smaller 58 nm clusters were formed (Figure 3.2A). When PEG300 was added (φN 
= 0.16-0.24) to raise the total extrinsic crowder volume fraction, φE, to 0.25 and 0.34, the 
Dh increased modestly to 111 nm (Figure 3.2B). Even larger 258 nm clusters were 
observed with a mixture of φp = 0.08 and φN = 0.16 despite a similar total φE of 0.33 as 
for the case without NMP. 
 The IgG concentration, ci, in the dispersion was diluted at constant compositions 
of all extrinsic crowders to define the “DLS solubility”, as shown in Figure 3.3. The ci 
where the Dh shifted from greater than ~50nm, to the hydrodynamic diameter of the IgG, 
11nm44, was defined to be the solubility of the IgG in the extrinsic crowder solution. By 
this DLS solubility technique, the IgG solubility at the pI (pH 6.4) with 250 mg/ml 
trehalose (φT = 0.15) was between a ci of 31 and 50 mg/ml as the large clusters were still 
visible at 50 mg/ml, however only the soluble monomer was visible at 31 mg/ml (Figure 
3.3A). When 0.16 φN and 0.08 φP with 200 mg/ml trehalose are used in combination as 
crowders (φE = 0.34), the IgG solubility decreased by 1 order of magnitude, to between 
1.25 and 2.5 mg/ml (Figure 3.3B). The DLS solubility at other crowder conditions, 
including the extrinsic crowder combination of PEG300 and trehalose, was also 
investigated (Table 3.1). Using the DLS IgG dilution method, the solubility was detected 
to be less than 1 mg/ml for an added 0.24 φP (Table 3.1). Solubilities of less than 1 mg/ml 
could not be detected by the DLS as the intensity of the scattered laser light was too 
weak. 
 Rapidly frozen and lyophilized SEM and STEM images of the concentrated 
nanocluster dispersions confirm the particle size and show the morphology of the clusters 




Figure 3.3. DLS hydrodynamic diameters at constant extrinsic crowder concentrations 
versus protein to determine protein solubilities. A) initial 250 mg/ml IgG in 
pH 6.4 buffer with 250 mg/ml trehalose (φT = 0.15).  The protein monomer 
solubility is between ~31 m and 50 mg/ml.  B) initial 200 mg/ml IgG in pH 
6.4 buffer with 0.16 φN/0.08 φP and 200 mg/ml trehalose (φE = 0.34). The 
protein monomer solubility is between ~1.5 and 2.5 mg/ml. 
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Figure 3.4 A) Cryo-SEMs and B)STEM images of the 157 mg/ml - 0.08 φP/0.16 φN IgG 




seen by both SEM (Figure 3.4A1) and STEM (Figure 3.4B), the particles are clusters 
formed of ~50nm and below primary particles. From SLS measured concurrently with 
the DLS at various scattering angles (30°, 45°, 75° and 90°), the fractal dimension of the 
nanoclusters can be determined as the exponent from a log-log plot of the scattering 
vector and the SLS intensity (see Appendix 1.2 for details).45 The fractal dimension of a 
cluster, Df, characterizes the structure of a flocculated particle by relating the volume 















 Eq. 3.1 
For a cluster composed of densely packed particles, Df approaches 3. For the nanoclusters 
formed with 250 mg/ml trehalose (φT = 0.15), a Df of 2.4 was measured experimentally 
by SLS (Figure A1.2.6) resulting in a φI of individual proteins of 0.29 (Table 3.2). For the 
clusters formed with 0.16φN and 0.08φP (φE = 0.34), a φI of 0.29 was calculated (Table 
3.2) using the measured Df of 2.6 (Figure A1.2.6). 
3.3.2 Effect of crowder concentration on equilibrium nanocluster diameter 
The effect of the total extrinsic crowder volume fraction (φE) on the size of the 
protein nanoclusters was determined by increasing and decreasing φE by a variety of 
paths at a constant ci (Figure 3.5). In Figure 3.5A path 1, φT was increased from 50 
mg/ml up to 300 mg/ml by adding trehalose from a concentrated solution of trehalose 
(500 mg/ml trehalose). At each point, the ci was maintained at 50 mg/ml by 
simultaneously adding a small volume of a 200 mg/ml concentrated protein dispersion 
with 200 mg/ml trehalose prior to measuring the Dh. The average Dh and standard 
deviation of 3 individual measurements at each condition is shown in Figure 3.5. The  
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Table 3.2. Characterization of protein stability. Maximum emission wavelength (λmax) for 
concentrated protein dispersions from tryptophan fluorescence assay where 
λmax for fully folded protein is 336nm and for fully unfolded protein is 
349nm. For ELISA and DLS, dispersions were diluted in pH 7.0 buffer to 1 
mg/ml.  















275 mg/ml  0.29 0.17 336 ± 1 1.1 ± 0.1 9 ± 2 
157 mg/ml - 0.08 φP/0.16 φN 0.29 0.33 336 ± 1 1.1 ± 0.2 10 ± 1 
*Relative EC50 was calculated as the difference between the EC50 of the reconstituted dry 






Figure 3.5. A) Dh of protein nanoclusters at a constant ci of 50 mg/ml. In path 1, trehalose 
concentration was increased with 500 mg/ml trehalose in pH 6.4 phosphate 
buffer along with constant ci. For decreasing sugar concentration, pure 
buffer was added while maintaining constant ci. In path 2, solid sugar 
crystals were added. In path 3, trehalose concentration was decreased using 
pure pH 6.4 phosphate buffer and 200 mg/ml IgG dispersion with trehalose. 
The values for the cluster diameters obtained from theory (Eq. 3.14-3.17) 
are also superimposed on the plot. B) IgG and trehalose concentration 
constant at 30 mg/ml. φN and φP were increased by adding a 1:2 volume 
solution of PEG300:NMP while maintaining constant IgG and trehalose 
concentrations. 
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individual DLS runs and peak width of these measurements is included in Table A1.2.4. 
By DLS, the protein at a concentration of 50 mg/ml trehalose was present as a monomer, 
as seen from the Dh of ~ 10 nm, up to a trehalose concentration of 150 mg/ml. Above 150 
mg/ml of trehalose, the protein formed clusters as shown by the increasing Dh. The 
protein cluster diameter increased linearly with trehalose concentration and reached ~ 80 
nm at a trehalose concentration of 300 mg/ml (Figure 3.6). In Figure 3.7, the mass of 
trehalose was converted to φT by using the mass density of trehalose (1.64 g/ml47). To 
verify the reproducibility of the cluster size by a separate pathway, the trehalose 
concentration starting from 300 mg/ml was decreased by adding a pure buffer solution. 
Again, the ci was maintained at 50 mg/ml by adding slight amounts of the concentrated 
protein dispersion mentioned above. The experimentally measured cluster size decreased 
at the same rate, based on φT, as it had increased while adding trehalose (Figure 3.5A 
decreasing sugar concentration after path 1). In a separate experiment (Figure 3.5A path 
2), an alternate method was used to increase the trehalose concentration. Trehalose 
crystals were dissolved directly in the protein solution at 50 mg/ml IgG and 50 mg/ml 
trehalose to increase the trehalose concentration. At each trehalose concentration, the size 
of the protein clusters produced by both methods, whether increasing or decreasing 
trehalose concentration, closely agreed. In addition, a third path, path 3, was tried where 
an initial trehalose concentration of 300 mg/ml and a constant IgG concentration of 50 
mg/ml was diluted to 100 mg/ml IgG by using pH 6.4 phosphate buffer with the requisite 
small amounts of a 200 mg/ml IgG dispersion to maintain the IgG concentration at 50 
mg/ml. All these different paths yield sizes that agree well with each other at the different 
trehalose concentrations that were tried and seem to fall on the same straight line.  
A second crowder composition, a 1:2 by volume solution of PEG300 and NMP, 
was also used to determine particle size at various total φE. In this case, a measured  
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Figure 3.6. Distribution of the hydrodynamic diameter from DLS for selected samples 





Figure 3.7 Universal scaling of hydrodynamic diameter measured by DLS for data in 
Figure 3.5 with increasing trehalose concentration (□) and constant φT with 
increasing NMP/PEG300 (◊). 
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volume of the 1:2 volume solution of PEG300 and NMP was added to increase total φE, 
while constant protein and trehalose concentrations of 30 mg/ml were maintained by the 
addition of a small amount of the 1:1 wt ratio protein to trehalose lyophilized powder. 
Cluster growth was observed as the φE of PEG300 and NMP was increased to 0.15 and 
higher. The largest particles of ~250nm were seen at a φE of PEG300 and NMP of 0.3. 
Actual hydrodynamic diameter distributions for some selected samples in Figure 3.5A 
obtained by DLS are shown in Figure 3.6. The distributions are fairly narrow with a 
relative standard deviation of less than 10% over the mean. Also, not only do the cluster 
sizes for different paths match up well as shown in Figure 3.5A but the distributions also 
are fairly consistent (Figure 3.6). The size of the protein clusters formed for both the 
trehalose crowder only and the 1:2 PEG 300:NMP crowder system was plotted against 
the total extrinsic crowder volume fraction in Figure 3.7. Both types of crowder systems 
give very comparable linear growth of the protein cluster size as shown in Figure 3.7. In 
fact, both crowder systems fall nearly on the same line. 
3.3.3 Properties of the nanocluster dispersions (low viscosity and high molecular 
stability) 
Syringable viscosities (< 50 cP) were obtained for most of conditions in Table 
3.1, except the final row with 204 mg/ml IgG (0.08 φP/0.16 φN). The viscosities for the 
samples with φP between 0.16-0.24 were modestly higher than those for the NMP-PEG 
mixtures. Even higher volume fractions of PEG300, 0.50, increased the viscosity to the 
point where it was not syringeable at 150 mg/ml IgG (results not shown). When only 
trehalose was used as an extrinsic crowding agent, the viscosity of the protein dispersion 
at 214 mg/ml, was 37 cP. Viscosities this low have rarely been reported, if reported at all, 
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for therapeutic proteins at such a high concentrations.6, 21, 48 Furthermore, solutions often 
cannot be formed at 200-300 mg/ml as the protein solubilities are not this high.2, 20 
The apparent dispersion viscosity is commonly described as a function of the 
intrinsic viscosity, [η], maximum volume fraction of particles, φmax, and the solvent 























o  Eq. 3.2 
The η may be reduced by lowering η0, or [η], which is a minimum of 2.5 for hard sphere 
colloids, and increasing φmax. In table 3.1, φI is the volume fraction of protein and φmax = 
0.55. Because we have an equal mass of trehalose as protein present in the solvent, the 
solvent viscosity is increased to account for the soluble sugar.49 For the samples with 
trehalose as the only extrinsic crowding agent, the solvent viscosity was approximated 
from a standard curve of trehalose solution viscosities49, while all other extrinsic crowder 
in buffer solutions were measured experimentally. For each of the PEG-NMP 
formulations, [η] was fairly low, between 13 and 16. At a concentration of 275 mg/ml 
IgG with only sugar as a crowder, the [η] for the protein dispersion is around the same 
value, 14. For the three experiments with only PEG as an added crowder, the [η] values 
are a little larger (19-20) than for the NMP-PEG samples but still smaller than for many 
reported proteins with intrinsic viscosities as high as 100. 
 Given that the dispersions offer low viscosities at high concentrations, the protein 
stability within the dispersion and upon dilution is examined. At a ci of 100 mg/ml, 
diluted from the concentrated dispersions with the crowders present, a fluorescence assay 
was utilized to show protein folding in the concentrated dispersion.43 Isolated protein 
amino acid side chains, tryptophan and to a lesser extent tyrosine, excited at 295nm, will 
emit a maximum signal at 350nm.43 Due to the local environment within a fully folded 
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protein, the maximum emission wavelength (λmax) will shift to 336nm for the sheep IgG 
(Figure A1.2.4). Upon full unfolding of the protein, the local environment of the amino 
acid residues will change and λmax will increase to 350nm. Thus a scan of the emission at 
wavelengths between 336 and 350 where the dispersed particles are excited at 295nm and 
λmax is recorded will indicate the folding of the protein within the nanoclusters. For both 
dispersions with pure sugar crowder and with NMP and PEG, the λmax of 336nm indicates 
the fully folded state of the protein (Table 3.2). High retention of monomeric protein and 
antibody activity for the protein diluted and dissolved to 1 mg/ml in a pH 7.0 phosphate 
buffer from the aqueous dispersion, is also shown in Table 3.2. As the sheep IgG used in 
these initial studies does not bind a single target, a polyclonal anti-sheep IgG capture 
ELISA was used to monitor loss of conformational epitopes due to denaturation.7, 50 The 
relative EC50 ~ 1. 1 indicates similar binding to the standard IgG, within error of the 
experiment (Table 3.2). The relative EC50 values close to 1 indicate a negligible change 
in activity. According to DLS measurements for the dissolved IgG from nanoclusters at 1 
mg/ml, the protein dissolves to a Dh of ~10nm, the Dh of the sheep IgG44 (Table 3.2). 
Additional size exclusion chromatography to quantify the % monomer of the protein 
upon dilution into a pH 7.0 buffer is found in the supplementary material (Table A1.2.3). 
3.3.4 Protein nanocluster interactions 
Interparticle interactions of the nanoclusters in dispersion were quantified by 
measuring the second virial coefficient, B2, by static light scattering (SLS). Since it was 
necessary to dilute the concentrated dispersion to remove multiple scattering, only the 
NMP-PEG system was utilized. A plot of KcP(θ)/Rθ versus c was used to determine B2 
with the relationship 
  Eq. 3.3 
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where K is an optical constant 
  Eq. 3.4 
Here n0 is the refractive index of the solvent and λ is the wavelength of the incident 
beam. The Rayleigh ratio (Rθ) for each sample was calculated based on the known Rθ of 
toluene51 and the experimentally measured count rates for toluene and the sample. The 
refractive index increment (dn/dc) for the nanoclusters was taken to be the same as that 
for protein aqueous solutions (0.185 ml/g52, 53), as additional crowders and the formation 
of the nanoclusters are not anticipated to affect the value of dn/dc (for additional 
information see Appendix 1.2 and Figure A1.2.7). In the nanoclusters, intraparticle 
interference influences the measured intensity. To reduce this effect, an additional factor, 
P(θ), was added to eq. 3.4 to account for the change from pure Rayleigh scattering to 
Debye scattering (Eq. 3.5).45, 54 
  Eq. 3.5 
A low scattering angle, 30º, was chosen to reduce the second term of the 1/P(θ) equation 
(Eq. 3.5). The slope in Figure 3.8 indicates a positive B2 of 6.6 *10-5 mol*ml/g2 thus 
signifying that the nanocluster interparticle interactions are slightly repulsive. The 
repulsive nature of the nanocluster interparticle interactions is supported by other indirect 
characterization techniques. If the nanocluster interparticle interactions were attractive, 
we may not have seen discrete individual particles by SEM or DLS. 
3.4 DISCUSSION 
3.4.1 Potential of mean force between two protein colloids in crowded solution 
The total potential of mean force for two protein molecules includes depletion 
(dep)35, van der Waals (VDW) and specific short-range (SSR) attraction along with 
electrostatic repulsion (EL).2, 13, 18 
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Figure 3.8 Static light scattering (SLS) data on dilutions of the protein/trehalose 




 Eq. 3.6 
The depletion attraction (also termed crowding) between two particles arises from a gain 
in entropy as cosolutes (crowders) are excluded from the overlap region between the 
particles.55 For the Asakura-Oosawa potential: 
  Eq. 3.7 
nC and RPHS are the number density and radius of extinisic crowders, approximated as a 
penetrable hard sphere, r is the center to center distance between two protein molecules 
and R is the radius of the colloid.56 The van der Waals attraction for two spheres of equal 
radii45 
  Eq. 3.8 
where A is the Hamaker constant. The attractive specific short-range interactions, which 
include hydrophobic interactions, hydrogen bonding and fluctuating charge dipoles, are 
often modeled with a square-well potential: 
  
Eq. 3.9 
where ε/kBT is the depth (~2.7 for a monoclonal antibody57) with a width (Δσ) of ~1nm 
in which σ is the diameter of the protein molecule.5, 18, 19, 28, 58 For a typical protein, it is 
reasonable to assume that the width, Δσ, is independent of colloid size as the range of 
hydrophobic interactions and hydrogen bonds does not scale with the size of the 
colloid.18, 59, 60 For an 11 nm protein molecule and a 0.5 nm crowding agent such as 
trehalose, the range of all of these potentials is similar, ~1nm (Figure 3.9A, 3.9B). The 
electrostatic repulsion can be modeled as 
  Eq. 3.10 
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Figure 3.9. Total potential (Vtot (r)), attractive potentials from van der Waals, Vvdw(r), 
specific short-range attraction, Vsr(r), and depletion-attraction, Vdep(r) for a 
0.5 nm radius crowder and electrostatic repulsive potential, Velectrostatic, 
for A) electrostatically stabilized protein monomer B) unstable protein 
monomer near the pI C) an electrostatically stabilized protein nanocluster 
near the pI D) an electrostatically stabilized protein nanocluster near the pI 
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where    Eq. 3.11 
and n∞ is the bulk ion concentration, κ-1 is the Debye length, zI is the valence of the 
electrolyte, e is the charge on an electron, and ψ0 is the surface potential of the protein. 
The charge is related to ψ0 by 
( )RRzneQ κψπεε +== 14 00  Eq. 3.12 
where ε is the dielectric constant and ε0 is the permittivity through free space.61 The 
stability ratio for a colloid is defined as the ratio of fast, diffusion controlled aggregation 
to slow, kinetically-controlled aggregation45, 62 
  Eq. 3.13 
where u is defined as r/R and the ratio D∞/D(u) is a hydrodynamic correction factor. 
 The colloidal interactions between two protein monomers are shown in Figures 
3.9A and B in terms of the various contributions to Vtot for a fixed φc of 0.17, 
corresponding to data in Table 3.1. Both r and the reduced range (r/σ) are indicated. In all 
cases throughout this study, the range of the specific short-ranged interactions Δσ was 1 
nm and the range of VDEP < 1nm for the extrinsic crowders. In Figure 3.9A for a protein 
molecule >2 pH units away from the pI, the charge/protein molecule ~5063, and 
consequently, VEL is dominant over the sum of all attractive interactions. The large 
repulsive barrier results in a high value of the stability ratio, W, 7 x 106, which is about 
the same with or without the VDEP term. This scenario with a large VEL and low sugar 
concentrations to minimize VDEP is typically utilized to form colloidally stable solutions 
of individual protein molecules. However, despite the highly repulsive Vtot, protein 
solubilities are often limited to ~150-200 mg/ml as described on phase diagrams of 
second virial coefficients, B2/B2HS.2, 19 In our unusual case near the pI of a protein, the 
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charge/protein molecule decreases to less than 10. Here, the zeta potential is small and 
not well defined.60, 63 Thus, we assumed a value of 6 charges/protein molecules, which 
results in a surface potential of 8.7mV. With this low charge, the strength of electrostatic 
repulsion was negligible relative to either the VDEP or VSR or VVDW attraction, as shown 
in Figure 3.9B, and thus W was ~ 1. With this strong attraction near the pI, concentrated 
solutions of protein monomer may not be formulated.19, 60, 64 In our case, we intentionally 
use the attraction to form nanoclusters of the protein monomer, as is described in the next 
section. 
3.4.2 Free energy model for equilibrium cluster size 
 Groenewold and Kegel25 proposed a model to predict the equilibrium aggregation 
number for large clusters of colloidal particles, in which short range attraction is balanced 
by long range electrostatic repulsion. This balance must satisfy simultaneously a 
secondary requirement that the colloidal interactions between clusters do not cause the 
clusters to aggregate to form gels. The free energy of a spherical cluster consisting of n 
colloidal particles per protein molecule is25 
 Eq. 3.14 
where FCl is the free energy of a protein cluster, β = 1/kBT, ε is the pairwise interaction 
potential between two protein molecules, z is the co-ordination number for the protein in 
the cluster, γ is the surface tension for the cluster, (γ = Є/4πR 2 where R is the radius of a 
protein monomer and Є (=βε) is the attractive pair potential between two protein 
molecules), Rc is the radius of the cluster, n is the number of protein molecules in a 
cluster, Q is the Bjerrum length, q is the charge on a protein molecule, q0 is the value in 
the absence of Coulombic interactions. The first term describes the interaction potential 
between adjacent protein molecules in the cluster. The second or surface tension term 
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describes the missing attractive interactions at the cluster surface. The third term is the 
Coulombic repulsion for a homogeneously charged sphere in terms of Q at which the 
interaction between two elementary charges is kBT. At room T, Q ~ 56/εr nm, where εr is 
the dielectric constant inside the cluster. The last term describes the combinatorial and 
translational entropy gain for the dissociating ions. The value of q0 is given by the 
equation25 
  Eq. 3.15 
where v is the volume of a single protein molecule, σc is the number of dissociable sites 
per surface area of the molecule, s is the surface area of the protein molecule, b is the 
typical distance between an ion pair, ΔЄ is the energy required to dissociate an ion pair 
(=Q/b) and φ is the colloid volume fraction in the solution. For the purpose of the further 
derivation, it is assumed that z~z0. 
To take into account the porosity of the clusters, we refine the model in terms of the 
fractal dimension Df according to the relationship 
   Eq. 3.16 
The minimization of fC = FCl/n by setting  yields the number of monomers in 
the cluster at equilibrium 
  Eq. 3.17 
which in the limit of Df =3 gives the result obtained in Groenewold and Kegel.25 
Eventually, at the point where the electrostatic repulsion becomes insufficient to balance 
the attractive forces, the protein forms a gel.65 The gel point may be defined by the 
spinodal curve, where the second derivative of the free energy per protein molecule with 
respect to q is zero (that is ), as been shown experimentally.24 
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Figure 3.10. Phase diagram for a protein dispersion based on the equilibrium theory 
described in Eq. 3.14-3.17. The steep solid line is the gel line above which 
the solution forms a gel phase. Each curve indicates clusters of the same size 




Figure 3.10 presents a set of contours for cluster sizes ranging from 20 to 230 nm, 
for a given φp, as a function of φc. The calculated q0, which depends upon φp, as shown in 
the appendix, is on the order of one charge/protein molecule near the pI.25, 63 Given the  
uncertainty in εr and qo, the value of Є was approximated as the contact value for the 
depletion potential in eq. B, which depends upon φC, while the other attractive terms were 
neglected as they are not influenced by crowding. Horizontal and vertical pathways for 
varying either φp or φc, which were also used in the experimental studies, are shown 
explicitly in Figure 3.10. For a given φp, an increase in φc raises the depletion attraction 
between protein monomer and hence increases the cluster diameter, D, in reasonable 
agreement with the data shown in Figure 3.5A given the simplicity of the model. For 
instance, the model does not consider charge screening, differences in εr inside and 
outside the cluster, and variations in the attractive interaction with increasing the distance 
from the surface. Similarly, at a given φc when φp increases, D increases as shown by the 
vertical dashed black line, corresponding to the experimental data in Figure 3.3. Here 
larger clusters are the result of a decrease in q0 with φp, thus a decrease in the Coulombic 
repulsion. A few specific cases are also denoted. For Case 1 at 100 mg/ml sugar and a φp 
of 0.037 (Table 3.3), the predicted Rc is ~35 nm while the experimental value was 10 nm 
(Figure 3.5A). For 275 mg/ml sugar and a φp of 0.037, the predicted and measured values 
of R were ~60 nm. For Case 3 (row 2 Table 3.1, 275 mg/ml sugar and protein) R ~140 
nm compared to the experimentally measured size of 88 nm. Case 4 from Figure 3.3B has 
a predicted size of 174 nm compared with 250 nm observed experimentally. The 
calculated spinodal curve or gel line and an experimental condition which results in a gel 
of equilibrium nanoclusters (gel point) also correspond. The translucent dispersion 
formed at the gel point (300 mg/ml ci with 300 mg/ml trehalose) could not be drawn  
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Table 3.3 Input and output variables for the equilibrium cluster model proposed. 
 Case 1  
Figure 3.10 
Case 2  
Figure 3.10 
Example from Kegel25 
Df 2.5 2.5 3 
Dielectric constant (Єr) 15 15 10.72 
Bjerrum Length (Q) (nm) 3.733 3.733 5.22 
Number of dissociable sites per 
unit area of colloid surface (σC) 
(nm-2) 
0.2 0.2 0.15 
Distance between opposite 
charges in an ionic bond (b) 
(nm) 
0.2 0.2 0.134 
Radius of primary particle (R) 
(nm) 
5.5 5.5 Disc (75 x 15) 
φC 0.061 0.167 NA 
Attractive energy (Є/kT) 2.63 7.26 7.5 
Surface Tension (γ) 0.006919 0.01910 0.002122 
φE 0.037 0.204 0.3 
z0 0.435 0.185 0.0004 
Z 9 116 80 




through a 25 gauge needle with a syringe. The location of the gel curve relative to the 
experimental point is quite reasonable given the simplicity of the model and complexity 
of the electrostatic interactions with the cluster. 
Table 3.3 provides the model input variables for the some of the cases described 
above, along with the calculated q0 and n. The total number of dissociable sites on the 
protein monomer at a given pH, σcs (where σc is the number of dissociable sites per unit 
surface area s), was chosen as 50 based on literature.63 Thus for a spherical protein with R 
= 5.5 nm, σc is ~ 0.2, as for cases 1 and 2 in Table 3.3. The εr was chosen as 15 given the 
low local dielectric constant of a pure protein. For this low εr, the Vrep inside the cluster is 
long ranged given the large value of κ-1, a necessary requirement for formation of an 
equilibrium cluster with a well defined radius. In the case of εr for pure water, the range 
of repulsion would be too short for formation equilibrium clusters. 
The large clusters may be contrasted with small clusters of highly charged 
lysozyme monomer at a pH of about 8, far from the isoelectric point, with aggregation 
numbers < 5 and lifetimes of ~25 ns.28, 29, 66 The small size and short lifetime are 
consistent with the dominance of the large repulsion for the highly charged particles 
relative to the attractive forces. In Table 3.3, results are shown for clusters of Boehmite 
rods in ortho-dichlorobenzene (εr  = 10.12) where several of the parameters are similar to 
the protein clusters.25, 67 However, the low q0 results in massive clusters with an 
aggregation number of 200,000 as observed experimentally and described theoretically.25 
The nanoclusters in the current study have a charge intermediate between these two 
cases, which results in long lived equilibrium clusters with n ~ 102 to 103. However, the 
size could be further manipulated by varying φc at a given φP. 
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3.4.3 Intercluster interactions 
Since the number of protein monomers is well defined for an equilibrium 
nanocluster below the gel point, the nanocluster may be viewed as an individual colloidal 
particle. A sufficient repulsive Vtot between two nanoclusters is required to prevent 
aggregation of the clusters and to maintain a low viscosity. As shown in Figure 3.9C, a 
large repulsive barrier is present for an 85nm protein nanocluster near the pI, consistent 
with the stable nanocluster dispersions for the case of φc = 0.17 in Table 3.1. In contrast, 
the protein monomer dispersion was unstable in Figure 3.9B, where the following 
parameters were held constant: 6 charges/protein monomer, Δσ= 1nm, and φc = 0.17. For 
~231 protein molecules within the cluster, the large charge of ~ 1380 produces a surface 
potential of ~34mV according to eq. 3.12, well above the value for the monomer of only 
8.7 mV. Thus, VEL is substantial for the nanocluster, despite the proximity to the pI, and 
simultaneously, negligible for the monomer. Furthermore, VEL scales as Rp such that the 
range of repulsion is much longer than for VDEP (<1 nm) and VSSR. Since the range of 
these attractive forces is not influenced significantly by Rp, it is similar for the protein 
monomer and the nanoclusters. Thus, the reduced range, r/σ, of these attractive 
interactions (< ~1.01) for the nanocluster is far below that of ~1.1 for the protein 
monomer. In contrast, VEL is relatively insensitive to r/σ. Since VEL is dominant for the 
nanoclusters, they do not aggregate and remain colloidally stable with a W of 6*108. 
Of the various attractive interactions for the nanoclusters, the range of the VDW 
interaction is the longest as it scales with R. However, since the nanocluster are porous, 
as shown in the SEM and STEM images (Figure 3.4), the Hamaker constant is reduced.68 
In Figure 3.9C and 3.9D, the Hamaker constant is reduced two fold to 2.5kT. Even with 
including the VDW attractions, the electrostatic interactions were much stronger and 
longer-ranged than the total attractive interactions.8 For a 250nm protein nanocluster 
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formed with a higher crowder volume fraction of 0.3 (similar to the experimental 
conditions in row 5 Table 3.1), electrostatic repulsion was even more dominant as shown 
in Figure 3.9D. With ~5870 protein monomers, the larger charge corresponded to a 
higher surface potential of ~96mV, and W reached 10103. Experimentally, repulsive 
interactions between the nanoclusters were measured by SLS, with a B2 of 6.6 x 10-5 
mol*ml/g2 (Figure 3.8). However, theoretical determination of B2 from Vtot is poorly 
defined as the contributions from VDEP and VVDW diverge at very small r. 
In summary, a direct comparison of the potentials in Figure 3.9B and 3.9C reveals 
a novel concept of hierarchical interactions where Vtot is strongly attractive for protein 
monomer and simultaneously, highly repulsive for the nanoclusters, consistent with the 
experimental data. This difference is due primarily to the increase in the range and 
strength of VEL with an increase in Q and Rp, relative to a negligible change in the range 
of interaction for VSSR and VDEP. The strongly attractive intracluster interactions at r/σ = 
1.1 are necessary to generate the nanoclusters, whereas the weak intercluster attraction at 
the same r/σ prevent aggregation and gelation of the clusters. This ability to control the 
hierarchical colloidal interactions may be expected to be universal and applicable to a 
wide variety of peptides and proteins. 
3.4.4 Stability of the protein within the nanocluster dispersion 
At high protein concentrations, φΙ, simulation with a coarse-grained model11 
indicates crowders tend to stabilize the native state due to excluded volume effects, 
regardless of any other interactions with the protein. In the presence of a crowder, the 
protein will attempt to minimize its excluded volume. Thus, the protein will prefer to be 
in its folded or native state.34, 35 In the unfolded state, the protein has a greater degree of 
surface hydrophobicity and hence displays increased protein-protein interactions leading 
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to the unfolded state being favored.69, 70 Therefore according to Cheung and Truskett11, at 
higher protein concentrations, the protein shows an increased tendency to be in the native 
state due to the balance between destabilizing protein-protein interactions and the 
stabilizing entropic crowding.69 In the interior of the cluster, the protein concentration is 
very high (~0.29) and therefore it favors the folded state. Also at such high 
concentrations, protein self–crowding plays a role. Measurements by tryptophan 
fluorescence confirm the present of the protein folded state within the nanocluster 
dispersions (Table 3.2). 
For therapeutic proteins to retain activity without inducing adverse immunogenic 
reactions, it is essential to maintain the native three-dimensional conformation during 
recovery and formulation.8, 71 Currently, antibodies are challenging to formulate at high 
concentrations as solutions, since the high-level of protein mobility facilitates protein 
denaturation and exposure of internal hydrophobic patches, leading to reversible 
intermolecular association and, eventually, irreversible aggregation.14, 32, 72 However, 
excluded volume interactions from added crowding agents thermodynamically increase 
the stability of the native protein state.33, 37, 38 As the φc increases, the protein molecule 
will entropically favor the reduced volume of the natively folded state over the unfolded 
state.34 For sugar as a crowding agent, the increase in the stability of a protein solution 
has been observed in terms of the negative preferential binding parameter between the 
protein and sugar.31, 32, 73 Thus the extrinsically crowded solution environment of the 
protein nanoclusters will prevent unfolding of the protein molecules. Upon dilution into a 
pure buffer, DLS confirms the presence of the monomeric protein and ELISA does not 
detect a difference in protein binding. These protein specific tests indirectly confirm that 
no changes occurred in the folding of the protein during the formation and dilution of the 
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nanoclusters that affected the binding of the protein or resulting in the formation of 
irreversible aggregates. 
The low levels of protein denaturation observed are achieved by stabilization of 
the protein native state during sample processing. Lyophilization is widely used in 
biopharmaceutical processing and has been shown to stabilize the protein native state by 
kinetically trapping protein molecules in an amorphous solid74-76, thus reducing protein 
mobility which can lead to aggregation. Addition of the crowder, trehalose, during 
lyophilization further stabilizes the protein native state in solution by excluded volume 
and upon dehydration  by forming hydrogen bonds with protein.33, 77, 78 Within the protein 
nanoclusters, the solid state is maintained, restricting protein mobility both in the 
particles and on the particle surface, relative to a solution.72, 79-82 Particle dissolution upon 
dilution occurs rapidly (~1 second), given the high particle surface area and solubility of 
the protein monomer in physiological buffers (upon dilution of the crowding agents). The 
presence of the diluted crowders such as trehalose and PEG300 in the dissolution buffer, 
further prefers the native protein state by entropically favoring it by excluded volume.72, 
75, 78, 83 
3.4.5 Decreased viscosity in nanocluster dispersions versus protein solutions 
For protein molecules in solution at high concentrations, for example φΙ = 0.1 to 
0.3,  the strong short-range specific attractive interactions24, 29, often produce viscosities 5 
to 100 times the hard sphere value to the Krieger-Dougherty eq. 2.21, 84 For monoclonal 
antibody solutions with concentrations of 150 mg/mL, viscosities greater than 100cP 
have been attributed to reversible self association of protein molecules, on the basis of 
measurements by analytical ultracentrifugation.21, 59 In contrast, the low viscosities in the 
present study for the nanocluster dispersions may be shown to be consistent with the 
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weak interactions between the nanoclusters, as suggested by the low intrinsic viscosities 
in Table 3.1. 
For hard spheres, gelation, the result of increased clustering, does not occur until 
at least a φ of 49%.85 Since nanocluster dispersions act more like hard spheres due to the 
decreased attractive interactions between nanoclusters, the viscosity should remain lower 
for nanoparticle dispersions at the same φ if the solvent viscosity remains the same. From 
the Krieger Dougherty equation (Eq. 3.2), the intrinsic viscosity ([η]) is used to compare 
the increase in viscosity due to the addition of particles.45 In the hard sphere limit, [η] 
approaches 2.5, where the increase in viscosity due to the particles is solely due to the 
excluded volume, as seen previously for non-aqueous protein suspensions.22 All values 
are significantly lower than the [η] reported for protein solutions, which can increase to 
greater than 50 cm3/g.86 Hydrogen bonding between the protein molecule and water 
molecules (“bound water”), up to now lumped together with hydrophobic effects and 
fluctuating charge-dipoles as specific attractive interactions, in addition increases the 
effective φ of the protein colloid, whether in solution or dispersion.8, 45 If the hydration 
layer is approximated as a 0.1nm increase to the radius of the protein colloid18, the ratio 
of φeff to φ will be 1.12 for the protein molecular solution but remain close to 1 (1.002) 
for the nanocluster dispersion. Since in the Krieger-Dougherty equation, an increase in 
φeff over the expected φ will be incorporated as an increase in [η]45, the decrease in 
hydration for the nanocluster dispersions versus a protein solution by itself results in a 
lower [η] for the nanocluster dispersions. 
In addition to specific attractive interactions, electroviscous as well as shape 
effects can also increase the intrinsic viscosity of a protein molecule when compared to 
the protein nanocluster dispersion. In the aqueous protein nanocluster dispersions, the 
surface charge is decreased by lowering the dielectric constant of the solution and 
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operating at the isoelectric point of the protein which results in a decrease the thickness 
of the double layer.8, 45, 61, 87 The decreased thickness of the double layer will reduce any 
electroviscous effects, known to contribute to the increased viscosity for protein solutions 
at high zeta potentials.21, 45, 60, 87-90 The molecular shape factor proportionally increases 
the intrinsic viscosity45 and is a function of the aspect ratio of the solution.8, 45, 86 At its 
minimum, spherical particles do not increase the intrinsic viscosity over the expected 
value.45, 86 In the case of protein solutions, the shape of the molecule in solution is 
dependent on the protein itself.8, 86 However, for the protein dispersion formed, the shape 
of the particle is dependent on the particle formation technique, and can therefore be 
tailored to be very spherical. Thus, for nanocluster dispersions, both the electroviscous 
and shape effects can be tailored to be insignificant increases to the viscosity. 
3.5 CONCLUSIONS 
Proteins may be crowded by extrinsic crowders into 80-250nm clusters to form 
highly concentrated dispersions, while the protein self-crowded state within the 
nanocluster preserves the native folded protein. These novel, equilibrium clusters are 
formed by balancing attraction from specific short-range attractive protein interactions 
and extrinsic crowders against very weak electrostatic charging near the isoelectric point 
of the protein. These large equilibrium clusters with aggregation numbers on the order of 
hundreds are formed at high protein concentrations in a molecularly crowded solution 
with a φ of total crowders > 0.13. In contrast, previously, small (n~10), dynamic clusters 
of lyozyme are formed at unsaturated conditions at a pH far from the pI of the protein 
which results in a large electrostatic repulsion preventing the formation of large, stable 
clusters.29, 91 The size of various equilibrium clusters, determined by DLS and confirmed 
by SEM, fall on a universal curve with increasing total φ crowder regardless of the 
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crowder type or combination of crowders used (trehalose, PEG300, and/or NMP). The 
highly self-crowded environment within the nanocluster (φ protein within the cluster 
~0.29)  prevents unfolding of the protein, as predicted previously.11, 39 The stability of the 
native state is confirmed experimentally by a tryptophan fluorescence assay within the 
crowded environment and upon dilution into buffer by ELISA and DLS. In contrast, in a 
protein solution at the same concentration without forming nanoclusters, low solubility 
prevents a sufficiently high φ to allow for protein self-crowding. 
The hierarchy of strong intracluster interactions used to form the nanoclusters and 
the weak intercluster interactions result in high colloidal stability and low viscosities 
despite high protein concentrations reaching 275 mg/ml. Protein molecules are clustered 
together due to high specific attractive protein interactions and the additional attraction 
due to the added molecular crowders. Since the ~ 1 nm range of these attractive 
interactions is essentially independent of particle size, the specific short-ranged 
interactions and the depletion-attraction from the molecular crowders have a negligible 
attractive effect on the nanoclusters. A weakly repulsive B2 confirms the weak 
interactions between nanoclusters experimentally. Decreased intercluster interactions 
result in particles that are more like hard spheres and thus should demonstrate lower 
viscosities than protein solutions at the same concentration.22 The viscosity, estimated 
through a 25 gauge needle, confirms relatively low intrinsic viscosities for the 
nanoclusters. The low viscosity (<50 cp) and high molecular stability for the highly 
concentrated nanocluster dispersions are of great interest in subcutaneous injection of 
protein therapeutics with a 25-28 gauge needle, where high dosages of up to 500 mg/ml 
are desired in an injection volume of only 1-1.5 ml.6 This hierarchical protein nanocluster 
concept is based on general scaling of short-ranged and crowding intermolecular and 
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intercluster interactions, and thus, may be expected to be applicable to a wide variety of 
protein and peptides. 
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Chapter 4:  Dispersions of Antibody Nanoparticles with Low Viscosity 
and High Concentration retain Activity and in vivo Bioavailability 
Monoclonal antibodies continue to command a large market share with numerous 
entities in clinical trials for a variety of therapeutic indications. In many cases, the doses 
required for therapeutic efficacy are large, limiting options for antibody delivery and 
administration. We have developed a novel formulation strategy based on dispersions of 
submicron antibody particles that allows for subcutaneous injection of highly 
concentrated antibody (190 mg/ml). A solution of monoclonal antibody 1B7 was rapidly 
frozen and lyophilized using a novel spiral-wound in situ freezing technology (SWIFT) 
technique to generate amorphous particles. Upon gentle stirring a translucent dispersion 
of protein formed rapidly in buffer containing the pharmaceutically acceptable crowding 
agents, trehalose, polyethylene glycol and n-methyl-2-pyrrolidone. Formulation near the 
antibody isoelectric point minimizes the charge per molecule, such that the attractive 
forces were sufficient to form large particles, specifically clusters composed of protein 
molecules (~200nm diameter), with a low apparent viscosity (~24 cp). Within each 
particle, there are no detectable changes in antibody tertiary structure, as the protein 
native state is stabilized by self-crowding of the protein, limiting unfolding and 
aggregation. Upon in vitro dilution of the dispersion, the particles revert to monomeric 
protein with full activity, as monitored by dynamic light scattering and ELISA. When 
administered to mice as an intravenous solution, subcutaneous solution or subcutaneous 
dispersion at similar doses (4.6-7.3 mg/kg), the distribution and elimination kinetics were 
similar. The dispersion formulation makes ultra-high dosages possible (51.6 mg/kg); this 
also exhibited a similar pharmacokinetic profile. Moreover, analysis of the terminal 
serum samples by in vitro binding and cellular neutralization assays indicates antibody 
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delivered as a subcutaneous dispersion retains full activity over the 14-day study period. 
Overall, this method of generating high concentration, low viscosity dispersions of 
submicron antibody particles is readily generalizable and could lead to improved 
administration and patient compliance, providing new opportunities for the biotechnology 
industry. 
4.1 INTRODUCTION 
Monoclonal antibodies have generated considerable interest as therapeutics 
because they specifically target distinct antigens with favorable pharmacokinetic, 
production, and safety profiles.1, 2 Currently, 28 monoclonal antibodies have received 
FDA-approval for treatment of a wide variety of diseases, commanding an annual market 
size of over $20 billion dollars.3, 4 Despite advances in protein drug development which 
allow tailoring of key biophysical properties, such as solubility5, stability6, and binding 
affinity7 via recombinant DNA techniques, few options have been developed to deliver 
these macromolecules at desired dosages (>2mg antibody/ kg body weight). Typically, 
large volumes of dilute protein solutions are delivered intravenously to avoid the 
chemical and physical destabilization and resulting loss in protein activity associated with 
high concentration formulations.1, 8 For instance, Rituxan doses of 100-500 mg are 
currently administered by intravenous infusion of a 10 mg/ml solution.9 Self-
administered subcutaneous injections offer several major advantages over intravenous 
infusion, including increased accessibility and patient compliance, along with reduced 
pain and cost. However, the required therapeutic dosages would indicate protein 
concentrations in excess of 100 mg/ml, given the maximum subcutaneous injection 
volume of 1.5 ml.10, 11 
 107 
Formulation of therapeutic proteins at these high concentrations is intrinsically 
difficult, demanding solutions customized for each new product. Frequently, formulation 
at high concentrations is not possible due to low protein solubility5, 12, protein 
instability13-15 and high solution viscosity1, 16, 17 resulting from short-range attractive 
protein-protein interactions. These interactions, which include hydrophobic interactions, 
hydrogen bonds and fluctuating charge dipoles17, act over distances up to ~1 nm18. At 
high protein concentrations (over 150 mg/ml), the average separation distance between 
individual antibody molecules is reduced to less than 10 nm.19 Thus, the probability that 
two protein molecules will be less than 1nm apart is high and the effect of the short-range 
attractive interactions between protein molecules becomes significant.19 This leads to the 
concentration-dependent formation of reversible and irreversible aggregates with 
potential adverse effects on protein activity, pharmacokinetics and immunogenicity. Most 
troubling are irreversible aggregates, high molecular weight aggregates comprised of 
monomers with altered native structure and reduced activity, which can result in a turbid 
solution or precipitation. The formation of these aggregates is highly protein specific20 
and can be formed through phsycial mechanisms, via partially unfolded monomers with 
exposed hydrophobic residues21 or through chemical mechanisms, via formation of 
intermolecular bonds mediated by reactive thiols on cysteine or methionine residues22. 
Protein structure and activity in low viscosity formulations can be preserved at 
high protein concentrations by minimizing the effects of these short-range interactions. 
For example, concentrated suspensions of protein microparticles in water-insoluble 
organic solvents23 and aqueous suspensions of protein crystals1 with low viscosity have 
been reported. These formulations succeed by using micron-sized (5-20 μm) particles of 
proteins as opposed to protein monomers, thus increasing the average distance between 
protein particles for a given protein concentration. However, formulations of proteins in 
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organic solvents are not patient-friendly as they require large-bore needles and can result 
in additional side effects such as redness and swelling at the injection site.24 In addition, 
while highly concentrated aqueous suspensions of crystalline insulin have a history of 
clinical use24, it is challenging to routinely crystallize large protein molecules such as 
immunoglobulins due to their high molecular weight, surface oligosaccharides, and high 
degree of segmental flexibility.1, 24, 25 Similarly, controlled release formulations in which 
proteins are encapsulated in polymeric matrices with non-aqueous26 or aqueous media27, 
28 have also been explored. In these cases, the low loadings of protein within the particle 
(~15-20 mass %) result in a low deliverable dose even at high particle volume fractions.29 
Moreover, most polymeric delivery systems suffer from challenges with sterility, protein 
stability, incomplete protein release, and increased immunogenicity.30-32 
Previously, we have reported a novel approach to preserve protein activity at high 
concentrations while achieving a low viscosity, in the form of concentrated dispersions of 
amorphous protein nanoclusters.19, 33 The addition of trehalose as a “crowder” molecule 
occupies a large volume and increases the short-range protein-protein attractive 
interactions.33 Consequently, most of the protein molecules are concentrated into densely 
packed equilibrium nanoclusters.19, 33 The mechanisms of nanocluster formation and 
stabilization were explained in terms of the specific short-ranged attraction, van der 
Waals and depletion attraction balanced against weak electrostatic repulsion. The weak 
electrostatic repulsion was accomplished by, formulation near the protein isoelectric 
point (pI) where the protein was only slightly charged. Simultaneously, the nanoclusters 
do not aggregate, since their large size reduces the impact of the short range attractive 
interactions between nanoclusters. Furthermore, the electrostatic repulsion increases from 
the cumulative effect of hundreds to thousands of slightly charged protein monomers.19 
This hierarchy of attractive and repulsive interactions results in a colloidally stable 
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protein nanocluster dispersion with low viscosity.19 In addition, the high volume fraction 
of the protein within the nanocluster, much higher than is possible with a protein solution, 
maintains the protein native structure due to a self-crowding, entropic stabilizing 
mechanism.34, 35 To date, only a single extrinisic crowder, trehalose, has been reported for 
formation of nanoclusters of a therapeutic protein and the pharmacokinetics of that 
formulation.33 Currently, it is unclear whether a single extrinisic crowder will be 
sufficient to optimize  protein formulations for the desired therapeutic properties for wide 
classes of proteins. A recent study suggests that multicomponent crowder mixtures 
provide further control over nanocluster properties, but only in vitro studies for a single 
polyclonal sheep antibody have been performed.19 
In this study, we demonstrate that a multicomponent mixture of three crowding 
agents can be used to create stable dispersions of highly concentrated, active monoclonal 
antibody particles which retain high activity and bioavailability upon subcutaneous 
administration in mice. Multicomponent crowding agent mixtures provide flexibility in 
formulation in response to specific biochemical characteristics of a particular protein 
such as high protein solubility. Murine IgG2a monoclonal antibody 1B7, which binds and 
neutralizes the pertussis toxin (PTx) associated with whooping cough infection36, 37, was 
selected to demonstrate applicability to a therapeutically relevant molecule. The 
amorphous protein particles were generated via a new freezing method, spiral-wound in-
situ freezing technique (SWIFT). In contrast, previous protein nanocluster studies used 
tray freezing to produce the protein particles.19, 33 As opposed to traditional tray freezing 
lyophilization, the much more rapid SWIFT freezing may offer advantages for achieving 
high  protein stability, as has been shown for spray freeze drying38, spray freezing into 
liquids39, and thin film freezing40. Unlike the other rapid freezing processes, in SWIFT, 
the particles are produced in the actual dosage vial to simplifying processing.40 Next, 
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these particles were gently dispersed in a dispersion buffer comprised of histidine buffer 
adjusted to the approximate 1B7 pI augmented with three pharmaceutically acceptable 
crowding agents, water-soluble organic n-methyl-2-pyrrolidone (NMP), polyethylene 
glycol (PEG), and trehalose to confer low viscosity and limit 1B7 solubility to prevent 
particle dissolution. Under these conditions, the translucent dispersion exhibits a low 
viscosity even at high antibody concentrations (<50 cP at 200 mg/ml), with ~200 nm 1B7 
particles in equilibrium with 2.5-5 mg/ml dissolved 1B7, as measured by DLS. 
Importantly, the protein native structure is preserved, as SDS-PAGE and ELISA analysis 
of diluted dispersions exhibit the same activity as untreated 1B7. 
Last, we performed an in vivo murine pharmacokinetic study to compare the 
bioavailability of three different subcutaneously administered dispersions with traditional 
IV and SQ administration of antibody solutions. To compare the dispersion and solution 
controls at similar dosages, we administered a standard dosage (~5 mg/kg) in a large 100 
μl volume. The 1B7 distribution and elimination half-lives were very similar for these 
three groups, while the time to peak serum concentration (tmax) was delayed for the SQ 
injections, consistent with the expected slower diffusion kinetics from this injection site. 
We then prepared the dispersion at high concentration (200 mg/ml) to compare the 
pharmacokinetics resulting from a small volume (1 μl), standard dose injection and a 
large volume (100 μl), high-dose (52 mg/kg) injection. Again, the pharmacokinetic 
profiles were remarkably similar for all SQ groups, although the small volume injection 
had a slightly shorter tmax, indicating that the more rapid diffusion kinetics of a small 
injection may impact the overall pharmacokinetics, consistent with results for the single 
crowder, trehalose, system33. Remarkably, analysis of terminal serum samples for total 
1B7 protein and specific PTx binding activity by ELISA, as well as an in vitro PTx 
neutralization test, were unable to detect a loss in 1B7 activity or development of anti-
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1B7 immune responses over a 14-day period. The high protein stability during injection, 
residence in the subcutaneous tissue and transport into the bloodstream is shown to be 
consistent with in vitro data previously reported19, 33, whereby folded protein molecules 
rapidly diffuse away from the surface of the equilibrium nanoclusters. The ability to 
achieve high stabilities for the severe test of extremely high dosages may offer new 
opportunities for more modest increases in dosages in subcutaneous injection. 
Dispersions are a promising approach to highly concentrated, low viscosity protein 
formulations that preserve activity and confer favorable pharmacokinetics. Moreover, 
dispersions can achieve dosages at least 10-fold higher than can be attained via solutions 
and can be formulated with a variety of pharmaceutically acceptable agents. 
4.2 MATERIALS AND METHODS 
4.2.1 Antibody expression, purification and biotinylation 
Murine hybridoma cells producing the IgG2a antibody 1B7 were grown in T-
flasks in Hybridoma-SFM serum-free media at 37˚C with 5% CO2 until cell death, as 
reported previously33, 37. Briefly purification of the antibody consisted of centrifugation at 
3000 rpm for 20 minutes, followed by filter sterilization using a 0.45 µm filter, dilution 
1:1 with binding buffer (20 mM pH 7.0 sodium phosphate) and loading with binding 
buffer onto a pre-equilibrated Protein-A column (GE Healthcare). After baseline 
stabilization, 1B7 was eluted into collection tubes containing 1 M Tris pH 8.0 using an 
elution buffer (0.1M glycine pH 2.7). Protein concentration was measured with micro-
bicinchonoinic acid (BCA) assay (Pierce, Rockford, IL), while non-reducing SDS-PAGE 
verified protein preparation homogeneity and purity. Purified 1B7 was labeled with biotin 
using EZ-link® Sulfo-NHS-LC-Biotin (Pierce, Rockford, IL). A 5 mM solution of the 
biotin reagent was added at a 5:1 molar ratio to a 1 mg/ml solution of the 1B7 in PBS at 
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room temperature and allowed to react for 30 minutes. Excess biotin was removed by 
buffer exchange using 50,000 MWCO Centricon concentrators with PBS. 
4.2.2 Particle formation by spiral wound in-situ freezing technology (SWIFT) 
Purified and biotinylated 1B7 was buffer exchanged into 20mM pH 5.5 histidine 
buffer using Centricons, as above. The protein concentration was measured again, solid 
α-α trehalose was added to a 1:1 wt ratio as a cryoprotectant and gently mixed to 
dissolve. The resulting solution was filter sterilized (0.22 µm), diluted to 20 mg/ml 
protein and transferred to a sterile 8ml (1.9 cm x 4.8 cm) glass vial for SWIFT freezing. 
During SWIFT, the base of the vial was contacted with liquid nitrogen while rotating the 
vial on its side (~1 revolution/second), resulting in a thin film of frozen solution on the 
inside edge of the vial, with subsequent thin films freezing in a spiral towards the center 
of the vial (Figure 4.1A). After the entire volume was frozen (~10-40 seconds), the 
samples were placed upright on a pre-cooled lyophilizer shelf at -40⁰C. The samples were 
then lyophilized for 12 hours at -40°C at 100mTorr, followed by a 6 hour ramp to 25°C at 
50 mTorr, and maintained for secondary drying at 25°C at 50 mTorr for at least an 
additional 6 hours. To assess protein activity after freezing, powder was reconstituted at 5 
mg/ml in PBS for analysis by dynamic light scattering (DLS) and enzyme-linked 
immunosorbent assay (ELISA) as described below. Samples of the dry powders after 
lyophilization for scanning electron microscopy (SEM) analysis were placed on adhesive 
carbon tape to fix the sample to the SEM stub. Each sample for SEM was platinum-
palladium sputter coated using a Cressington 208 bench top sputter coater to a thickness 
of 10nm. Micrographs were taken using a Zeiss Supra 40 VP scanning electron 
microscope with an accelerating voltage of 5 kV.  Further characterization of particles 





Figure 4.1 Schematic of SWIFT freezing process and dry powder SEM. A) The unfrozen 
protein solution in a cylindrical vial is placed on its side and rolled while 
exposed to liquid nitrogen. This causes a thin film of the protein solution to 
freeze on the inside edge of the vial followed by subsequent films towards 
the center of the vial resulting in a frozen annulus of protein solution which 
is placed in the lyophilizer to remove water. B) Morphology of SWIFT 





4.2.3 Dispersion formation 
To form the dispersion, SWIFT frozen and lyophilized 1B7 protein powder was 
compacted into 0.1ml conical vials (Wheaton Science Products No. 986211) such that the 
total powder weight was 0.04 ± 0.001g. An aqueous-based solvent dispersion buffer, 
containing 10% (v/v) PEG300 and 20% (v/v) n-methyl-2-pyrrolidone (NMP) in a 50mM 
phosphate buffer with the pH adjusted to match the measured antibody pI (pH 7.2, see 
Figure S1), was added to the lyophilized protein. Gentle stirring with the tip of a needle 
removed air pockets, to yield a uniform, optically clear dispersion with a final 1B7 
concentration of 160-200 mg/ml. Neither sonication nor violent mixing was necessary to 
form a uniform translucent dispersion. 
4.2.4 Viscosity measurement 
The apparent viscosity of the 1B7 dispersion was measured as the time to draw 50 
μl of the dispersion into a 25 gauge 1.5” long needle attached to a 1ml tuberculin slip tip 
syringe, as reported previously for sheep IgG dispersions19. Briefly, videos of the conical 
vial containing the dispersion were taken and the time to draw from a height 0.4” from 
the bottom of the cone to a height 0.1” from the bottom of the cone was measured using 
Image J software. A standard curve using known solutions with various viscosities 
provided a linear correlation between the time to draw 0.05 ml from the conical vial to 
the viscosity with an r2 value greater than 0.9919. These results are consistent with 
previous work with suspensions of model proteins and protein solutions which found that 
the time to draw up a specified amount of the sample in a syringe was correlated linearly 
to viscosity.16, 19, 23 
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4.2.5 Colloidal size determination/characterization 
Dynamic light scattering (DLS) was used to measure the sizes of particles present 
in the purified 1B7 preparation, concentrated 1B7 dispersion and dilutions of the 
dispersion using a custom-built DLS apparatus41 modified to include backscattering 
angles up to 165⁰19, 33. Particle sizes in the concentrated dispersion were measured with a 
small volume cell (60 μl, Beckman Coulter #A54094) at ~23⁰C and a 160⁰ scattering 
angle, while all other measurements were made in a standard 1 ml cell at ~23⁰C and 
scattering angles optimized to detect the relevant particle size. To estimate the solubility 
of 1B7 in the dispersion buffer, the 200 mg/ml dispersion was diluted 1:40, 1:80 and 
1:160 in dispersion buffer and particle sizes measured at a 90⁰ scattering angle. We 
define the concentration of 1B7 at which the protein monomer peak is observed by DLS 
as the solubility.19 To mimic the effects of dilution on particle size and detect formation 
of aggregates, the dispersion was diluted 1:40 in PBS to give a final 5 mg/ml 1B7 
concentration and the resulting particle sizes measured at a scattering angle of 30⁰. The 
size of purified 1B7 monomeric antibody in PBS was measured at 5 mg/ml and a 
scattering angle of 30°.  
4.2.6 In vitro antibody activity and aggregation assays 
The 1B7 tertiary structure within the dispersed particles was assessed by intrinsic 
tryptophan fluorescence, as the emission maximum shifts based on the local environment 
of the tryptophan side chain.42 A SpectraMax M5 spectrophotometer (Molecular Devices) 
was used to fluoresce protein samples at a wavelength of 295nm, with the emission 
spectrum recorded at 1nm increments between 310-380nm. For 1B7, a shift in the 
emission maximum is observed from 342 nm for folded protein to 350 nm for fully 
unfolded protein. This approach was used to qualitatively look for evidence of an altered 
tertiary protein structure of the protein dispersed in 200nm particles at 200 mg/ml.43 
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All subsequent assays of protein activity and structural stability were conducted 
on 1B7 dispersion diluted to 1 mg/ml in PBS. Controls included lyophilized 1B7 
(reconstituted in PBS at 1 mg/ml) and purified 1B7 with no further processing (1 mg/ml 
in PBS). First, the formation of insoluble and di-sulfide linked aggregates was monitored 
by non-reducing SDS-PAGE. Briefly, 3 μg 1B7 sample was combined with loading 
buffer and separated on a 4-20% precast linear gradient polyacrylamide gel (Bio-Rad) 
and stained with Gel-Code Blue (Bio-Rad). 
To monitor ligand-binding activity, an indirect PTx ELISA was employed as 
reported previously.33, 37 High-binding ELISA plates (Costar) were coated with 50 μl 
pertussis toxin (PTx, List Biological Laboratories) at 0.75 μg/ml in PBS and incubated at 
4⁰C overnight. Wells were blocked with assay buffer (PBS-1% milk) for 1hr, prior to 
addition of 1B7 samples in a √10 serial dilution scheme from 50 μg/ml in assay buffer. 
After one hour incubation at room temperature and triplicate washes with PBS-0.05% 
Tween 20, 50 μl goat anti-mouse IgG-horseradish peroxidase conjugate (1:2000 dilution 
in assay buffer, Sigma) was incubated for one hour at room temperature. Plates were 
washed in triplicate and signal developed with tetramethylbenzidine dihydrochloride 
(TMB) substrate (Pierce), quenched with 1N HCl and the resulting absorbance at 450 nm 
recorded using a SpectraMax M5 instrument. The EC50 value was calculated from the 
linear range of the dose-response curve as the antibody concentration corresponding to 
50% of the maximum absorbance (Eq. 4.1). 
  Eq. 4.1 
For comparison between samples, the relative EC50 was calculated as the ratio of the 
sample EC50 to unprocessed control antibody EC50. All samples were run in triplicate. 
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4.2.7 In vivo bioavailability in BALB/c mice 
An in vivo pharmacokinetic study of the 1B7 dispersion and control solution was 
performed over a 14 day period using four to six healthy 24-27g, female BALB/c mice 
per group. Mice were administered a single 1 or 100 μl subcutaneous (SQ) injection of 
1B7 at low (4.6-7.3 mg 1B7/kg body weight) or high (51.6 mg/kg) doses. The five 
sample groups compared in this study included two groups (1) IV and (2) SQ injections 
of 100 µl of a 1B7 solution (1.4 mg/ml solution for a final 5.6 mg/kg dose) reported 
previously33, as well as (3,4) SQ injections of 100 µl antibody dispersion at low (4.6 
mg/kg) and high (51.6 mg/kg) doses; and (5) SQ injection of 1 µl at a low (7.3 mg/kg) 
dose of the antibody dispersion in the dispersion buffer. The previously reported solution 
samples (groups 1 and 2) were prepared from a 20 mg/ml 1B7 solution in PBS diluted to 
1.4 mg/ml in PBS33 while the dispersion samples were diluted in the dispersion buffer 
from a 200 mg/ml 1B7 dispersion to a concentration of 1.2 mg/ml for group 3, 12.9 
mg/ml for group 4, and 182 mg/ml for group 5 immediately prior to injection. 
Prior to the injection and at eight additional timepoints between 12 and 336 hours, 
mice were weighed and a blood sample (~20 μl) collected from the tail vein. After 
collection, the samples were allowed to clot, centrifuged at 5000rpm for 10 minutes and 
serum transferred to a new tube. At the terminal timepoint (336 hours), mice were 
anaesthetized and between 0.2 and 1 ml serum collected by cardiac puncture. These 
samples were used in ELISA assays, to measure the total and active concentrations of 
1B7 in the serum and, for the terminal time point, to measure antibody activity via an in 
vitro neutralization assays and to provide an initial estimate of mouse anti-1B7 responses. 
This study was performed with approval by the Institutional Animal Care and Use 
Committee at the University of Texas at Austin (protocol #AUP-2010-00070) in 
compliance of guidelines from the Office of Laboratory Animal Welfare. 
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4.2.8 Measurement of 1B7 in serum samples 
To determine the concentration of active 1B7 in serum samples, a standard 
ELISA approach was used with the following modifications as previously reported33, 44. 
ELISA plates were coated with PTx at 1.5 μg/ml in PBS. The assay buffer used as diluent 
in all steps consists of 4% bovine serum albumin, 4% fetal bovine serum (FBS), 0.05% 
Tween 20, in PBS, pH 7.4. After blocking with assay buffer, 2.3 μl serum sample was 
serially 1:√10 diluted in 50 μl per well assay buffer. Each plate included mouse serum 
(Sigma) as a negative control and a 1B7 standard curve diluted to an initial concentration 
of 100 μg/ml in mouse serum. Additional samples were analyzed for total protein 
detected using a streptavidin coating on the ELISA plates to detect the biotinylated 1B7 
(results not shown). 
After measurement of the resulting absorbances, SoftMax Pro v5 was used to 
calculate EC50 values based on the serum dilution using a 4 parameter logistic (4PL) 
model for each individual curve. Concentrations of active 1B7 in each serum sample 
were calculated from a linear correlation between the log [(sample EC50)/ (standard 
EC50)] versus the log of the known 1B7 concentration in the standard curve. A linear 
correlation with a fit > 0.95 from at least 5 independent standard curves was determined 
(Figure A1.3.2). 
4.2.9 Measurement of active antibody by CHO cell neutralization assay 
As an orthogonal activity measurement to determine the concentration of serum 
1B7 able to neutralize PTx activity in vitro, we employed a CHO cell neutralization assay 
modified from Gillenius et al.37, 45 The concentration of neutralizing antibody was 
measured as the sera dilution that completely inhibited PTx-induced CHO cell clustering 
relative to a standard curve of purified 1B7 with known concentration. Briefly, 50 μl of 
1.5 ng/ml pertussis in Dulbecco’s Modified Eagle Medium (DMEM) with 10% FBS was 
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added directly to each well of a sterile 96 well tissue culture plate. Terminal serum 
samples (2.3 μl) were serially diluted using a 1:√10 dilution scheme to maintain a 
constant PTx concentration. After incubation for 30 minutes at 37⁰C and 5% carbon 
dioxide, 100 μl / well of freshly trypsinized CHO cells at 105cells/ ml were seeded in 
each well. After 24 h of incubation at 37⁰C and 5% CO2, wells were scored for CHO 
clustering using 0-3 scale, with 0 as elongated (non-clustered) and 3 as completely 
clustered. 
4.3 RESULTS AND DISCUSSION 
Here, we report formation of highly concentrated, low viscosity dispersions of 
antibody nanoclusters, in which the antibody retains native structure and binding activity 
upon dilution and in vivo subcutaneous administration. In contrast to our prior work, we 
used a novel freezing technique to form particles and multiple crowding agents to tune 
particle size. The combination of these innovations allowed us to administer 
subcutaneous antibody dispersions to mice at typical therapeutic doses (5-7 mg/kg) as 
well as an ultra-high dose, more than 10-fold higher than current practice (51.6 mg/kg). 
4.3.1 Stable protein particles made by SWIFT freezing 
The first step in preparation of concentrated aqueous dispersions is the formation 
of a dried powder of protein particles. The choice of freezing method is critical to both 
protect antibody structure and activity during freezing as well as to produce particles of 
the appropriate size and morphology to yield a colloidally stable dispersion. To address 
these concerns, we developed a novel freezing technique, SWIFT, which rapidly freezes 
an antibody solution directly in the final packaging vial prior to lyophilization (see Figure 
4.1A). The rationale in developing this technique is that two major sources of protein 
denaturation during freezing are exposure to liquid-gas interfaces during spray-freeze 
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drying and the slow rate of freezing in larger volumes which can result in freeze 
concentration and subsequent concentration-dependent aggregation.38, 39, 46, 47 By rotating 
the vial of protein solution while in contact with liquid nitrogen, each concentric layer 
freezes in less than a second. The remaining liquid is gently mixed due to rotation, 
normalizing any concentration gradients. 
We used SWIFT followed by lyophilization to form submicron particles of the 
1B7 antibody used in the dispersions. To prevent protein aggregation during freezing, the 
protein solution was adjusted to contain a 1:1 weight ratio of trehalose as a 
cryoprotectant.48 The buffer selected, 20 mM histidine pH 5.5, is commonly used during 
lyophilization steps and will not crystallize resulting in large pH variations.49 SEM 
analysis of the frozen and lyophilized 1B7 clearly indicates the presence of submicron 
particles, similar to the size desired in the final dispersion (Figure 4.1B). Importantly, 
antibody processed in this manner retains native conformation and activity upon 
reconstitution with PBS at 5 mg/ml.  At this concentration, DLS detected a single species 
with a ~10nm hydrodynamic diameter, as expected for an antibody monomer50 (Figure 
4.2A). The absence of larger particles indicates that the antibody did not form irreversible 
aggregates during SWIFT and lyophilization. In addition, an ELISA to monitor the 
specific PTx-binding activity of the reconstituted antibody revealed no significant change 
in activity due to these processing steps versus the untreated control (Figure 4.3A). 
The SWIFT process was designed to produce particles of the desired morphology 
while protecting protein structure and activity. This is achieved via rapid freezing with 
minimal liquid-air interface, goals inspired by related process, thin film freezing (TFF)39, 
40. In SWIFT, each film layer, corresponding to a single vial revolution, is ~200nm thick 
(see Appendix B). Indirect contact with liquid nitrogen as a heat sink confers cooling 
rates of ~102 K/s. In TFF, a small volume of protein solution is deposited on a  
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Figure 4.2 Size distribution of antibody particles. A) Comparison of unprocessed, 
lyophilized and dispersed 1B7 by DLS. All samples were diluted to 5 mg/ml 
in PBS. B) Effect of antibody concentration on particle size in dispersion 
buffer. At high concentration (200 mg/ml) in dispersion buffer, dynamic 
light scattering (DLS) detects only large particles of ~200 nm. Upon dilution 
below the solubility limit in the dispersion buffer, concentrations of 2.5 and 





Figure 4.3 Characterization of antibody recovered from dispersion. A) Comparison of 
unprocessed, lyophilized and dispersed 1B7 by PTx ELISA to monitor 
antibody activity. B) SDS-PAGE gel comparing unprocessed, purified 
mAb1B7 (lane 1) and dispersion diluted from 200 to 1 mg/ml in PBS (lane 
2). 
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cryogenically cooled surface, where it spreads to ~210 nm thickness, freezing within a 
single second40. Scaling-up to compare freezing times for equal volumes, TFF freezes at 
a rate of ~5.1 seconds per ml of protein solution, while SWIFT results in a similar rate, 
~7.5 seconds/ml (Appendix B.1.3). 
As a result of the similarities in freezing rates and film thicknesses, TFF and 
SWIFT processing of similar protein solutions yields dry particles with similar 
morphologies (Figure 4.1B).40 As with TFF, the rapid cooling and freeing rates generate 
high supersaturation, thus a large number of ice nuclei and the formation of many thin 
liquid channels between the frozen water domains, containing the remaining unfrozen 
solution. The rapid vitrification of the thin liquid channels then decreases the number of 
collisions between protein and sugar particles thus inhibiting growth by coagulation of 
particles relative to traditional tray freezing lyophilization, which contains much larger 
liquid channels.40 In addition, as the concentrations of the protein and sugar are increased 
in the unfrozen liquid, the rapid increase in viscosity will further reduce the mobility of 
the growing particle nuclei. Thus smaller submicron protein particles, as shown in Figure 
4.1B, are formed during SWIFT freezing versus standard tray freezing lyophilization. 
With both SWIFT and traditional tray lyophilization, low levels of protein 
denaturation and aggregation are achieved by kinetic and thermodynamic stabilization of 
the native protein structure during freezing and lyophilization. The native protein state is 
stabilized during lyophilization by kinetically trapping protein molecules in an 
amorphous solid48, 51, 52, thereby reducing protein mobility which can lead to aggregation. 
Addition of the lyoprotectant trehalose during lyophilization further thermodynamically 
stabilizes the protein native state during freezing by entropically favoring the native 
folded state51-53 and during dehydration by forming hydrogen bonds with proteins.54, 55 
However, processes to form submicron protein particles such as spray freeze drying 
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(SFD), have been shown to increase  protein aggregation versus standard tray freezing 
lyophilization due to the large gas-liquid interface in the spraying step.38, 56 The large 
area/volume of the gas-liquid interface of ~6000 cm-1  in SFD for 10 µm sprayed droplets 
can lead to protein adsorption at the interface, denaturation and aggregation.38, 40, 48, 57, 58 
In the case of SWIFT, the gas-liquid interface is minimized as the only exposure of the 
liquid protein solution to the air is the liquid interface inside the glass vial. As a result, 
the estimated gas-liquid interface decreases 3 orders of magnitude when compared to 
SFD to ~4 cm-1. Thus the 1B7 was anticipated and found to remain stable upon 
reconstitution to monomer from the dry powder form after SWIFT freezing and 
lyophilization. 
One practical advantage of SWIFT freezing is the ability to freeze directly in the 
final dosage vial when compared to other rapid freezing techniques such as TFF and 
SFD.40, 46, 47 This approach avoids the need for costly, solid transfer steps while 
maintaining aseptic conditions. In this case, if a dosage of 80 mg of the protein is 
required at a concentration of 20 mg/ml, the 8 ml vial used in the study can serve as both 
the freezing and reconstitution vial. However, since the cooling rate SWIFT freezing is 
governed by the liquid cryogen used and the thickness of the glass vial, as well as the 
heat transfer coefficients of the materials used, the vial can be readily scaled-up or down 
to meet dosage requirements. In addition, by removing the transfer step to the final vial, 
all of the protein can be recovered after lyophilization and utilized in the formation of the 
final dosage. 
4.3.2 Colloidal characterization of 1B7 particles in dispersion 
To form the colloidally stable, translucent dispersion, the dry, sub-micron 
particles of antibody and trehalose produced via SWIFT were combined with a specially 
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formulated dispersion buffer.  To reduce protein solubility, this includes a 50 mM 
phosphate buffer adjusted to the antibody pI (pH 7.2) and two additional crowding 
agents: 20% n-methyl-2-pyrrolidone (NMP) and 10% polyethylene glycol 300 (PEG300) 
by volume. After combining the SWIFT particles and dispersion buffer, the trehalose 
contained in the dry powder will dissolve. A fraction of the trehalose will diffuse into the 
solution, increasing the volume fraction of crowding agents as observed previously for 
sheep IgG19. Sufficient dispersion buffer was added to the dry powder to yield a final 
antibody concentration of 190 mg/ml with a final volume fraction (φ) of crowding agents 
of 0.34. 
Under these conditions, DLS analysis of the dispersion using a low volume 
(60μL) cell identifies a single population of particles with a ~200 ± 14 nm diameter. This 
colloid size was reproduced in three separate experiments, measured each time in 
triplicate, with a representative curve shown in Figure 2B. This particle size was further 
confirmed by SEM images of the dispersion after dilution to 100 mg/ml in the dispersion 
buffer, rapid freezing and lyophilization onto an SEM stage (Figure 4.4B). This image 
shows nanoparticles of a size consistent with DLS measurements, but a different shape 
due to coating with crystallized trehalose. Previously, SEM and STEM images of 
dispersed sheep IgG and 1B7 particles at lower trehalose concentrations, visualized the 
dispersed particles as clusters of smaller particles19. We were able to obtain similar 
images for the current formulation after adding dispersion buffer to reduce the trehalose 
concentration, simultaneously reducing the 1B7 concentration to 40 mg/ml (Figure 4.4C). 
To confirm that these results are not affected by dissolution of the 1B7 nanoparticles, we 
measured the 1B7 solubility in dispersion buffer, using methods reported previously.19 
Starting with the 200 mg/ml dispersion, we progressively added dispersion buffer to 
reduce the protein concentration and measured the resulting particle sizes by DLS (Figure  
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Figure 4.4 Visual appearance of dispersion. A) Digital image of suspended particles B) 
SEM image of the 1B7 dispersion (200 mg/ml) when diluted to 100 mg/ml 
in the dispersion buffer, rapidly frozen with the water removed by 
lyophilization and C) Highly magnified SEM image of a 1B7 particle 








4.2B). We observed a single peak at ~200 nm until the protein concentration was reduced 
to 2.5 mg/ml or less. At this concentration, only a single ~10nm peak at is present, 
corresponding to the hydrodynamic diameter of a single monoclonal antibody molecule59-
61 From these data, we conclude that the solubility of 1B7 this dispersion buffer is ~2.5 
mg/ml and that 1B7 nanoparticles formed with trehalose, PEG and NMP are fully 
reversible. 
The dispersed particles were formed and exhibited colloidal stability due to a 
balancing of the intermolecular attractive and repulsive interactions at the protein 
molecular and colloidal levels, respectively.19 Briefly, individual protein molecules are 
subject to highly attractive depletion and specific short-ranged interactions such as 
hydrophobic interactions, hydrogen bonding and charge-dipole interactions62, 63 resulting 
in low protein solubility.19 Near the 1B7 pI, electrostatic repulsion is relatively weak and 
thus the attraction force dominates between individual protein molecules. However, once 
these molecules assemble into nanoclusters, the interactions between particles are slightly 
repulsive, stabilizing the dominant size.19 Each protein monomer on the cluster surface 
will have a small number of charges, thus the repulsive interactions become significant 
when summed over all the monomers19. Attractive specific and short-range depletion-
attraction interactions between clusters are minimized as the average distance between 
clusters increases as the colloid size increases, but the distance over which these forces 
act is fixed. To exert the same force, an interaction with a range of 1 nm on a 10nm 
protein monomer would need to act over 20 nm on a 200 colloid. Between clusters, short-
range attractive interactions are negligible relative to electrostatic repulsion resulting in a 
colloidally-stable dispersion of protein nanoclusters, as has been previously shown for 
sheep IgG.19 
 128 
To formulate a stable antibody dispersion and balance repulsive forces, the 
depletion attraction forces can be fine-tuned by varying the concentrations of the 
crowding agents.19, 64, 65 As observed here and previously19, an increase in crowder 
concentrations dramatically reduces 1B7 solubility due to depletion-attraction 
interactions. While 1B7 and the sheep IgG dispersions could both be formulated with a 
single crowding agent, trehalose, the ternary crowder system used here may provide 
additional flexibility to tune solubility and formulate dispersions with highly soluble 
proteins or to further control the nanocluster size, protein stability, dispersion viscosity 
and nanocluster degradation during delivery. 
The low apparent viscosity, 24 cP, of the ~190 mg/ml 1B7 dispersion was 
measured as the viscosity through a 25 gauge 1.5 inch needle (Table 4.1). This viscosity 
measurement was previously characterized for subcutaneous injections of highly 
concentrated solutions of monoclonal antibodies16 and non-aqueous suspensions of 
lyosyzme23. The apparent dispersion viscosity is commonly described as a function of the 
intrinsic viscosity, [η], maximum volume fraction of particles, φmax, and the solvent 
























 Eq. 4.2 
The η may be reduced by lowering η0, or [η], which has a minimum of 2.5 for hard sphere 
colloids, and increasing φmax. For protein molecules in solution at high concentrations, for 
example φ = 0.1 to 0.3, strong short-range specific attractive interactions63, 67, often 
produce viscosities 5 to 100 times the hard sphere value.16, 68 For monoclonal antibody 
solutions with concentrations of 150 mg/mL, viscosities greater than 100cP have been 
attributed to reversible self-association of protein molecules, on the basis of 
measurements by analytical ultracentrifugation.16, 69 In contrast, the low viscosities  
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Table 4.1 Biophysical characterization of 1B7 dispersions  
*Maximum emission wavelength (λmax) of protein within the nanocluster excited at 
295nm. Native, fully folded protein had a maximum emission wavelength of 






















190 ± 20 >2.5 196 ± 14 24 ± 7 1.50 ± 
0.32 
340 ± 2 
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observed in the present study for the nanocluster dispersions may be consistent with the 
weak interactions between the nanoclusters, as suggested previously19. 
 In addition to specific attractive interactions, shape effects can also increase the 
intrinsic viscosity of a protein molecule when compared to the relatively spherical protein 
nanoclusters in the dispersion. The molecular shape factor proportionally increases the 
intrinsic viscosity66 and is a function of the aspect ratio of the molecule.66, 70, 71 At its 
minimum, spherical particles do not increase the intrinsic viscosity over the expected 
value.66, 70 In the case of protein solutions, the shape of the molecule in solution is 
dependent on the protein itself.70, 71 However, for the nanocluster dispersion in the current 
study, surface tension forces will favor a relatively favorable spherical shape. 
4.3.3 In vitro molecular stability of 1B7 in dispersion 
The conformation of antibody contained within the dispersion and after dilution 
was assessed using multiple techniques. Tryptophan fluorescence assay, As reported 
previously for sheep IgG19, no change in the maximum emission wavelength solvent 
exposed tryptophans was observed, measured by a tryptophan fluorescence assay, 
suggesting preservation of the active protein structure within the dispersed particles. 
After 10-fold dilution from the 200 mg/ml dispersion into PBS, DLS measured a single 
species with a ~10nm hydrodynamic diameter, as expected for a single antibody 
monomer50 (Figure 4.2A). As with the 1B7 reconstituted from the SWIFT frozen and 
lyophilized powder, a lack of larger particles suggests that the antibody does not form 
irreversible aggregates upon dispersion and can recover its individual monomer size upon 
rapid dilution. This is further confirmed by non-reducing SDS-PAGE (Figure 4.3B), in 
which a single band is observed, with a molecular weight corresponding to that of an 
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antibody monomer, ~150 kDa72, indicating an absence of irreversible thiol-linked and 
SDS-resistant aggregates. Finally, an ELISA to monitor the specific PTx-binding activity 
of the antibody reveals no significant change in activity due to the formation or dilution 
of the dispersion versus untreated control (Figure 4.3A). 
To maintain therapeutic efficacy  without inducing an adverse immunogenic 
response upon in vivo injection71, 73, the conformational stability of the antibody must be 
maintained through every processing and delivery step: from creation of the dry, 
lyophilized powder to dispersing of the powder in the dispersion buffer. While instability 
of protein molecules includes both chemical degradation as well as physical denaturation, 
the higher order dependence on protein concentration of physical denaturation is 
expected to be a more severe challenge for the successful development of stable high 
protein concentration formulations and thus is examined in further detail.10, 71 As 
discussed above, the protein powder formed by SWIFT freezing and lyophilization did 
not lose activity or develop aggregates after reconstitution in buffer. Stability of the 
protein within the dispersed particles is maintained due to the high volume fraction of 
protein within each particle. A high protein volume fraction allows protein self-crowding 
effects to result in the thermodynamic favoring of the natively-folded lowest surface area 
conformation of the protein.19, 34, 35 This anticipated result is shown by the tryptophan 
fluorescence assay where no additional solvent exposed tryptophan residues are observed 
when the protein is dispersed. The concept of self-crowding to increase the fraction of 
natively folded proteins is similar to the idea that within cells proteins are stabilized by a 
high concentration of molecular crowding agents.74, 75 In the case of self-crowding, the 
only difference is that the protein acts as its own molecular crowding agent.34, 35 As a 
result when compared to a solid protein crystal, the difference between the amorphous 
protein particles formed in this case and crystalline protein particles does not lead to a 
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reduction in the stability of the native conformation of the protein, as expected by Yang 
and coworkers1. The entropic stabilization of the native protein state from self-crowding 
has been shown previously in theoretical arguments34, 35, however, as protein solutions 
cannot achieve the high (>0.15) volume fractions necessary, it has only been realized 
recently for protein dispersions19, 33. In addition, unfolding and aggregation of the protein 
molecules in the dispersion are also reduced by decreased protein mobility of the solid 
state versus the solution state.8, 76, 77 Kinetically, the protein molecules on the outside of 
the particles in the dispersion are also stabilized by the reduction in collisions which 
could lead to the formation of aggregates.13, 19, 78 
The retention of active protein and lack of detectable aggregates of the protein 
upon dilution from the concentrated dispersion is an important indication of potential in 
vivo protein stability. The predicted dissolution time in PBS using the Noyes-Whitney 
equation for high surface/volume 200nm particles with a solubility of greater than 50 
mg/ml is less than 1 second. In a previous study, a misfolded protein refolded during the 
slow dissolution process.79 In the present study, the protein starts out in the folded state 
and has little time to unfold during the rapid dissolution. In addition, the molecular 
crowders present in the dispersion formulation will also be present simultaneously in the 
boundary layer surrounding the protein particles and help preserve the folded state.80 For 
1B7, high protein stability was observed upon diluting the protein at a constant crowder 
concentration by DLS and ELISA measurements, consistent with this rapid 
dissolution/crowding mechanism.33 The fact that the clusters are natively-folded and 
reversible is highly beneficial for maintaining protein stability during dissolution of the 
clusters. With sheep IgG, at a constant protein concentration, a steady decrease in 
nanoparticle size was achieved upon diluting a single low molecular weight crowder, 
trehalose, to weaken the attractive forces.19 At each step the protein in the cluster was 
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found to be folded and full activity of the protein upon dissolution of the cluster was 
confirmed by ELISA.19 The protein molecules on the cluster surface are crowded by 
interior protein molecules and on the exterior by sugar molecules. As the folded 
molecules rapidly diffuse off the cluster surface into the PBS media, they remain folded 
as shown by the DLS and ELISA experiments. 
4.3.4 In vivo bioavailability of stable 1B7 from dispersions 
No reliable in vitro models exist to mimic in vivo dissolution of the rapidly 
dissolving (<1 second predicted dissolution time) dispersion after subcutaneous injection. 
Thus, we proceeded to a mouse model to measure the pharmacokinetic parameters as 
well as the specific activity of in vivo dissolved antibody material. The five treatment 
groups included three control groups to allow direct PK comparison, a low volume, high 
concentration and large volume, high concentration dispersion test groups.  The control 
groups received a standard antibody dose (4.6-5.6 mg/kg delivered in 100 μl) to allow for 
a direct comparison of pharmacokinetics resulting from a subcutaneous dispersion 
injection and intravenous and subcutaneous delivery of an antibody solution. In order to 
deliver the same total amount of antibody in the same volume, the dispersion preparation 
was diluted in dispersion buffer to 1.4 mg/ml, a concentration readily achieved with 
antibody solution controls33. The fourth group was designed to assess the combined 
effects of dispersion concentration and delivered volume on in vivo dissolution rates and 
the resulting pharmacokinetics. These mice received a standard dose (7.3 mg/kg) 
administered as a high concentration dispersion (182 mg/ml) in a small 1 μl volume. The 
fifth group was designed to administer an ultra-high dose, which can only be achieved 
with high concentration, low viscosity formulations such as dispersions.  These mice 
received a ten-fold higher dose than the other groups (51.6 mg/kg in 100 μl). For all 
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groups, serum samples were collected from the tail vein over 14 days, with the 
concentrations of total and active 1B7 antibody in each sample measured by streptavidin 
and PTx capture ELISAs, respectively. The efficacy of antibody present at the terminal 
time point was also assessed using an in vitro activity assay, based on antibody-mediated 
inhibition of toxin activity. 
Overall, the 1B7 pharmacokinetic profile is quite similar for all groups, with 
nearly identical distribution and elimination kinetics. The primary differences result from 
the injection site and injection volume, affecting the time to reach the maximum 
concentration (tmax) and the value of the maximum concentration (Cmax/ dose). 
Looking first at the three control groups, delivery via subcutaneous dispersion resulted in 
a reduced burst phase (lower Cmax/dose and delayed tmax) as compared to IV and SQ 
delivery of solutions (Table 4.2; Figure 4.5A). The IV solution group reached a 
maximum serum concentration at the first measured time point (12 hours), followed by a 
rapid decrease as the antibody is distributed throughout the tissues.33 In comparison, the 
SQ solution group displayed a slightly reduced Cmax/dose (24 versus 18 ug/ml/ mg/kg) 
and statistically significant delayed tmax (12 versus 21 hrs; p<0.05). While IV-
administered material is instantly diluted in the blood volume, material administered SQ 
must diffuse from the injection site through interstitial fluid to reach the lymphatic and 
blood vessels before distribution in the blood volume, delaying these PK parameters 
(Figure 4.4A).33, 81 The SQ dispersion injections exhibit similar trends as the SQ solution 
but with a lower Cmax and delayed tmax when compared to the SQ solution. This may 
reflect the effects of the dispersion buffer on mixing and antibody diffusion, as the effect 
is minimized with SQ dispersion 2, which was injected as a 1 ul volume instead of a 100 






Figure 4.5 Serum concentrations of mAb after delivery. A) Comparison of mAb1B7 
delivered via 100 μl injection of an IV solution (5.6 mg/kg dose), 
subcutaneous solution (5.6 mg/kg), subcutaneous dispersion (4.6 mg/kg) or 
dispersion buffer only SQ control (0 mg/kg). B) Comparison of mAb1B7 
pharmacokinetics when delivered via subcutaneous dispersion with varying 
concentrations and injection volumes. SQ dispersion 1 is 4.6 mg/kg dose 
with a 100 µl injection volume, SQ dispersion 2 is 7.3 mg/kg dose with a 1 
µl injection volume, and SQ dispersion 3 is a 51.6 mg/kg dose with 100 µl 
injection volume. 
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Table 4.2 Pharmacokinetic parameters for mAb 1B7 formulations. 














t1/2,α (hours)  t1/2,β (hours)  In vitro 
neutralization 
titer 
IV solution  6 100 5.6 24 ± 4 2070 ± 360 12 ± 0 46± 23 227 ± 25 500 
SQ solution  4 100 5.6 18 ± 4 1630 ± 200 21 ± 6 43 ± 17 * 210 ± 17 400 
SQ dispersion 1 5 100 4.6 8.7 ± 3.0 925 ± 260 29 ± 11 54 ± 21 * 219 ± 25 400 
SQ dispersion 2 5 1 7.3 7.1 ± 1.2 1174 ± 470 22 ± 5 49 ± 29* 180± 16 ND 
SQ dispersion 3 6 100 51.6 7.3 ± 2.6 757 ± 290 30 ± 15 51 ± 23 * 250± 24 5900 
ND- not determined 





Once the maximum serum concentration is attained, all groups show similar 1B7 
pharmacokinetics. As seen in Figure 5, these data fit a biphasic exponential profile, with 
α distribution and β elimination time constants that are within experimental error for all 
groups, based on 1B7 concentrations measured by the PTx ELISA (Table 4.2). The β 
elimination half-life was also within error for all groups when measured using a total 
protein ELISA assay (results not shown). The distribution phase represents passive 
antibody diffusion from the well-mixed blood volume into other tissues, driven by the 
1B7 concentration gradient and the elevated vascular pressure, while antibody 
elimination rates are controlled by interactions with specific receptors such as the FcRn. 
Notably, both mechanisms require a monomeric, properly folded antibody molecule. A 
soluble aggregate will have a larger size and consequently larger diffusion constant and 
slower t1/2α, while a misfolded monomer or soluble aggregate will exhibit different 
binding kinetics for the FcRn and a different t1/2β. The similar kinetics observed for all 
groups indicate that the antibody delivered as a SQ dispersion is able to dissociate from 
the nanocluster and diffuse away from the injection site while retaining an active, 
monomeric form, similar to the in vitro observation in which active 1B7 monomer is 
rapidly recovered upon dispersion dilution. 
These experiments were performed in mice, where the large allowed injection 
volume per body mass (100 μl/25g) allows for direct comparisons between solutions and 
dispersions formulated at the same concentration. A similar comparison is not possible in 
humans, as SQ injections are restricted to ~1.5 ml volume. To demonstrate that 
dispersions can achieve dosages relevant for humans, we prepared group 4 as a scaled-




(182 mg/ml) was administered subcutaneously, for a final 7.6 mg/kg murine dosage. 
Scaling-up to calculate the human dosage, in which a 182 mg/ml dispersion could be 
administered in a 1.5 ml volume, this is equivalent to a 4.3 mg/kg human dose, exceeding 
current dosing guidelines (2 mg/kg).  To evaluate the potential for dispersions to result in 
less-frequent administration of ultra-high antibody dosages, which are not currently 
achievable with solutions, group 5 mice received a large, 100 μl injection volume of 
dispersion (12.9 mg/ml), for a 51.6 mg/kg dose. This group also exhibited similar 
pharmacokinetics (similar tmax, t1/2,α, t1/2,β) and 1B7 bioavailability indicating 
concentration and dose-independent pharmacokinetics. 
To provide an orthogonal measurement of antibody quality to complement 
antigen ELISA, we measured 1B7 biological activity with an in vitro CHO cell 
neutralization assay using sera from the terminal time point. Free PTx will bind cell-
surface receptors, undergo receptor-mediated endocytosis and eventually ADP-
ribosylation of Gi/o coupled receptors; phenotypically, this results in loss of contact 
inhibition and CHO cells grow in a clustered morphology. Antibody-mediated 
neutralization of PTx blocks toxin entry into cells, protecting normal growth phenotype. 
Sera were diluted in the presence of a fixed PTx concentration, CHO cells added and, 
after 24 hrs growth, scored for normal or clustered morphology. The highest sera dilution 
completely preventing CHO cell clustering was recorded and compared versus purified 
control 1B7 antibody. This assay resulted in no statistically significant differences 
between groups on titre per μg antibody basis. Based on this assay, there is no evidence 
for a loss in antibody efficacy as a result of injection site (SQ vs. IV) or formulation 




changes in serum antibody due to formulation and administration route, such as 
formation of insoluble or disulfide bonded aggregates (Figure A1.3.5). 
As shown by both in vitro and in vivo data, the protein within the dispersion 
shows no detectable loss of native conformation during any processing step or after 
dissolution and systemic absorption. As described previously within the dispersion, the 
native conformation is maintained by protein self-crowding and the addition of crowding 
agents entropically stabilizing the native conformation.35 For aggregation to occur upon 
dissolution, the native protein must reversibly unfold to an aggregation-prone 
intermediate and collide with another aggregation-prone protein molecule to form an 
aggregate, which leads to irreversible inactivation of the protein.21 As in the in vitro 
dilution experiments, initially in vivo the crowders within the dispersion (trehalose, PEG, 
and NMP) are still present as the particles dissolve and thus entropically prevent the 
protein from unfolding.53, 82 Due to the fast dissolution time, the nearby crowders from 
the dispersion will help prevent unfolding of the protein. In vivo, as the crowders from 
the dispersion are diluted, additional crowders in the extracellular environment around 
the SQ injection or in the blood stream will help maintain the protein stability. Thus 
during the in vivo particle dissolution and distribution of 1B7 near the injection site, 
stabilizing crowders, either from the injection or naturally occurring within the body, 
reduce the number of aggregation-prone protein intermediates. Furthermore the fast 
dissolution kinetics will dilute the therapeutic protein and decrease the number of 
collisions that lead to the formation of aggregates. As the dissolved crowder is diluted 
upon injection, if individual protein molecules diffuse away from the nanocluster surface, 




remaining protein molecules in the nanocluster. Preliminary immunogenicity studies 
support this conclusion as no propensity for the generation of anti-drug antibodies is 
detected in any sample (Figure A1.3.6). Therefore, with the result from the CHO assay, 
the protein particles from dispersion likely retain the native antibody state even after in 
vivo injection. 
4.4 CONCLUSIONS 
Nanocluster dispersions allow formulation of a monoclonal antibody at high 
concentration and low viscosity, with no detectable loss in antibody structure or activity 
in vitro or in vivo and similar pharmacokinetics when administered subcutaneously to 
mice. Highly concentrated ~200 mg/ml aqueous-based dispersions of a therapeutically 
relevant antibody, 1B737, were formed from stable, submicron protein particles 
containing a 1:1 weight ratio of trehalose in an aqueous buffer with multiple crowding 
agents, including trehalose, PEG and NMP. These particles were produced by rapid 
freezing in a dosage vial using spiral-wound in-situ film technology (SWIFT) to 
minimize protein denaturation and aggregation. The solubility of 1B7 was lowered in the 
aqueous-based solvent by adding pharmaceutically acceptable crowding agents, PEG300 
and NMP, along with the trehalose from the dry powder to facilitate formation of the 
dispersion. The protein particles retain their native conformation in the dispersion as 
shown by fluorescence of the tryptophan residues on the protein. Additional analyses, 
ELISA, DLS and SDS-PAGE upon dilution of the dispersion into a pure buffer, indicate 
that the protein rapidly recovers monomeric form with full activity. The apparent 
viscosity through a 25 g 1.5” needle of the 190 mg/ml IgG dispersion with NMP and 




the low intrinsic viscosity. Similar in vivo distribution and elimination half-lives were 
measured from the dispersion and solution formulations at similar doses, while the time 
to peak serum concentration (tmax) was delayed for the SQ injections, consistent with the 
expected slower diffusion kinetics from this injection site. Remarkably, in the terminal 
serum samples, testing for specific PTx binding activity by ELISA, as well as an in vitro 
PTx neutralization test, was unable to detect a loss in 1B7 activity or development of 
anti-1B7 immune responses. In combination with previous work with sheep IgG19 and 
1B733, the mechanism of excluded volume from crowding agents, which results in 
formation of reversible nanoclusters of stable protein that dissociate upon dilution, is 
shown to be applicable for multiple IgG proteins with multiple crowding agents, 
demonstrating flexibility in formulation for other therapeutic proteins. The ability to form 
stable, highly concentrated dispersions of a protein therapeutic with low viscosities and 
favorable bioavailability will increase the potential use of subcutaneous injection, 
possibly for treatment of many chronic diseases. 
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Chapter 5: Flocculated Amorphous Itraconazole Nanoparticles for 
Enhanced in vitro Supersaturation and in vivo Bioavailability  
 
Rapid flocculation of nanoparticle dispersions of a poorly water soluble drug, 
itraconazole (Itz), was utilized to produce amorphous powders with desirable dissolution 
properties for high bioavailability in rats. Antisolvent precipitation (AP) was utilized to 
form Itz nanodispersions with high drug loadings stabilized with 
hydroxypropylmethylcellulose (HPMC) or the pH-sensitive Eudragit® L100-55 
(EL10055). The HPMC dispersions were flocculated by desolvating the polymer through 
the addition of a divalent salt, and the enteric EL10055 by reducing the pH. The 
formation of open flocs by essentially diffusion limited aggregation, facilitated 
redispersion of the flocs at pH 6.8. Upon redispersion of the flocculated nanoparticles at 
pH 6.8, the particle size was modestly larger than the original size, on the order of 1 μm. 
High in vitro supersaturation (AUC) of the flocculated nanoparticle dispersions was 
observed in micellar media at pH 6.8, after 2 hours initial exposure at pH 1.2 to simulate 
the stomach, relative to the AUC for a commercially available solid dispersion Itz 
formulation, Sporanox. Greater in vivo bioavailability in rats was correlated directly to 
the higher in vitro AUC at pH 6.8 with micelles during the pH shift experiment for the 
flocculated nanoparticle dispersions relative to Sporanox. The ability to generate and 
sustain high supersaturation in micellar media at pH 6.8, as shown with the in vitro pH 





A major challenge in oral drug delivery is the low bioavailability of poorly-water 
soluble therapeutics.1-3 Two known mechanisms to increase the bioavailability of poorly-
water soluble drugs are to increase the surface area and to create stable amorphous 
particles. A higher surface area increases dissolution rates, while an amorphous form of 
the drug allows for high supersaturation in a metastable state relative to the crystalline 
equilibrium solubility.4-6 From configurational heat capacities of the amorphous state,  
predictions indicate that supersaturation for amorphous drugs may reach as high as 1,600 
times the crystalline solubility.6-9 Increases in supersaturation have also been found to 
lead to greater flux through biomembranes further increasing the bioavailability of the 
drug.10, 11 Amorphous solid solutions and dispersions have been created by numerous 
techniques including co-grinding12, solvent evaporation13-16, hot-melt extrusion17, 18, and 
antisolvent precipitation5. Many of these amorphous forms are stabilized against 
crystallization during formation, storage and dissolution with high quantities (>50% of 
the formulation) of polymers such as hydroxypropylmethylcellulose (HPMC) and 
poly(vinylpyrolidone).6-8, 12, 13, 15, 19-22 
In previous work, dispersions with high surface areas produced by antisolvent 
precipitation (AP), up to 50 m2/g, rapidly dissolve to high supersaturations close to the 
predicted supersaturation from the configurational heat capacity.5, 6 These formulations 
also increase the drug to polymer ratio able to form a stable amorphous formulation (less 




used to produce aqueous dispersions of particles is the ability to recover the particles in 
the amorphous state as a dry powder. Common techniques include spray drying, 
ultrafiltration, and freeze drying. High processing temperatures near the glass transition 
(Tg) of the drug can increase the crystallinity of the recovered powder.23 We have 
previously presented a method to rapidly flocculate with salt and filter the nanoparticle 
dispersions. During salt flocculation the overall volume fraction of solids is constant such 
that the flocs are formed rapidly prior to filtration. Otherwise, slow increases in the 
volume fraction of the particles during removal of water may cause irreversible 
coagulation of the particles.23 The temperature was well below the Tg of the drug, which 
allows for the recovery of filtered and dried (at room temperature) stable amorphous 
particles.23 However, in some cases the increase in salinity is not sufficient to reach the 
cloud point of the polymer at a reduced temperature; therefore there is a need to explore 
other methods to rapidly flocculate these amorphous nanoparticles. For example, in the 
case of polymers where a change in dissociation with pH influences solvation, the cloud 
point temperature can be readily accessible near room temperature. Previously, 
flocculation by electrostatic self-assembly of nanoparticles has been achieved from the 
addition of positively charged nanoparticles to a dispersion of strongly negatively 
charged nanoparticles.24 
To better understand in vivo bioavailability of  poorly water soluble drugs such as 
itraconaozle (Itz), a number of recent studies have explored the implications of high 




vitro dissolution tests have been performed based on sink conditions or high values of 
supersaturation relative to equilibrium crystalline solubility in a variety of medias to 
simulate the stomach, intestines or both.5, 23, 25, 26, 28-31. Many of these dissolution tests do 
not account for permeation. When an in vivo bioavailability study is run concurrently 
with the in vitro dissolution test, neither an increased rate of dissolution under sink 
conditions nor a higher maximum supersaturation value were found to correspond 
directly to an increase in bioavailability.25, 26 To further complicate the correlation 
between an in vitro dissolution test and the in vivo bioavailability, the bioavailability 
measured for the same formulation may not change directly proportional to the dose 
administered to the animal32, 33 or remain the same if the diet provided to the animal is 
changed prior to administration32, 34, 35. Future efforts to create more reliable in vitro – in 
vivo correlations will likely hinge on designing amorphous nanoparticles with better 
morphologies to provide greater control over the levels of superaturation values 
generated and maintained upon their dissolution.  
For Itz, previous studies have indicated that the primary site of absorption is the 
proximal small intestine.25, 26, 29 In the small intestine, the addition of bile salts and the 
change in pH from the stomach result in a slight decrease in solubility of Itz. However, if 
the bile salt micelles are neglected, an abrupt change of 3 orders of magnitude in 
solubility is predicted and seen experimentally.36 Thus, micelles are an integral part of the 
overall solubility of Itz in the small intestines. Previous, supersaturated dissolution tests 




dry powders, show that a surface area of 2-5 m2/g was optimum for maintaining 
supersaturation over a 4 hour experiment. The higher area under the curve (AUC) for 
these experiments is due to the rapid generation of high supersaturation and the relatively 
slow subsequent growth of precipitate from solution by coagulation and condensation.27 
The main objective of this study was to improve the oral delivery of the poorly 
water soluble drug, Itz by using amorphous dry powders formed by antisolvent 
precipitation (AP), which were then flocculated, filtered and dried at room temperature. 
Stable nanoparticles are coated with negatively charged EL10055 at a pH (pH 6.8) well 
above the pKa of the polymer (pH 5.5).27 As previously reported for AP, the hydrophilic 
polymer is oriented towards the particle surface and provides steric stabilization at low 
levels, for example, high drug loadings up to 94%.5 Rapid flocculation of the nanoparticle 
dispersion occurred upon decreasing the pH of the dispersion to 2.5 where the polymer 
was no longer charged. As in previous reports of nanoparticle dispersions flocculated 
with salt, the rapid and strong increase in interparticle attraction with the pH change 
caused essentially diffusion limited aggregation of the nanoparticle dispersion under 
constant volume fraction resulting in relatively large open flocs.23, 27, 37 As for salt 
flocculation, crystallization of Itz was minimal, since the large flocs were rapidly filtered 
at room temperature.23, 27 For the pH flocculated particles high drug loadings were 
maintained from AP through the flocculation and filtration process. Upon redispersion at 
pH 6.8, solvation of the enteric polymer results in only a slight increase in size of the 




previous studies of  flocculation with divalent salts, is the potential for a significant 
decrease in salt impurities in the final product.23, 37  
A series of in vitro dissolution tests and an in vivo bioavailability study were used 
to compare flocculated amorphous Itz particle formulations, either formed by pH 
flocculation with EL10055, or by salt flocculation with HPMC, with a commercially 
marketed form of Itz, Sporanox®. The multiparticulate capsule form of Sporanox is 
produced by drug layering of Itz and HPMC onto sugar spheres which results in a 21% 
drug loading.26 A pH shift dissolution test was established, starting at simulated stomach 
conditions (pH 1.2) for 2 hours, followed by a pH shift to small intestine conditions, pH 
6.8. A micellar solution was utilized to simulate micelles formed with bile salts in the pH 
6.8 media. The in vivo bioavailability for each formulation was compared with the AUC 
in the neutral media with micelles from the pH shift in vitro test at supersaturated 
conditions. The good in vitro – in vivo correlation suggests that the high initial 
supersaturation of Itz in the rat stomach and the properties of the supersaturated solutions 
in the intestines are captured reasonably well by the pH shift in vitro model. 
5.2 MATERIALS AND METHODS 
5.2.1 Materials 
B.P. grade itraconazole (Itz) was purchased from Hawkins, Inc. (Minneapolis, 
MN). HPMC E5 (viscosity of 5 cP at 2% aqueous 25°C solution) grade was a gift from 
The Dow Chemical Corporation and methacrylic acid-ethyl acrylate copolymer (1:1 




(Piscataway, NJ). Sporanox capsules were purchased from Janssen Pharmaceutica 
Products, L.P. (Titusville, NJ). Stabilized p.a. grade 1,3-dioxolane was obtained from 
Acros Organics (Morris Plains, NJ). HPLC grade acetonitrile (ACN) and HPLC grade 
methanol were used as received from Fisher Chemicals (Fairlawn, NJ). N. F. grade 
sodium taurocholate (NaTC) was purchase from Spectrum Chemical Mfg. Corp. 
(Gardena, CA). All other chemicals utilized in this study were ACS grade chemicals 
purchased from Fisher Chemicals. 
5.2.2 Antisolvent Precipitation (AP) of Amorphous Itz 
Antisolvent precipitation of Itz was used to produce nanoparticle dispersions of 
Itz stabilized by HPMC or EL10055. Deionized water (50 g) was used as the antisolvent 
phase into which 15 g of 1,3-dioxolane containing 3.3% (wt) Itz was injected to form a 
fine precipitate through a 19G syringe. For the HPMC stabilized dispersion, 0.25 g of 
HPMC was added to the deionized water prior to the addition of the dioxolane containing 
Itz, producing a final 2:1 ratio of Itz:HPMC as reported previously.23, 27 For the EL10055 
stabilized dispersion, 0.25 g of EL10055 was added to an aqueous pH 6.8 buffer 
composed of a 1:3 volume ratio of 0.2M tribasic sodium phosphate to 0.1N HCl, which 
was used in place of the 50g of deionized water as the antisolvent. Particle size was 
immediately quantified using the Malvern Mastersizer-S, as described below. 
5.2.3 Flocculation to produce a Dry Powder 
Immediately after the dispersion particle size was quantified, a desolvating 





Figure 5.1 Schematic of the pH flocculation process to create particles by rapid 
flocculation (2), filtration (3) and drying (4). 
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Figure 5.2 Images of the particles throughout the pH flocculation process: A) 
immediately after AP of ITZ with Eudragit®L100-55 stabilizer B) after 
flocculation and creaming by addition of HCl C) dried powder, scraped off 
the filter and placed in a vial D) resuspended suspension of ITZ particles 





of a 1.5M solution of Na2SO4 was added, producing a final SO4-2 concentration of 1.0M 
in the mixture.23, 27 For the EL10055 stabilized dispersion, 20 ml of 0.1N HCl was added 
to lower the pH of the final mixture to 2.5 ± 0.5 (Figure 5.1). In both cases, the 
dispersions sat for 3 minutes, allowing the flocculated dispersion to cream (Figures 5.1 
and 5.2A and B). The large flocs were then filtered through an 11 cm diameter P2 filter 
paper (Fisher Scientific, Fairlawn, NJ) under vacuum. Filtration continued until no liquid 
was observed on top of the filter cake, typically between 5 and 10 minutes. The HPMC 
stabilized flocculated dispersion was then rinsed with a chilled solution of 5mg/ml 
HPMC, as described previously.23, 27 The EL10055 stabilized flocculated dispersion was 
not rinsed. The filter cake was then allowed to dry overnight at atmospheric conditions 
after which the dried powder was obtained by gently scraping the filter paper (Figure 
5.2C). 
5.2.4 Determination of Particle Size and Morphology 
Particle size distributions were measured by light scattering using a Malvern 
Mastersizer-S (Malvern Instruments Inc., Southborough, MA). For the particle 
dispersions, ~5 ml of the suspension was diluted with 500 ml of pure deionized water to 
produce an obscuration between 10-15%. For the dried powders, ~0.1g of the dried 
particles was added to 20 mL of DI water and sonicated for 1 minute using a Branson 
Sonifier 450 (Branson Ultrasonics Corporation, Danbury, CT) with a 102 converter and 




deionized water to produce an obscuration between 10-15%. Distributions, based on 
volume fractions, were calculated using the refractive index of itraconazole (1.610 38). 
Powder specific surface area was measured using a Quantichrome Instruments 
Nova 2000 series surface area analyzer (Boynton Beach, FL) using nitrogen as the 
adsorbate gas. Six points, taken over a range of relative pressures from 0.05 to 0.25, were 
used to fit with the Brunauer-Emmett-Teller (BET) equation to quantify the specific 
surface area of the powder. A correlation coefficient greater than 0.999 indicated a good 
linear fit to the data. 
Approximate particle size and morphology was also determined by scanning 
electron microscopy (SEM). Immediately after AP, the organic phase was separated from 
the aqueous dispersion via vacuum distillation at 40 torr and 38°C. A few drops of the 
aqueous dispersion were then flash frozen onto aluminum SEM stages maintained at -
200°C with liquid nitrogen. Lyophilization with 24 h. of primary drying at -35°C 
followed by 36h. of secondary drying at 25°C left a dried powder sample on the SEM 
stage. For dry powder samples, a small quantity was placed on adhesive carbon tape to 
form a thin film. All samples were gold-palladium sputter coated for 40 seconds. 
Micrographs were taken using a Hitachi S-4500 field emission scanning electron 
microscope with an accelerating voltage of 15 kV. 
5.2.5 Determination of powder amorphous content 
Dried powder samples of ~5 mg were placed in hermetically sealed aluminum 




New Castle, DE) with a refrigerated cooling system. The samples were purged with 
nitrogen at a flowrate of 150 ml/min. For temperatures from 20-200ºC, an amplitude of 
1°C, a period of 1 min, and an underlying heating rate of 5°C/min were used to determine 
both total and reverse heat flow. The percent crystallinity (%cryst) was quantified by 
integration under the recrystallization peak around 120°C (Δhcryst) and the melting 







=%  (5.1) 
ΔhmeltITZ is the heat of melting for pure crystalline ITZ. This equation assumes that the 
heat necessary to melt equivalent amounts of crystalline Itz and amorphous Itz are the 
same. 
5.2.6 Drug and Salt Content Determination 
The drug concentration of the final powder form was determined for the EL10055 
samples by dissolving 3 separate ~10mg measured quantities of the powder. Each sample 
was dissolved in a solution of 14 ml ACN, 6 ml DI water, and 10 ml of methanol. After 
stirring the solutions overnight, 3 aliquots from each solution were taken and diluted by 2 
with ACN. These 9 samples were then analyzed by HPLC for Itz concentration as 
described below. 3 samples of ~10 mg were also measured to determine salt content. 
These samples were exposed to 0.2ml of deionized water and shaken frequently for 2 
weeks. The remaining powder was then filtered out using 0.2 μm syringe filter, and the 




MA) calibrated with 100 and 500 mOsmol standards. The drug and salt content 
determination for the HPMC samples was conducted as reported previously.23 
5.2.7 Contact Angle Measurements 
50 mg ± 1 mg of each dried powder was compacted with ~500 kg weight using a 
Model M Carver Laboratory Press (Fred S. Carver, Inc., Menomeonee Falls, WI) to form 
a flat sided pellet. Solutions of pH 1.2, pH 6.8 media, and pH 6.8 media with 0.17% SDS 
were made as described previously.5, 23, 27 A media containing 30 mM (1.6wt%) NaTC 
was prepared in deionized water with the ionic strength of Na+ ion adjusted to 0.1M with 
NaCl, as prepared by Crisp et al. and Bakatselou et al.39, 40 A 10 μl drop of the solution 
was placed in the center of one side of the tablet and the contact angle was measured 
within 15 seconds using a contact angle goniometer, described previously for high 
pressure.41 Briefly, the tablet was placed on a stand attached to an optical rail with a light 
source (Chiu Technical Corporation, model HG-DM) illuminating the solution droplet 
onto a Sony CCD camera (model XC-73CE) attached to a computer. The images were 
analyzed using a software package from KSV Instruments Ltd. (Helsinki, Finland) to 
estimate the air/water/tablet contact angle using the Young-Laplace method. 
Measurements were made in quadruplicate with the average and standard deviation 
reported. Sides where cracks or visible imperfections were observed were disregarded 




5.2.8 Dissolution under Supersaturated Conditions 
Rates of supersaturation for metastable amorphous dry powder formulations were 
measured in pH 6.8 phosphate buffer with 0.17 % (w/v) SDS preheated to 37.2°C. The 
equilibrium crystalline solubility was 14 μg/ml in this media.23 A sample weight 
equivalent to approximately 25-times the crystalline solubility (17.6 mg Itz) was added to 
50 ml of the media. Sample aliquots (~1ml) were taken after 10, 20, 30, 60, 120, and 240 
minutes, filtered and diluted for analysis. For the pH shift experiments, dry powder (10 
mg Itz for the 45x acid supersaturation and 17.6 mg Itz for the 80x acid supersaturation) 
was added to 60 ml of 0.1N HCl (pH 1.2) and sample aliquots were taken after 10, 20, 
30, 60, and 120 minutes. After 120 minutes, 20 ml of 0.2M tribasic sodium phosphate 
with or without 0.68% SDS added was added to shift the pH to ~6.8 and either 0 or 
0.17% SDS. Sample aliquots were taken at 10, 20, 30, 60, and 120 minutes after the pH 
shift. For all dissolution experiments, the USP paddle method was adapted to 
accommodate small sample sizes using a ValKel VK6010 Dissolution Tester (VanKel, 
Cary, NC) equipped with small 100 ml capacity dissolution vessels (Varian Inc., Cary, 
NC) with a Vanderkamp VK650A heater/circulator (VanKel, Cary, NC). Each 0.8ml 
aliquot was filtered immediately using a 0.2 μm syringe filter and diluted with 0.8 ml of 
ACN. In all cases, the filtrate was completely clear upon visual inspection and dynamic 
light scattering of select samples of the filtrate gave negligible count rates. The drug 




5.2.9 In Vivo Bioavailability in Sprague-Dawley Rats 
An institutionally approved in vivo study was conducted using pre-catheterized 
(vascular catheter surgically inserted into the jugular vein) CD IGS Sprague-Dawley rats 
(Charles River Laboratories, Inc., Wilmington, MA). All rats received weighed ~300 g. 
For the duration of the study, the animals were stored in individual cages and subjected to 
12h.-12h. cycles of light and darkness with access to food and water ad libitum. The 
catheter was flushed daily with 0.3ml of 50 U/ml heparinized normal saline. After an 
acclimatization period of at least 3 days, an aqueous dispersion of the engineered 
formulations at a dose of 15 mg Itz/kg body weight was administered by oral gavage to 
the rats (n=6 per formulation). Immediately prior to dosing, each formulation was 
dispersed in deionized water to a concentration of 4.5 mg Itz/ml to provide volumetric 
doses below 4 ml/kg body weight to prevent spontaneous release through the pyloric 
sphincter.26, 42 The Sporanox control test was reported previously with other studies run 
concurrently.26 The only difference between the in vivo tests was that the Sporanox® 
pellets were filled into a size 9 porcine gelatine capsule to achieve the target dose of 4.5 
mg Itz per capsule and dosed using an oral capsule dosing syringe (Torpac, Inc., 
Fairfield, NJ) followed by administration of 200 μl of deionized water by oral gavage. 
Blood samples (~0.3 ml each) were withdrawn through the jugular vein catheter at 0, 2, 
3, 3.5, 4, 4.5, 5, 5.5, 6, 8, 12, and 24 hours after dosing and replaced with an equal 
volume of heparinized saline. Blood samples were placed in pre-heparinized 




3,000g for 15 minutes, transferred into a clean 1.5 ml microcentrifuge tube, and kept at -
20°C until it was analyzed. 
Calibration standards and plasma samples were analyzed as was previously 
reported.29, 43, 44 In summary, upon thawing, a volume of harvested plasma was 
transferred to a clean 1.5 ml microcentrifuge tube. To each microcentrifuge tube, 50 μl of 
each 0.3N barium hydroxide and 0.4N zinc sulfate heptahydrate solution were added 
prior to vortex mixing for 30 seconds to precipitate water-soluble proteins. As an internal 
standard, 1 ml of ACN containing 1,200 ng/ml ketoconazole was added to each sample 
followed by an additional 1.5 minutes of vortex mixing. The samples were then 
centrifuged at 3,000g for 15 minutes. Afterwards, the supernatant was extracted and 
transferred to a clean 1.5 ml centrifuge tube and dried in an aluminum heat block at 70°C 
under a stream of nitrogen. The dried samples were then reconstituted with 250 μl of a 
62% ACN: 38% 0.05M potassium phosphate monobasic buffer adjusted to pH 6.7 with 
NaOH (mobile phase for in vivo study). The reconstituted sample was vortex mixed for 1 
minute and then centrifuged for an additional 15 minutes. A 150 μl aliquot of the 
supernatant was extracted and filled into a low volume HPLC vial insert and analyzed by 
HPLC as described below. 
5.2.10 High Performance Liquid Chromatography (HPLC) 
In vitro dissolution study samples and dissolved dried powders were analyzed for 
drug concentration using a Shimadzu LC-10 liquid chromatography (Shimadzu 




column (Alltech Associates, Itc., Deerfield, IL). The mobile phase of ACN/water/DEA 
70:30:0.05 by volume set at a flowrate of 1 ml/min. Using a detection wavelength of 263 
nm, the Itz peak eluted at ~5.5 min. The standard curve linearity was verified from 500 to 
1 μg/ml with an r2 value of at least 0.999 and reproducibility of replicate injections was 
within 2% relative standard deviation (RSD). 
In vivo bioavailabilities were analyzed for drug concentration using a Waters 
HPLC system (Milford, MA) equipped with a photodiode array detector (Model 996), a 
model 717 Plus auto sampler, and the Empower® Version 5.0 software. A Phenomenex® 
Luna 5 μm C18(2) 100Å HPLC column (250x 4.6 mm) was used and maintained at 37°C 
for the duration of the injection set. The mobile phase was 62% ACN and 38% 0.05M 
potassium phosphate monobasic buffer adjusted to pH 6.7 with NaOH at an isocratic 
flowrate of 1 ml/min. Using the detection wavelength of 263nm and a sample injection 
volume of 100 μl, the retention times of ketoconazole and Itz were approximately 5.5 min 
and 14.7 min with limits of detection of 10ng/ml and 30 ng/ml, respectively. Each 
individual run maintained suitable limits for linearity (r2 ≥ 0.999) and reproducibility of 
replicate injections (% RSD ≤ 2.0%). Additional samples run concurrently are found in 
DiNunzio et al.26 
5.2.11 Pharmacokinetic Analysis 
Blood plasma concentrations were analyzed with WinNonlin v4.1 software 
(Pharsight Corporation, Mountain View, CA) using non-compartmental analysis for 




data, AUC was calculated by the linear trapezoidal method, and t1/2 was determined by 
calculating the lambda z parameter. For statistical significance of the AUC, tmax, and cmax 
values, a t-test was performed using p ≤ 0.05 as the criteria for statistical significance. 
5.3 RESULTS AND DISCUSSION 
5.3.1 Particle Morphology of pH Flocculated Samples 
Particle size and morphology for the EL10055 stabilized particles was determined 
before and after flocculation by light scattering, BET, and SEM. Prior to flocculation, 
~300nm primary particles are observed in the SEM images (Figure 5.3a) and are 
consistent with the high specific surface area (35 m2/g) measured by BET.27 By light 
scattering in a pure aqueous environment without pH control, 90% of the particles (by 
volume) were between 1-4 µm with an average diameter of 2µm prior to flocculation. 
The pH of the dispersion diluted into pure water was between 5-6, where some of the 
methacrylic acid groups on the polymer will be protonated. The reduced charge 
stabilization of the nanoparticle dispersion results in slight aggregation of the particles. 
After flocculation and drying, the redispersed particles in distilled water have a slightly  
larger average particle diameter of ~ 5μm on the basis of light scattering. In the same 
manner, the slightly lower specific surface area (7.7 m2/g) measured by BET corroborates 
the ~1 μm small nanoparticle aggregates visible on the SEM. Light scattering, BET 
surface area, and SEM all confirm that slight particle growth is observed between the 
initial nanoparticles formed by AP and the final dry powder after flocculation, filtration 








Figure 5.3 SEM of 2:1 Itz:Eudragit®L100-55 formulation: A) flash frozen and 
lyophilized immediately after precipitation B) and C) final particles formed 











buffers at higher pH values where the particles are more fully charged. However, the 
current study clearly illustrates the behavior of the pH flocculation process, and the 
particles produced are shown to offer high supersaturation in vitro and enhanced 
bioavailability in vivo. 
Open fractal flocs form upon rapid, diffusion limited flocculation of the 
nanoparticle dispersions under very poor solvent conditions.23, 45 In the case of an 
EL10055 stabilized nanoparticle dispersion, poor solvent conditions occur upon lowering 
the pH well below the pKa of the polymer (pH 5.5), which results in protonation of the 
methacrylic acid groups. Almost instantaneous flocculation of the EL10055 stabilized 
nanoparticle dispersions is observed upon lowering the pH due to a change in turbidity.  
Previously reported HPMC stabilized and HPMC/poloxamer 407 stabilized Itz 
nanoparticle dispersions flocculated with salt were found to undergo similar rapid 
changes in turbidity.23, 27 In the case of salt flocculated Itz/HPMC/poloxamer 407 
dispersions, the fractal dimension of the floc (1.76) approaches that of open fractal flocs 
produced by rapid diffusion-limited aggregation (1.7).23 The change in turbidity upon 
flocculation and the extent of creaming after flocculation at equal concentrations for the 
salt flocculated Itz/HPMC/poloxamer 407 dispersions and the pH flocculated EL10055 
stabilized dispersions were similar. Open fractal flocs were produced in both cases. Upon 
returning the flocculated, filtered and dried nanoparticle dispersions to good solvent 




dispersions of small particles. In contrast, denser flocs with a fractal dimension ~2.9 out 
of a maximum of  3 are produced by spray drying.23 The denser flocs may not redisperse 
as effectively into primary particles during redispersion in drug delivery.23 
Slight particle growth was observed for the pH flocculated EL10055 stabilized 
particles upon redispersion in pure water and by specific surface area and SEM particle 
size measurements following flocculation and filtration. Similar behavior has been 
reported previously for salt flocculated HPMC-stabilized particles upon redispersion.27 
However, no growth in particle size after flocculation and redispersion was seen when a 
combination of HPMC and poloxamer 407 polymer stabilizers were used.23 Poloxamer 
407 is a triblock copolymer consisting of a central hydrophobic block of polypropylene 
glycol surrounded by hydrophilic blocks of polyethylene glycol. When poloxamer 407 is 
used to stabilize the hydrophobic Itz domains, the drug nanoparticle will primarily 
associate with the more hydrophobic central block. Thus, the  more hydrophilic end 
blocks will sterically stabilize the individual nanoparticle domains throughout the 
flocculation and filtration process.27 In a similar manner, silica nanoparticles flocculated 
with crosslinked poly(N-vinylformamide) redisperse due to increased steric stabilization 
after hydrolysis of the crosslinking agent, bis[2,2’-di(N-vinylformamido)ethoxy] 
propane.46 Both HPMC and EL10055, unlike poloxomer 407, associate with the 
individual nanoparticle domains over the entire length of the polymer. As a result, when 
the HPMC or EL10055 stabilized nanoparticles are desolvated by either addition of salt 




flocculation and filtration process due to reduced steric stabilization. Thus, polymers can 
be chosen to tune the surface area and size of the final dry powder formulation. 
As shown in Figure 2.4A, two separate glass transition temperatures are indicated 
for both a 2:1 and 4:1 ratio of Itz to EL10055. The first, at ~59°C, is consistent with that 
of pure itraconazole31, 47, while the second, at ~105°C, is consistent with a solid solution 
of approximately 30% Itz in EL10055.31 These two distinct glass transition temperatures 
indicate the formation of two separate phases, a polymer rich phase and a pure drug 
phase, consistent with previous AP formulations.5, 23, 27 To further characterize the two 
distinct phases, the contact angle of the formulation is compared to that of the pure drug 
and polymers. The data indicate a characteristic contact angle for the formulations which 
was significantly closer to that of the pure polymer than pure Itz (Table 5.1). Thus, the 
exposed area of the final particles is primarily that of the polymer rich phase, which is 
also consistent with previous work with AP particles (Table 5.1).5, 23 During particle 
formation, the hydrophilic polymer migrates towards the particle surface for favorable 
interactions with water. Thus, relatively small loading of polymer provide stabilization of 
the nanoparticles, unlike the case for more conventional solid dispersions. 
Previously, mixtures of Itz and EL10055 have been found to produce solid solutions with 
Itz up to a drug loading of 70%.31 Therefore, it is significant that AP followed by 
flocculation and drying produces particles containing two separate domains at ratios 
where a solid solution is still theoretically possible. This morphology will improve 





Figure 5.4 MDSC of pH flocculated formulations and pure Itz control: A) reverse heat 





Table 5.1 Contact angle of formulations in various media, pH 1.2, pH 6.8 pure buffer, pH 
6.8 with SDS micelles, and pH 6.8 with NaTC micelles 
Sample Media Average Contact 
Angle 
% RSD 
Micronized Itz pH 1.2 109.9 9% 
HPMC 100.9 5% 
EL10055 67.4 6% 
2:1 Itz: EL10055  
pH flocculated 
84.5 6% 
2:1 Itz:HPMC salt 
flocculated 
60.1 25% 
Micronized Itz pH 6.8 with no 
added surfactant 
64.4 18% 
HPMC 91.3 5% 
EL10055 75.4 15% 
2:1 Itz: EL10055  
pH flocculated 76.1 16% 
2:1 Itz:HPMC salt 
flocculated 83.2 7% 
Micronized Itz pH 6.8 with 0.17% 
SDS 
47.1 13% 
HPMC 78.3 5% 
EL10055 37.3 15% 
2:1 Itz: EL10055  
pH flocculated 35.5 13% 
2:1 Itz:HPMC salt 
flocculated 75.0 8% 
Micronized Itz 30 mmol NaTC 
buffer 
40.4 16% 
HPMC 87.5 6% 
EL10055 46.1 14% 
2:1 Itz: EL10055  
pH flocculated 46.3 11% 
2:1 Itz:HPMC salt 





measurements in neutral media (Table 5.1). In addition, since the Itz domains are 
surrounded by a shell composed of mostly polymer, the enteric effect of the pH 
flocculated particles should be enhanced over pure solid solutions containing the same 
drug loading. 
The amorphous nature of the pH flocculated and filtered particles is further 
confirmed by the small melting peaks observed in the DSC total heat flow measurements. 
The minor Itz melting peak for the 2:1 EL10055 stabilized pH flocculated formulation 
gave a %cryst of 5%, indicating an almost fully amorphous Itz formulation. Since the 4:1 
EL10055 stabilized pH flocculation formulation showed a recrystallization peak at 
~125°C in addition to a melting peak at ~160°C, the %cryst was determined to be even 
lower at ~3% by equation 1 (Figure 5.4B). 
The low processing temperature (25°C) utilized in the pH flocculation process 
helps to preserve the amorphous morphology of Itz and reduces the excipients needed in 
the formulation. In hot-melt extrusion formulations, solutions formed with a methacrylate 
based polymer, such as EL10055, must use a plasticizing agent such as triethyl citrate to 
lower the processing temperature to 130°C.25, 48 The use of these high temperatures 
during processing will cause partial crystallization of Itz during cooling, leading to lower 
dissolution and bioavailability. To prevent the partial crystallization of Itz, low drug to 




room temperature processing during flocculation and filtration, much higher drug to 
polymer ratios (up to 4:1) can be used while retaining the amorphous nature of the Itz. 
Recovery of particles after flocculation and drying was found to be near 100% as 
previously reported.23 For the pH flocculated samples, the potency of the dried powder 
formed by flocculation and filtration according to HPLC remained at ~ 66% for the 2:1 
ratio of drug to polymer initially added and 80% for the 4:1 ratio. Besides Itz and the 
polymer stabilizer, the only additional components present during AP flocculation, 
filtration and drying are the relatively dilute buffer ions, sodium, hydrogen phosphate and 
phosphate. To induce flocculation, hydrochloric acid was added with H and Cl 
concentrations of 10-2.5 M. The residual salt remaining in the dried formulation after 
flocculation and filtration, measured by osmolality was less than 0.15% even without 
washing. Most of the salt ions are presumed to be filtered out of the dry powder during 
the filtration step, as was observed previously for samples that were flocculated with 
salt.23, 37 When compared to previous samples flocculated with a divalent salt with much 
higher ion concentrations of 1.5M, the residual salt present in the pH flocculated 
formulation is an order of magnitude lower.23  
5.3.2 In Vitro Generation and Depletion of Supersaturation in Dissolution Media 
To maintain the same initial ratio of drug to polymer, in vitro dissolution studies 
and the subsequent in vivo study were conducted with a 2:1 drug to polymer ratio for both 
the pH flocculated EL10055 and the HPMC stabilized salt flocculated formulation. Both 




Dissolution experiments at supersaturated conditions were conducted by adding 25 times 
the crystalline solubility of Itz to pH 6.8 media with 0.17% SDS (sufficient to form 
micelles). In this media (Figure 5.5), all flocculated formulations produced 
supersaturation values greater than 7x (12-17x), the maximum supersaturation of the 
Sporanox® beads. The HPMC stabilized salt flocculated formulation obtained the highest 
maximum supersaturation at ~ 17x27, followed by the EL10055 pH flocculated and 
lyophilized AP formulations both with ~ 12x. When the pH flocculated and the 
lyophilized AP formulations are compared, the decrease in the decay rate in 
supersaturation results in a higher overall AUC for the pH flocculated formulation versus 
the lyophilized AP formulation. This phenomena has also been observed for the salt 
flocculated HPMC sample when compared to an HPMC stabilized lyophilized control at 
the same drug to polymer ratio.27 
As described in detail previously, the micron-sized flocculated particles have been 
found to produce an overall higher AUC in pH 6.8 media with SDS micelles versus 
higher surface area AP lyophilized nanoparticles.27 The higher AUC is a manifestation of 
the negligible change in the maximum supersaturation followed by a dramatic decrease in 
the rate of heterogeneous nucleation and growth out of the supersaturated solution.27 
Significantly larger microparticles are not shown to increase the overall AUC due to the 
low surface area available for initial supersaturation. Previously, large 100 µm particles 
are shown to crystallize during the slow dissolution given their low surface areas.7 The 





Figure 5.5 Dissolution of drug formulations (pH flocculated, salt flocculated27, and 
Eudragit lyophilized control27) and Sporanox® Bead control in pH 6.8 





markedly relative to the results predicted for the initial amorphous form from the 
configurational heat capacities.6 The lower surface area particles decrease the available 
surface area for nucleation and growth after the maximum supersaturation has been 
achieved.27 Thus, an optimum range of dry powder specific surface area of ~ 2-5 m2/g 
has been shown to achieve the highest in vitro AUC in the pH6.8 media with SDS 
micelles.27 
Additional experiments were performed to establish how the dissolution history of 
the formulation in the acidic media affected the depletion of supersaturation following a 
pH shift to neutral pH media with or without micelles. As shown in Figure 5.6A, the 
HPMC stabilized salt flocculated formulation rapidly supersaturated the acidic media at 
either loading (45x or 80x crystalline solubility) to the point where few particles were 
visible in the remaining solution. The maximum supersaturation achieved was 34x when 
45x was loaded and 57x when 80x was loaded. When no micelles were present in the 
neutral pH media, the supersaturation obtained in the acid phase rapidly decayed in the 
first 10 minutes following the pH shift to a level below 1 μg/ml. This result was observed 
with hot melt extruded particles stabilized by HPMC E5 in previous work.25, 30 When 
SDS micelles were added to the pH 6.8 media to simulate micelles in the intestines, the 
extent of supersaturation was maintained at ~8x for 2 hours for the initial loading of 45x. 
With the higher initial loading of Itz (80x in the acidic media), 7x the crystalline 





Figure 5.6 Dissolution of A) 2:1 Itz:HPMC salt flocculated formulation B)2:1 
Itz:EL10055 pH flocculated formulation at various doses in pH 1.2 media 





pH shift due to constant decay in supersaturation. Since the temperature (T), molar 
volume (Vm), and surface tension (γ) are equal in the two experiments, homogeneous 
nucleation (Bo) at the higher loading increases based on the higher degree of 













πγ  (5.2) 
Subsequently, for the higher initial loading, the higher homogenous nucleation rate 
allows for additional growth out of solution. This results in a higher stable 
supersaturation level obtained for a lower initial loading after 2 h.  
Given the small charge on the polymer at low pH, the supersaturation for the 
EL10055 pH flocculated formulation was limited in the acidic media. The percent of the 
Itz dissolved in the acid phase, ~19%, was comparable to that for a EL10055 hot melt 
extrusion formulation containing a much higher (1:2) Itz: polymer ratio.25 The core-shell 
morphology of the flocculated AP particles allows for less of the Itz to be exposed to the 
pH 1.2 media on the surface of the particles than for the hot melt extrusion formulation. 
Because the Itz in the pH flocculated particles is surrounded by a shell of the enteric 
EL10055 polymer, reduced exposure of Itz to the pH 1.2 media minimizes dissolution of 
the drug. As a result, a significantly higher drug to polymer ratio has the same enteric 
effect as a hot melt extrusion formulation with lower drug loading. After the pH shift to 
neutral media without surfactant, slower depletion in supersaturation for the EL10055 




μg/ml was only seen after 60 minutes which is consistent with the results for EL10055 
stabilized hot melt extrusion particles.29 When experiments were performed with SDS 
micelles in the neutral media, the dissolved concentration of Itz increased to a maximum 
supersaturation of ~8x and then decreased over the 2 hour period to ~6.5x for the 
EL10055 stabilized pH flocculated formulation.  
Previous studies demonstrate that Sporanox® almost fully dissolves to a 
supersaturation of 70x when 80x the crystalline solubility in acidic media at pH 1.2. 
Upon the pH shift with micelles, the high amount of Itz solubilized in the acidic media 
results in high supersaturation over the micellular solubility of Itz  at pH 6.8 (22x). A 
high supersaturation of 22x causes rapid nucleation and growth out of the supersaturated 
solution. Thus a relatively low supersaturation of only 2x remains after only 30 min in the 
pH 6.8 media with micelles.27 Therefore, very high supersaturation of the acidic media 
(70x) aides in the rapid nucleation and growth out of solution following the pH change.  
While the solubility of Itz in the neutral media with SDS micelles is higher than 
the solubility in the acidic media (Table 2.2), the stability of the supersaturation values is 
inherently lower in the former. For supersaturation of Itz in micellar solutions (relative to 
the equilibrium solubility without micelles), the enhanced solubility is a consequence of 
the hydrophobic micelles cores.49 The decreased stability of supersaturation in the pH 6.8 
micellular media versus the pH 1.2 solution media is especially noticeable for Itz. A 










pH 1.2 4.4 experimental 
pH 6.8 buffer 0.001 Brewster et al. J Incl Phenom Macroycycl Chem (2007) 57 
pH 6.8 buffer 
with 0.17% SDS 14 experimental 
30 mmol NaTC 
buffer 0.55 Derived from Mithani et al. Pharm Res (1996) 13(1) 
 
Table 5.3 In vitro AUC over 2 hours in pH 6.8 media and in vivo AUC, Cmax, and Tmax. 







(ng*hr/ml) Cmax (ng/ml) Tmax (hr) 
2:1 Itz: HPMC  
salt flocculated 
 
17743 ± 1050 5084 ± 1970 389 ± 169 8.3 ± 3.3 
2:1 Itz: EL10055  
pH flocculated 
 










maximum supersaturation of 14x in the neutral media with SDS micelles followed by 
rapid decay due to nucleation and growth.5, 23 Based on the AUC in the neutral pH media 
with SDS micelles of the pH shift experiment, the HPMC stabilized formulation is 
superior to the EL10055 formulation and both flocculated formulations are superior to the 
Sporanox® reference (Table 5.3). 
5.3.3 In Vivo bioavailability of Itz from engineered formulation 
As shown in Table 5.3, a dramatic result is that the higher in vivo bioavailability  
for the 2:1 Itz: HPMC salt flocculated formulation is statistically significant relative to 
the current marketed Sporanox® solid dosage formulation at a constant dose of 15 mg/kg 
(Table 5.3). While oral administration of the 2:1 Itz: EL10055 formulation did not lead to 
a statistically significant higher bioavailability, a >40% decrease in the standard deviation 
of the AUC24hr and the shift in tmax are significant and will be discussed in more detail 
below (Table 5.3, Figure 5.7). Both of the flocculated nanoparticle formulations have 
much higher drug loadings, in this case to 67%, relative to ~21% for Sporanox® which 
can lead to decreased side effects from the excipients.5 
In general, comparison between animal studies conducted by different protocols 
and at different initial doses is difficult, especially for a drug such as Itz where 
bioavailability is dose-dependant.33 Itz bioavailability has also been found to be vary by 
food intake26, 32, 34, 35, 50, making comparisons even more difficult. However, Itz 
bioavailability for the HPMC salt flocculated formulation and a previous 1:2 Itz:HPMC 




























2:1 Itz:EL10055 pH flocculated
2:1 Itz:HPMC salt flocculated
Sporanox Reference
 
Figure 5.7 Plasma concentration over time for the 2:1 EL10055 stabilized pH flocculated 





under similar conditions. In the current HPMC salt flocculated formulation, the actual 
AUC was twice as high, while the actual amount dosed was half as much.30 In another 
study with MethocelTM E50, a higher viscosity grade HPMC, at a 1:2 drug to polymer 
ratio, the AUC was similar to that for the HPMC salt flocculated particles, with twice the 
dose.25 Higher loadings of Itz result in similar or increase bioavailability for the HPMC 
salt flocculated formulation when compared to the 1:2 drug to polymer ratio of the 
extruded particles.25, 30 
Previously, the bioavailability was studied for an EL10055 stabilized formulation 
made by hot-melt extrusion at the low 1:2 drug to polymer ratio.25 Again, this previous 
study as well as the current study were run under similar conditions, with the only 
difference being the dose. In the previous study using hot-melt extrusion, the mean AUC 
appears significantly larger then that achieved for the EL10055 pH flocculated. However, 
the standard deviation was greater than the mean, leading to inconclusive results.25 The 
large standard deviation may be have been caused by acidity resulting from the 20% 
triethyl citrate plasticizer, also known as citric acid, which may lower the dissolution of 
the enteric polymer in the small intestines.25 The reduced dissolution of the particles may 
result in the high mean plasma concentrations noted after 12 and 24h.25 Since the pH 
flocculated samples have no need for a plasticizing agent, this effect will not occur, 
which will result in more reproducible release kinetics for a pH sensitive polymer 
stabilized formulation. The enteric nature of both EL10055 formulations leads to a 




for the pH flocculated formulation, the increased loading of the drug results in a 
decreased quantity of enteric polymer that must be solubilized to release the drug. As a 
result, the pH flocculated formulation may give a more reproducible result with a 
significantly decreased standard deviation when compared to the hot-melt extruded 
particles. 
5.3.4 Comparison of In Vitro and In Vivo Results 
The order of the values for the AUC2hr for the pH shift experiment in the neutral 
media containing SDS is the same as for the bioavailability results from the animal study 
(Table 5.3). However, the AUC2hr values from the neutral media without micelles are low 
and do not provide insight into the bioavailability. Alternately, the AUC4hr solely in pH 
6.8 media without a pH shift, for both the pH flocculated EL10055 and the HPMC salt 
flocculated formulations would incorrectly predict similar in vivo bioavailabilities. 
Based on the dosage delivered to the rats, high supersaturation in the stomach and 
intestines is expected. Given the dosage to the animal (15 mg/kg body weight) in rats that 
weigh ~ 300 g, a total of ~4.5 mg Itz per rat was delivered. Since a rats stomach can hold 
~2.5 ml51, a total supersaturation in the stomach of 400x the crystalline solubility at low 
pH is expected. This high degree of supersaturation indicates that Itz is likely 
supersaturated, even after substantial dilution while in the gastrointestinal tract. 
For the in vitro supersaturation experiment, the use of micelles turned out to be 
important. In general, the solubilization from the micelles is additive with the solution 




MICWTOT CSS κ+=  (5.3) 
STOT is the total molar mass of the solute, SW is the water solubility, κ is the molar 
solubilization capacity of the surfactant, and CMIC is the molar concentration of the 
micellular surfactant.52 In the case of Itz, an increase in solubility of the 3 orders of 
magnitude is observed by adding micelles to the neutral media (Table 5.2). This dramatic 
change in solubility results in a significant change in dissolution behavior at pH 6.8, 
regardless of the particle composition (Figure 5.6). 
Previously, in vitro dissolution tests have been studied in simulated stomach and 
intestinal fluids containing the appropriate bile salts for the fed and fasted states.53-56 
However, as a screening technique for multiple formulations, an inexpensive alternate 
micellular media is desired.28 Recently this has been demonstrated for formulations of 
cilostazol using sodium lauryl sulfate (SLS) where the percent SLS used in the 
dissolution media was chosen based on matching surface tension measurements with the 
simulated intestinal fluid in a fed state.28 While the contact angles measured in the media 
with NaTC and SDS are not equal (Table 5.1), they are very similar for Itz, the pure 
polymers and the flocculated formulations tested. In addition, the dissolution of a similar 
drug, danazol, was found to be primarily rate limited by the surface reaction for both 
NaTC and SDS micellular medias.39 As a result, SDS can be considered an appropriate 
model surfactant to be used in the screening process. 
The dissolution rate of Itz into the media is not the only important factor 




studies were conducted at supersaturated conditions where nucleation and growth are also 
important to determine the AUC in the neutral media.27 The high 400x supersaturation 
dosed to the stomach of the rat compared to the lower stability of Itz supersaturation 
(~90x in acidic media and ~7x in pH 6.8 media with micelles) indicates that the decay in 
supersaturation may be highly significant. Thus, especially in the pH 6.8 media 
containing micelles, nucleation and growth kinetics of Itz out of solution may decrease 
the bioavailability of Itz. As the primary site for Itz absorption is the proximal small 
intestine25, 29, the decreased soluble Itz concentration in the small intestines, due to 
nucleation and growth out of solution in the pH 6.8 media is expected to be an important 
factor.  
Nucleation and growth of Itz from the neutral media containing micelles is 
dependent on the available surface area for heterogeneous nucleation and the initial dose 
of particles added. Thus the maintenance of supersaturation for high in vivo 
bioavailability will be dose-dependent.32, 33 When comparing Figures 5.5 and 5.6, the 
enteric nature of the EL10055 coating results in similar dissolution and subsequent 
nucleation and growth out of the pH 6.8 media with SDS micelles, regardless of previous 
exposure to acidic media. Since the EL10055 does not dissolve in acidic media, the 
available particle surface area for nucleation and growth out of solution will be similar 
whether or not the particles were previously in an acidic environment. Thus, if only 
comparing enteric Itz formulations, a pH shift dissolution with SDS or a direct 




immediate release HPMC formulation will rapidly supersaturate the acidic media thereby 
changing both the dissolution and nucleation and growth behavior in the pH 6.8 media 
with SDS. Thus to compare immediate to enteric release polymers, in vitro dissolution 
tests should be designed to account for the natural pH shift between the stomach and the 
small intestines as well as the increased solubility due to the bile salt micelles. In 
addition, these tests should also provide high in vitro supersaturation in micelles to allow 
for loss of supersaturation by nucleation and growth to alter the AUC in the neutral 
media. 
5.4 CONCLUSIONS 
Nanoparticle dispersions of poorly water soluble drugs, in this case Itz, stabilized 
with an enteric polymer, Eudragit® L100-55, were flocculated, filtered and dried at room 
temperature to recover high yields (close to 100%) of amorphous particles. The negative 
charge on the enteric polymer coating, which stabilized the nanoparticle dispersions at 
pH 6.8 electrosterically, was neutralized by lowering the pH to 2.5 by adding HCl to 
flocculate the particles. The large flocs were filtered rapidly at room temperature, and at 
this low temperature, Itz did not crystallize. For the nanoparticle dispersions formed by 
antisolvent precipitation, high drug to polymer ratios were achieved. Here only small 
amounts of hydrophilic polymer oriented towards the particle surface are required for 
steric stabilization.5 For the pH flocculation/filtration process, this high drug to polymer 




attraction with the pH change produced diffusion limited flocculation of the nanoparticle 
dispersion under constant volume fraction, and consequently relatively open flocs. Upon 
reionizing the COOH groups on the enteric polymer at netural pH conditions, the open 
floccs redisperse to form  ~1 µm particles with a surface area of ~7.7 m2/g. Similar 
results were reported previously for salt flocculation of HPMC coated Itz upon 
redispersion.27 In contrast, drying of nanoparticle dispersions by common techniques, 
such as spray drying, often produce densely packed flocs, which do not redisperse as 
well. Unlike related previous studies where nanoparticles were flocculated with high 
concentrations of salts23, 27, the flocculation with pH introduces far less salt impurities in 
the final dried powder.  
The dissolution behavior of both the HPMC and EL10055 flocs was tested by 
starting at simulated stomach conditions pH 1.2, followed by a pH shift to small intestine 
conditions, pH 6.8 with micelles to simulate bile salts. The HPMC based flocs generated 
a highest overall higher AUC2hr followed by the EL10055 based flocs and lastly, the 
commercial Itz formulation, Sporanox. The higher AUC2hr for the HPMC salt flocculated 
formulation, when compared to Sporanox, is a manifestation of slower decay in 
supersaturation at pH 6.8. This slower decay was determined for a control study of 
supersaturation versus time for dissolution experiments performed at a single pH, 6.8. 
The in vivo bioavailability was highest for the HPMC salt flocculated formulation, 
second for the EL10055 pH flocculated formulation and lowest for Sporanox. The same 




micelles at neutral pH. This correlation suggests that the high supersaturation for 
amorphous nanoparticles was important, which would not be available for crystalline 
drugs. The in vivo data were not correlated to the in vitro data without micelles, which 
may be expected given the presence of bile salts in the intestines. The 3 order of 
magnitude increase in Itz solubility from the micelles in the pH 6.8 media, and the 
minimization of nucleation and growth of Itz crystals from the supersaturated solution, 
appear to play an important role in achieving high in vitro AUCs that are more closely 
correlated to the in vivo bioavailability. The improved bioavailability of amorphous flocs 
produced by flocculation and filtration relative to the sugar-based solid dispersion, 
Sporanox, provides an alternative for more effective oral delivery of poorly water soluble 
drugs. 
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Chapter 6:  Highly Supersaturated Solutions of Amorphous Drugs 
Approaching Predictions from Configurational Thermodynamic 
Properties 
Dissolution of pure solid itraconazole in metastable amorphous states was used to 
produce high supersaturation in low pH media. For a pre-wet dispersion of particles on 
the order of 1 µm produced by antisolvent precipitation, an experimental supersaturation 
of 63 times the crystalline solubility was achieved. This experimental value approached 
the calculated value of 95 from the configurational free energy, Gconf, which was 
determined from modulated differential scanning calorimetry measurements. A high 
fragility, quantitatively determined by the fragility parameter, γcp, is dependant on the 
configurational heat capacity, Cpconf, favoring a high Gconf and thus high supersaturation. 
However, high fragility also increases the driving force for crystallization of the solid 
during dissolution. The relatively fragile pre-wet dispersions dissolved rapidly and 
produced high supersaturation without crystallizing, in contrast with much lower 
supersaturation values for slowly dissolving particles with low wetted-surface areas 
formed by spray drying or lyophilization of aqueous dispersions. 
6.1 INTRODUCTION 
Over one-third of presently discovered drugs are poorly water-soluble, resulting 
in poor or highly variable bioavailability from oral absorption as well as other forms of 
delivery.1 For biopharmaceutical classification system (BCS) type II drugs, the level of 
dissolved drug may be enhanced by engineering particles with accelerated dissolution 
rates and enhanced thermodynamic driving forces for dissolution.2-5 The dissolution rate 









sat −=                                                   (6.1) 
where D is the diffusivity, A is the specific surface area of the particles , h is the 
diffusional path length in the boundary layer about the particle, Csat is the solubility of the 
drug, and C is the concentration of drug in solution. Formation of a high energy 
metastable state, amorphous or semicrystalline, has the potential to increase the 
solubility, Csat, and absorption of the drug substantially relative to its crystalline form.3 
For example, in some cases, the predicted solubility of the amorphous drug is as much as 
1600-times that of its crystalline form, based on Gibbs free energy calculations.3,6,7 In 
addition to increasing the dissolution rate via Csat, the higher solubility will also enhance 
the permeation rate through biomembranes in the gastrointestinal tract.8,9 However, these 
high energy amorphous polymorphs are kinetically unstable and relax towards the 
equilibrium liquid’s disordered structure of lower energy and entropy and by surpassing 
the free energy barrier may nucleate to the lowest energy crystalline state during storage 
or during the dissolution process upon exposure to aqueous media.10 In addition, different 
techniques will produces non-crystalline states with different free energies.11Therefore, 
the formation, characterization and stabilization of these high energy polymorphs in the 
solid phase is a major goal for improving dissolution in oral delivery.2,12,13 
The configurational thermodynamic properties of amorphous drugs relative to 
their crystalline state, such as enthalpy, entropy, and free energy, can be used to predict 
the solubility ratio of the amorphous to crystalline forms.3,6,7 In studies that have 
compared experimentally measured solubility ratios with the predicted values, the 
amorphous drug was typically made by quench cooling the melt or by solvent 




Table 6.1 Different poorly-water soluble drugs, their theoretical and measured solubility 
ratios, the method the drug particles were produced, and the media the 
solubility was measured in. {1Hancock 2000, 2Mosharraf 1999, 3Elamin 











Celecoxib6 7-216 1.3-1.5 Quench-cooled 35°C, 45°C, 55°C, 
65°C, 75°C, water 
Indomethacin1  38-301 4.4 Quench-cooled 5°C, water 
  25-104 4.5 Quench-cooled 25°C, water 
  16-41 2.8 Quench-cooled 45°C, water 
Glibenclamide2  112-1652 14 Quench-cooled 23°C, pH 7.4 buffer 
(Aq.) 
Griseofulvin2 38-441 5.5 Quench-cooled 23°C, pH 7.4 buffer 
(Aq.) 
Griseofulvin3 38-441 1.4 Quench-cooled 21°C, water 
Hydrochlorthiazide
4  
21-113 1.1 Spray drying 37°C, HCl & PVP 
(Aq.) 










experimental solubility ratios of these particles was typically less than 20% of the 
predicted values (Table 6.1).3,14-17 For example, in the case of ~125 µm indomethacin 
particles, the predicted solubility ratio in water ranged from 25-104, while the 
experimentally measured value was only 4.5.3 The experimental values were reduced by 
crystallization in the solid phase during wetting and dissolution.3,7 Novel strategies are 
needed to address these limitations. 
The objective of the current study was to design pure drug amorphous particles to 
achieve experimental solubilities approaching theoretical values predicted from 
configurational thermodynamic properties. The particle dispersions were made by 
antisolvent precipitation (AP), in which rapid nucleation and slow growth quenches the 
pure drug in the amorphous state as a fine particle dispersion in aqueous media. The 
dissolution behavior of the drug formed by AP was determined in acidic media, where 
the drug is more soluble, for two cases: (1) the original aqueous dispersion, and (2) dried 
particles formed by rapid freezing of the dispersion followed by lyophilization. In the 
first case, the particle dispersion was added dropwise to 0.1N HCl (pH 1.2) media in 
order to minimize buildup of excess undissolved particles and generate sustained levels 
of supersaturation relative to the crystalline solubility for up to 4 hours. In the second 
case, when the dispersions were frozen and lyophilized to produce a powder, the 
supersaturation achieved was much lower given poor wetting of the powder decreasing 
the dissolution rate and the partial crystallization of the powder form. 
A comparison of two solid powder forms, the AP lyophilized powder and a spray 
dried powder will show the effect of different configurational thermodynamic properties 




result for the pure drug dispersion is compared with recent results for similar particles 
made by AP with a polymer stabilizer, hydroxypropylmethylcellulose (HPMC) to aid 
wetting of dried particles, reduce the particle size and reduce crystallization to maximize 
levels of supersaturation.18 However, the configurational properties of the amorphous 
drug could not be measured for the polymer-stabilized samples given the contributions of 
the HPMC to these properties. Depending on the future application of the particles, it can 
be desirable in actual practice to use polymeric stabilizers to aid particle stabilization and 
wetting during dissolution. 
6.2 MATERIALS AND METHODS 
6.2.1 Materials 
B.P. grade itraconazole (ITZ) was purchased from Hawkins, Inc. (Minneapolis, 
MN). HPMC E5 (viscosity of 5 cP at 2% aqueous 25°C solution) grade and spray dried 
intraconazole were gifts from the Dow Chemical Corporation. Stabilized p.a. grade 1,3-
dioxolane was purchased from Acros Organics (Morris Plains, NJ). HPLC grade 
acetonitrile (ACN), A.C.S. grade hydrochloric acid (HCl), and diethanolamine (DEA) 
were used as received from Fisher Chemicals (Fairlawn, NJ). 
6.2.2 Antisolvent Precipitation (AP) of Amorphous Itraconazole 
Deionized water (50 g) was used as the anti-solvent phase into which 15 g of 1,3-
dioxolane containing 3.3% (wt) ITZ was injected to form a fine precipitate. The organic 
phase was separated from the aqueous suspension via vacuum distillation. To recover the 
particles, the dispersion was added dropwise to liquid nitrogen and lyophilized to form a 




24 hours of primary drying at -35 °C followed by 36 hours of secondary drying at 25 °C. 
Dried powders were stored in a 13% relative humidity environment. 
6.2.3 Temperature Modulated Differential Scanning Calorimetry (MDSC) 
Dried powder samples of approximately 5 mg were placed in hermetically sealed 
aluminum pans. Using a 2920 modulated DSC (TA Instruments, New Castle, DE) with a 
refrigerated cooling system, the samples were purged with nitrogen at a flow rate of 150 
mL/min. The amplitude of 1°C, the period 1 min, and the underlying heating rate of 
5°C/min were used. Crystallinity in the original sample (prior to DSC heating) was 
estimated from the total heat flow curve by integrating the area under the ITZ melting 








=                                                     (6.2) 
where xcryst is the percent crystallinity, ∆hmelt is the heat of melting, ∆hcryst is the heat of 
crystallization, and the denominator, ∆hmeltItz, is used to normalize the results by the heat 
of melting for pure crystalline ITZ. This equation is based upon the assumption that the 
heat necessary to melt 1 g of crystalline ITZ and to crystallize 1 g of amorphous ITZ are 
equal. For a purely crystalline sample, a crystallization peak is not present, ∆hcryst = 0, 
and ∆hmelt  = ∆hmeltItz,  giving xcryst = 1. For a completely amorphous material, the 
crystallization peak area will be equal to the melting peak area, such that xcryst = 0. 
6.2.4 Quench Cooling of Molten ITZ Using MDSC  
In order to form a purely amorphous ITZ sample, the bulk drug was placed in a 
hermetically sealed aluminum pan and heated at a rate of 5°C/min using the modulated 




of 40°C/min. Reheating the amorphous ITZ using the MDSC indicated 0% crystallinity 
as no melting peak was observed at ~168°C. 
6.2.5 Calculation of Heat Capacity 
The heat capacity as a function of temperature was determined by de-convoluting 
the total heat flow curve into the non-reversing and heat capacity signals using TA 
Instruments Universal Analysis Software. Heat capacities of amorphous materials were 
measured between 25 and 200 °C. 
6.2.6 Dissolution under Supersaturated Conditions 
Metastable solubility limits were measured in 0.1 N HCl (pH 1.2) media at 
37.2°C. A USP paddle method was adapted to accommodate smaller sample sizes using a 
VanKel VK6010 Dissolution Tester with a Vanderkamp VK650A heater/circulator 
(VanKel, Cary, NC). Dissolution media (50 mL) was preheated in small 100 mL capacity 
dissolution vessels (Varian Inc., Cary, NC). Particle dispersions were added dropwise to 
the dissolution media at a rate of approximately 10 drops/min to reduce the excess 
particle dosing. The drops were no longer added when particles could barely be detected 
by the naked eye, minimizing heterogeneous sites for nucleation of the supersaturated 
solutions. In the case of dried powder dissolution, a sample weight (~17.6 mg drug) 
equivalent to approximately 80-times the crystalline equilibrium solubility (4.4 µg/mL18) 
of ITZ in 0.1 N HCl was added to the media. Sample aliquots (1.5 mL) were taken at 
various time points. The aliquots were filtered immediately using a 0.2 µm syringe filter 
and 0.8 mL of the filtrate was subsequently diluted with 0.8 mL of ACN to double the 
volume. In all cases, the filtrate was completely clear upon visual inspection and dynamic 




size analysis) indicating that not even nanoparticles were coming through the filter. For 
all samples, the drug concentration was quantified by high performance liquid 
chromatography as described below. 
6.2.7 High Performance Liquid Chromatography (HPLC) 
ITZ concentrations were quantified using a Shimadzu LC-600 HPLC (Columbia, 
MD). The mobile phase was ACN:water:DEA 70:30:0.05 and the flow rate was 1 
mL/min. Using a detection wavelength of 263 nm, the ITZ peak eluted at 5.4 min. The 
standard curve linearity was verified from 1 to 500 µg/mL with an r2 value of at least 
0.999. 
6.2.8 Scanning Electron Microscopy (SEM) 
Dried powders were placed on double sided adhesive carbon tape and gold-
palladium sputter coated for 35 sec.  Micrographs were taken using a Hitachi S-4500 
field emission scanning electron microscope with an accelerating voltage of 10-15 kV. 
6.2.9 Dispersion Particle Size Analysis 
Particle size of the dispersion was measured by multiangle laser light scattering 
using the Malvern Mastersizer-S (Malvern Instruments, Ltd., Worcestershire, UK). The 
prewet AP dispersion was diluted in water in the large recirculation cell (~500ml) 
immediately after the particles were prepared giving an obscuration between 10-15 % for 
the measurement. The refractive index of pure water was used as the refractive index of 
the solvent and the refractive index of itraconazole was used as the refractive index of the 




6.2.10 X-ray Diffraction (XRD) 
A sample of powder was pressed onto a portion of a glass slide to form a flat 
sample surface where wide angle X-ray scattering was used to detect the crystallinity of 
the dried drug powder. A Philips PW 1720 X-ray generator (Philips Analytical Inc., 
Natick, MA) giving Cu Kα1 radiation at a wavelength of 1.54054 Ǻ at 40 kW and 20 mA 
was used and the reflected intensity was measured at a 2θ angle between 1 and 30° with a 
step size of 0.05° and a dwell time of 4 s. 
6.3 THEORY 
6.3.1 Prediction of Amorphous Solubility with Excess Thermodynamic Properties 
In the method of Parks,6 the solubility ratio (σamorph/σcryst) of the amorphous and 














ln                                                 (6.3) 
where Gconf is the configurational free energy difference of the two forms, R is the gas 
law constant, and T is the temperature. Here, the Gibbs free energy difference between 
crystalline and amorphous forms is directly proportional to the natural log of the 
thermodynamic activity ratio, which is approximated as the solubility ratio under dilute 
solution conditions.7 The value of Gconf can then be related to other thermal properties by 
confconfconf TSHG −=                                                    (6.4) 
where the configurational enthalpy (Hconf) and entropy (Sconf) may be determined from 























=∆                                                              (6.7) 
Cpconf is defined as the difference in heat capacity between the amorphous and crystalline 
drug forms and represents the temperature dependence of nonvibrational molecular 
mobility.7,19 
The values of Hconf and Sconf may be estimated by choosing  a constant value of 
Cpconf, specifically at the Tg (CpconfTg)3 















CSS mTgpconffconf ln*                                          (6.9) 
This simplified calculation has been shown to give values in good agreement with those 
from equations 2-6 for solubility ratios at temperatures above Tg.3 
6.3.2 Fragility of the Amorphous State from Heat Capacity Measurement 
The concept of fragility for a glass was proposed by Angell.20 The fragility is 
defined as deviation from Arrhenious-type behavior of the relaxation time dependence on 
temperature. This relationship can be modeled by a modified Vogel-Tamman-Fulcher 













Aexpτ                                                  (6.10) 
where A is a constant representing the time scale of vibrational motions, D is the strength 
parameter, and To is the temperature at which molecular mobility is negligible.7 For a 




which is proportional to the relaxation time) increases approximately linearly with 1/T. A 
classic example of a strong glass, molten SiO2, has a nearly constant activation energy 
that indicates a uniform mechanism throughout presumed to be the breaking and 
reforming of Si-O bonds.21 For a glass characterized as fragile (low D values), the log of 
viscosity increases more rapidly with 1/T and the glass can reorganize to a wide variety 
of molecular arrangements and coordination states.7 The fragility of an amorphous 
(glassy) drug provides insight into the physical stability of the solid dosage form in terms 
of its tendency to crystallize upon storage or in the presence of solvent during 
dissolution.7,19,22,23 
An alternative method for determining the fragility of an amorphous material uses 














=γ                                                    (6.11) 
where l, g, and x indicate the equilibrium supercooled liquid, glass, and crystalline states 
with the heat capacities calculated at the Tg.7,19 γCp ranges from 0 to 1, where a value 
approaching 1 indicates a strong glass with a Cp similar to that of the crystal. When 
γCp=0, the glass is considered fragile, as the Cp is nearly equal to that of the equilibrium 
liquid.  This simplified correlation between γcp and the fragility is not the case with 
hydrogen-bonded liquids.19 However, for pharmaceuticals similar to those analyzed, this 





6.4.1 Morphology of pure ITZ particles 
The morphology of three pure drug samples, AP/lyophilized, spray dried, and bulk 
crystalline ITZ, was investigated. According to XRD, crystallinity was detected in all 
three pure ITZ dry powder samples, as evident by peaks at 20.5, 23.5, and 25.5 degrees 
2θ (Figure 6.1). Further analysis by MDSC confirmed the presence of crystallinity 
demonstrated by the melting peaks seen for all three samples. The % crystallinity was 
estimated as the area under the crystallization and melting peaks described in equation 
6.2 (Table 6.2). Removal of water by lyophilization of the frozen AP dispersion resulted 
in 44% crystallinity, and spray drying lead to 24% crystallinity. The amorphous ITZ, 
made by quench cooling the molten drug using the MDSC, contained no crystallinity. 
The bulk ITZ, assumed to be 100% crystalline, was used as a basis for calculating the % 
crystallinity of the other samples. As seen in Figure 6.2, SEM of the dried powders 
revealed that the pure ITZ particles made by AP were polydisperse in size, ranging from 
1-5 µm. This is confirmed by the particle size (5.21 µm) of the prewet dispersion prior to 
lyophilization measured by static light scattering. The spray dried ITZ particles were 200 
nm to 1 µm. The dried particle sizes were not measured by static light scattering since 
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Figure 6.1 X-ray diffraction of antisolvent precipitated (AP) ITZ, spray dried ITZ, and 





Table 6.2 Cpconf, solubility ratios, and γCp of DSC quench-cooled, spray dried, and AP 
lyophilized amorphous ITZ powders compared with Indomethacin 










Tg (°C) 59 63 60 421 
Cpconf at Tg 
(J/gK) 0.3949 0.2425 0.3229 0.41
1 
σamorph / σcryst  
at 37°C  
using eq. 3-7 
125 175 25 ~80 
σamorph / σcryst 
at 37°C   
using Cpconf at Tg 
95 237 147 28 
Experimental 
solubility 63* 10 16 2.8-4.5
1 
% crystallinity 0 28 44 NA 
γCp 0.79 0.66 0.72 0.922 
Tm (°C) 168 168 168 1623 














6.4.2 Predicted Solubility Ratios and γCp of Amorphous ITZ Particles 
The heat capacity versus temperature profile for the three pure ITZ samples is 
shown in Figure 6.3. The resulting Cpconf versus temperature profile is shown in Figure 
6.4. Predicted solubility ratios of pure ITZ particles were calculated by two methods, as 
reported in Table 6.2. The first method used equations 6.3-7, where Cpconf of amorphous 
ITZ particles was integrated over the appropriate temperature range (T to Tm). The 
second calculation method used equations 6.8 and 6.9, where CpconfTg was determined for 
each sample at the Tg of ITZ, assumed to be the mid-point in the rise of the Cpconf near the 
reported Tg of ITZ, ~58.5°C,24 and used as a constant over all temperatures. From the first 
method, the excess enthalpy, entropy, and Gibbs free energy were estimated over a 
temperature range from 25 to 168°C as shown in Figure 6.5. The resulting solubility ratio 
versus temperature profile is shown in Figure 6.6, where the vertical line indicates the 
temperature at which dissolution experiments were conducted, 37°C. The experimentally 
measured solubility ratios reported in Table 6.2 are also shown. The solubility ratio 
decreases with increasing temperature since the difference between T and Tm decreases. 
For the samples formed by DSC quench cooling and spray drying, the calculated 
solubility ratios by the two methods equations 6.3-7 versus equations 6.8 and 6.9, were 
much closer to each other than for the lyophilized AP particles. The values of γCp for each 
sample are given in Table 6.2. The spray dried amorphous ITZ was slightly more fragile, 





Figure 6.3 Heat capacity of a) DSC quench-cooled amorphous, b) spray dried partially 
amorphous, c) antisolvent precipitated (AP) lyophilized partially amorphous 

























Figure 6.4 Configurational heat capacity of DSC quench-cooled, spray dried, and 






Figure 6.5 Configurational a) enthalpy, b) entropy, and c) free energy as a function of 


































Figure 6.6 Predicted solubility ratios as a function of temperature and experimentally 




respectively. For comparison, the solubility ratio and thermal properties for another 
poorly water soluble drug, indomethacin, are also provided in Table 6.2. 
6.4.3 Supersaturated Acidic Aqueous Media from Dissolution of ITZ Particles 
Pure ITZ particles were dissolved for 4 hours to generate supersaturated solutions 
in 0.1 N HCl (Figure 6.7). In the case of spray dried and AP lyophilized pure ITZ 
particles, solubility ratios were only 10 and 16, respectively. These dried particles 
remained on the surface of the dissolution medium and few particles dispersed into the 
medium even after 4 h. Alternatively, the pure ITZ AP particle dispersion was added to 
the dissolution medium immediately after removal of the organic solvent (without 
drying). In this case, the particle dispersion was added dropwise until particles no longer 
instantly dissolved upon contacting the dissolution medium. Visually, the particles in 
dispersion were observed to rapidly disperse into the medium and immediately dissolve. 
The resulting supersaturation level of 63 was nearly 4-times higher than that from 
dissolution of the lyophilized AP particles. 
For comparison, additional dissolution curves for both the pre-wet dispersion of 
particles made by AP with HPMC as a polymer stabilizer in a 1:2 ITZ/HPMC ratio and 
the final lyophilized particles are also shown in Figure 7.18 In this case, when the 
lyophilized dried particles were added to the dissolution media, the degree of 
supersaturation over the crystalline solubility reached a level of 73, even higher then that 
of the pre-wet dispersion of pure ITZ.18 An even higher supersaturation of 91 was 
achieve when the pre-wet dispersion of the 1:2 ITZ/HPMC particles was added in the 






Figure 6.7 Supersaturation in pH 1.2 media from dissolution of 100% ITZ AP before and 






6.5.1 Predicted Solubility of Pure Amorphous Itraconazole 
The Cpconf, plotted in Figure 4 verses T, increases markedly near the Tg reflecting 
a rise in the molecular specific volume at the glass transition temperature.7,19 The larger 
the increase in mobility between the glassy and supercooled states, as reflected in CpconfTg,  
is an indication of the fragility that can be quantitatively described by γCp. In this case, the 
similarity of the jump (0.24-0.39 J/gK) relative to indomethacin (0.46 J/gK) can indicate 
a relatively strong glass.19 Backing this up are the γcp values calculated for the three 
amorphous forms, all of which fall between 0.66-0.79, which also indicate a moderately 
strong glass, since a value of 0.46 for celecoxib was classified as having moderately 
fragile behavior (Table 6.2).7 
Similar basic trends for the Hconf, Sconf, and Gconf are observed for all three 
amorphous forms (Figure 6.5). The enthalpy of crystallization for the glass –(Hconf) 
becomes more favorable with increasing temperature. Likewise, the entropy barrier to 
crystallization, –Sconf, or the loss in the disorder of the glass upon crystallization, 
becomes more unfavorable. As a net result of enthalpy-entropy compensation, the 
configuration free energy or thermodynamic driving force for crystallization decreases as 
the temperature increases. All these basic trends are similar to those found for other 
amorphous pharmaceuticals.22 As a result of the decrease in Gconf, the theoretical 
solubility ratios also decreased as the temperature increased. However, at physiologically 
relevant temperatures, the theoretical solubility ratio was still substantial ranging from 




6.5.2 Experimental Solubility of Pure Amorphous Itraconazole 
The experimental solubility ratio of the pure ITZ AP pre-wet dispersion came 
within 66% of predicted values for the pure DSC quench-cooled amorphous ITZ. This 
agreement surpasses previous studies of pure amorphous drugs using configurational 
thermodynamic properties for solubility prediction (Table 6.1). The majority of the 
particles utilized in these previous studies were quench cooled with liquid nitrogen 
resulting in diameters on the order of 100 μm.3 In comparison, the AP amorphous ITZ 
particles were on the order of 1 μm. The smaller particle size has been shown to increase 
the degree of supersaturation achievable for amorphous particles.18 The increase in 
particle specific surface area by decreasing particle size increases the dissolution rate (see 
equation 1 above), thus reducing the time for the undissolved solid phase to crystallize, 
especially in the presence of a solvent. The lower degree of crystallization during 
dissolution can lead to higher supersaturation levels.18 
A comparison of the pre-wet dispersion of pure AP ITZ to the spray dried and 
lyophilized powder samples probes the effects of the degree of crystallinity and wetting 
on the potential to achieve the theoretical solubility ratio predicted by thermodynamics. 
Supersaturation of both powder samples appeared to level off to a plateau indicating that 
the dissolution attained a meta-stable thermodynamic state (Figure 6.7). It appeared that 
the supersaturated solution did not precipitate to any significant level over four hours, 
consistent with our previous study.18 However, the achieved solubility ratio is far below 
the predicted values (Table 6.1). On first glace, the partial crystallinity of these powders 
causes the resulting achievable experimental solubility for both powders to lie 





In addition, the fact that the non-dissolved powder was hydrophobic and therefore 
floated at the top of the dissolution vessel decreased the surface area exposed to the 
dissolution media, thereby decreasing the initial dissolution rate. As a result, the decrease 
in the initial dissolution rate increases the time allowed for additional crystallization of 
the particles from exposure to the solvent. Therefore, for a hydrophobic drug like ITZ, a 
powder rapidly dispersed in the media at the start of the measurement should increase the 
dissolution rate and therefore the achievable experimental solubility ratio demonstrating 
how wetting can reduce the achievable experimental solubility ratio. 
Comparing the AP lyophilized and spray dried formulations demonstrates how the 
configurational free energy (Gconf) can explain the difference in experimental solubility 
ratio measured. Only considering that the spray dried powder has a slightly smaller 
particle size and lower % crystallinity indicates that the spray dried sample should, from 
previous arguments, have a higher solubility ratio than the AP lyophilized sample.17,18 
When comparing two methods of producing amorphous material, looking at the 
configurational free energy at the temperature of interest for dissolution, 37°C, can 
compare the samples for their different propensity to crystallize. However, since the Gconf 
of the spray dried formulation is the highest, at dissolution conditions, it will have the 
highest overall driving force for crystallization. As a result, the higher driving force for 
crystallization caused the lowest measured solubility ratio of the three amorphous ITZ 
samples analyzed. 
6.5.3 Comparison to Amorphous Indomethacin 
A comparison of the thermodynamic characteristics of ITZ and indomethacin 




Tg(Table 6.1). Using this information and looking at the reduced crystallization 
temperature ((Tc-Tg)/(Tm-Tg)), which represents a normalized measure of how far a 
compound must be heated for spontaneous crystallization to occur22, indicates that 
indomethacin should be more likely to crystallize than itraconazole. In addition, 
indomethacin has been shown to produce a stronger glass according to its γcp value 
(Table 6.2). The higher γcp value indicates that the average degree of mobility is less 
sensitive to temperature at temperatures below the Tg.23 This confirms that indomethacin 
will have a reduced configurational free energy, which will lead to a lower predicted 
solubility ratio. In addition, obtaining the predicted solubility ratio for indomethacin will 
be more difficult and require an even faster initial dissolution rate than ITZ due to the 
faster crystallization predicted from the reduced crystallization temperature. In a previous 
study, the larger particle size used did allow solvent-mediated crystallization to occur and 
was confirmed by analysis of the indomethacin particles left after the solubility study. 
These particles were reanalyzed and showed all three solid forms, the amorphous, γ-
crystals and α-crystals after being exposed to the media for only 2 hours.3 
6.5.4 Surface Stabilization with Polymer for Measurement of Higher Metastable 
Solubility 
As was shown previously, the only pure ITZ sample that exceeded 50% of the 
theoretical supersaturation was an aqueous dispersion that was dissolved immediately in 
acidic media after being prepared. After drying, the experimental supersaturation was 
about 4 fold smaller, as a result of poor wetting and partial crystallization of the particles. 
No stabilizing polymers were used in forming these dispersions as they would have 




To create a practical formulation for drug delivery, it is important to protect the 
dosage form from crystallization during storage in the amorphous state, for example with 
a high Tg polymer.26-28 In addition, the polymer may be utilized to increase the wetability 
of the powder 18,26 and decrease the particle size to accelerate the generation of 
supersaturation.7,18 Recently we reported supersaturation values up to 91 for ITZ AP 
particles stabilized with HPMC, in contrast with a value of only 63 in the current study 
for the pure ITZ AP suspension.18 Considering that polymer-drug interactions do not 
contribute significantly to the increase in solubility ratio18, this supersaturation is in the 
range of that predicted by theory for the pure amorphous ITZ. Comparing the pure ITZ 
lyophilized formulation with the ITZ:HPMC lyophilized sample demonstrates how the 
polymer reduces particle size, increases wettability and reduces crystallization, leading to 
an experimental solubility ratio of 73, almost complete solubility of the 80 times 
supersaturation added in this test.18 
6.6 CONCLUSIONS 
The higher Cpconf values typical for a more fragile glass, when integrated over 
temperature, produce a larger Gconf and thus a larger supersaturation than for a stronger 
glass. However, fragile glasses are more likely to crystallize during storage and 
dissolution. Thus, it is beneficial to design fragile glass particles with high surface areas 
and rapid wetting to produce high supersaturation values during dissolution, before the 
undissolved solid crystallizes. Typically, the high supersaturation values for amorphous 
drugs, predicted from configurational thermodynamic properties, have not been achieved 
experimentally. For example, slowly dissolving large particles, formed by quench cooling 




3,7,14-17 In the present study, a similar limitation in supersaturation was observed for 
particles produced by spray drying and lyophilization of aqueous dispersions resulting 
from poor wetting and slow dissolution. In contrast, supersaturation values reached 63 for 
dissolution of a pre-wet amorphous dispersion of pure ITZ micron-sized particles in 
acidic media, relative to a predicted value of 95. With even smaller particles stabilized 
with HPMC during antisolvent precipitation, supersaturation values reached 90.18  The 
high predicted values of supersaturation from configurational properties are thus 
reasonable goals for amorphous particles designed with sufficient wetting and high 
surface areas for rapid dissolution. 
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Chapter 7:  Conclusions and Recommendations 
This chapter summarizes the key advances made by the research described in this 
dissertation as well as recommendations for future research. In the first section, 
suspensions and dispersions of protein particles formed by multiple techniques suspended 
in either aqueous or non-aqueous solvents are used to demonstrate the potential of 
subcutanenous injections of a highly concentrated protein therapeutic. Understanding 
mechanisms which allow for the formation of the dispersions while simultaneously 
retaining the activity of the protein and a low viscosity formulation provide the basis to 
increase the use of protein therapeutics. The second section improves upon the 
mechanistic understanding of amorphous particle formation and how to enhance poorly-
water soluble drug concentrations in vivo. The final section demonstrates the need to 
understand freezing of a bulk monoclonal antibody solution for long term storage 
stability. 
7.1 CONCLUSIONS 
7.1.1 Dispersions of protein particles for subcutaneous delivery 
In chapter 2, viscosities below 50cp for concentrated suspensions up to 300-400 
mg/ml of ~10 μm milled particles of the model protein, lysozyme, were obtained for 
subcutaneous injection through a 25 to 27-gauge needle. The apparent viscosity of these 
suspensions was correlated with volume fraction at all conditions according to the 
Krieger-Dougherty equation resulting in an intrinsic viscosity close to 2.5, indicating 
weak interparticle interactions. The various factors that produce large increases in 




deviations of the particle shape from a spherical geometry, have almost negligible effects 
for the non-aqueous protein suspensions in this study. 
In chapter 3, a polyclonal antibody, sheep IgG, forms equilibrium nanoclusters 
that simultaneously provide a low dispersion viscosity at high protein concentrations (up 
to 270 mg/ml) and preserve the native folded state of the protein. These equilibrium 
clusters are formed by balancing attraction from specific short-range attractive protein 
interactions and extrinsic crowders against very weak electrostatic charging near the 
isoelectric point of the protein. The hierarchy of strong intracluster interactions used to 
form the nanoclusters and the weak intercluster interactions result in high colloidal 
stability and low viscosities. The highly self-crowded environment within the nanocluster 
prevents unfolding of the protein, as predicted previously.1, 2 
In chapter 4, the formation, dissolution and bioavailability of a nanocluster 
dispersion of a protein monoclonal antibody is characterized to deliver highly 
concentrated monoclonal antibodies via a subcutaneous injection. In this case, highly 
concentrated 190 mg/ml aqueous-based dispersions of a therapeutically relevant 
antibody, 1B73, were formed from particles formed by SWIFT. In vitro stability was 
confirmed within the dispersion by tryptophan fluorescence and upon dilution into a pure 
buffer by ELISA, DLS and SDS-PAGE. Upon in vivo injection, similar distribution and 
elimination half-lives were measured from the dispersion and solution formulations at 
similar doses, while the time to peak serum concentration (tmax) was delayed for the SQ 
injections, consistent with the expected slower diffusion kinetics from this injection site. 




well as an in vitro PTx neutralization test, was unable to detect a loss in 1B7 activity or 
development of anti-1B7 immune responses. 
In conclusion from chapters 3 and 4, nanoclusters formed from the balancing 
attraction from specific short-range attractive protein interactions and depletion attraction 
from extrinsic crowders against very weak electrostatic charging near the isoelectric point 
of the protein are suitable for subcutaneous injections. The hierarchy of strong 
intracluster interactions used to form the nanoclusters and the weak intercluster 
interactions to limit their size result in high colloidal and molecular stability and low 
viscosities. The hierarchical protein nanocluster concept is based on general scaling of 
short-ranged and crowding intermolecular and repulsive intercluster interactions, and 
thus, has been expanded to multiple proteins and multiple crowding agents. As a result, 
this concept may be expected to be applicable to a wide variety of protein and peptides. 
7.1.2 Oral delivery of amorphous itraconazole  
In chapter 5, nanoparticle dispersions of itraconazole stabilized with an enteric 
polymer, Eudragit® L100-55, were flocculated, filtered and dried at room temperature to 
recover high yields (close to 100%) of amorphous particles. Flocculation of the particles 
occurred by neutralizing the negative charge on the polymer by lowering the pH to 2.5. 
By remaining at room temperature throughout processing, crystallization of the 
antisolvent precipitated nanoparticles of itraconaozle was prevented. The in vitro 
dissolution behavior and in vivo bioavailability of the pH-flocculated particles was 
compared to previously analyzed salt flocculated particles4 and the commercially 
available itraconazole formulation, Sporanox. The in vivo bioavailability was highest for 




Sporanox. The same order was followed for the in vitro pH shift experiments to 
determine AUC2hr in the micelles at neutral pH. This correlation suggests that the high 
supersaturation for amorphous nanoparticles was important, which would not be 
available for crystalline drugs. The improved bioavailability of amorphous flocs 
produced by flocculation and filtration relative to the sugar-based solid dispersion, 
Sporanox, provides an alternative for more effective oral delivery of poorly water soluble 
drugs. 
Analysis of the increase in suspersaturation of amorphous particles based on 
configurational thermodynamic properties is found in Chapter 6. The higher 
configuration heat capacity for a more fragile glass, when integrated over temperature, 
produced a larger configuration free energy and thus a larger supersaturation than for a 
stronger glass. However, fragile glasses are more likely to crystallize during storage and 
dissolution. Thus, it is beneficial to design fragile glass particles with high surface areas 
and rapid wetting to produce high supersaturation values during dissolution, before the 
undissolved solid crystallizes. 
7.2 RECOMMENDATIONS AND FUTURE RESEARCH 
7.2.1 Dispersions of protein particles 
Biopharmaceutics and delivery of these types of therapeutic agents is an active 
area of research as few of the conventional delivery techniques, such as oral delivery, for 
small molecule drugs work.5-7 In chapters 2-4, a novel method to formulate protein 
therapeutics into nanoclusters of proteins is demonstrated for use in subcutaneous 
delivery. The research presented in this section is one that has many future applications 




various sizes from small peptides and antibody fragments8 to larger multi-domain 
proteins could further confirm the generality of the approach described in this 
dissertation. In addition, future work can involve tracing the antibody once it is injected 
in vivo to quantitatively show the protein concentration in any part of the body.9 This 
method could help demonstrate the specificity of the protein utilized to the therapeutic 
target and show relative ratio of the active drug compound to the total drug injected, 
demonstrating the percentage of the drug remaining at the injection site. Beyond 
verifying the protein characteristics, further research could be done on different methods 
of delivery for these nanocluster dispersions, including pulmonary10 to find how to best 
utilize the biopharmaceutics. These alternative methods of delivery have shown promise 
in vitro however would need to be expanded to the in vivo studies to demonstrate 
pharmacokinetics and efficacy. 
In addition, while the research in this dissertation does not show an immune 
response, further animal studies to test for immunogenicity would be necessary using 
multiple injections and tracer molecules to track the dissolution of the particles 
throughout the host. Beyond proving the lack of an immune response to the nanoclusters, 
larger nanoclusters can be potentially created to act as a vaccine. Larger nanoparticles 
which do not dissolve as rapidly can elicit an immune response without the need to add 
an adjuvant.11 As a result, this mechanism can be utilized for vaccine production and 
injection, especially for a large molecular weight biologic molecule.  
While much colloidal characterization has been obtained, a better understanding 
of the exact protein volume fraction would require specialized imaging devices. 




various sizes can increase the understanding of the mechanism leading to their formation. 
This knowledge can be used to increase the understanding of several degenerative human 
diseases including Alzheimer’s12 and eye cataracts13. In these cases, protein aggregation 
and the formation of a highly ordered superstructure of the protein lead to changes in a 
humans biological response. Misfolding of the proteins which leads to the formation of 
the fibrils can be analyzed within the context of the formation of misfolded proteins into 
nanoclusters. By purposely misfolding the protein, the aggregation kinetics and influence 
of solution parameters such as pH and tonicity can be independently varied. Increased 
understanding of the factors affecting protein aggregation can result in novel techniques 
utilized to combat diseases such as Alzheimers and eye cateracts that result from an 
increase in protein aggregation. The realm of possibilities is still open and hopefully just 
the stepping stone to future ideas. 
7.2.2 Recommendations to extend oral delivery of amorphous poorly-water soluble 
drugs 
The use of amorphous forms of poorly-water soluble drugs has greatly expanded 
over the last 10 years and significant advances have been made.14 Specific to the 
flocculation project, future work would be to expand the techniques of antisolvent 
precipitation and flocculation by both pH and salt to a greater number of drug molecules 
and polymers. pH sensitive polymers that have shown increased in vivo bioavailability 
without the use of higher surface area powders would be of great interest.15 In addition, 
the variation in surface area and resulting pharmacokinetics from compressing the 
powder into a tablet or enclosing the powder in a capsule would be of great interest. 




relationship between sustained supersaturation of the drug molecule and resulting in vivo 
bioavailability. 
Beyond simple additional experiments, the addition of a mucoadhesives to the 
formulation can be analyzed. Since a mucoadhesive will adhere to the mucosal layer 
lining of the body, including the gastrointestinal tract, the combined drug molecule will 
be slowed through the gastrointestinal tract resulting in an increase in residence time of 
the drug molecule.16, 17 An increase in residence time of the drug molecule to the 
absorption surface of the gastrointenstinal tract, will result in an increase in the 
bioavailability of the drug.18 To date, little research has utilized the combination of a 
mucoadhesive with high surface area drug particles. Such a combination could result in 
the prolonged supersaturation of the drug molecule and higher bioavailability.  
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Appendix A: Supplemental Information for Various Chapters 
A.1 SUPPLEMENTAL INFORMATION FOR CHAPTER 2 
A.1.1 Time to draw 1 ml of solution correlation to the viscosity for 25 and 27 g 
needles  
Each graph in the figure below (Figure A.1.1) contains four points on the line 
containing the known viscosities of perfluorodecalin, benzyl benzoate, ethyl oleate and 
olive oil compared to their measured time to draw 1mL through the respective needle 
gauge. As described in the text, this correlation is backed up by the basic Hagen-

















0 20 40 60 80 100



















0 50 100 150 200 250








Figure A.1 Linear plots of the time to draw 1 mL of a suspension through a) a 25g 5/8” 







A.1.2 Optical Density Absorbance Values 
The actual optical density values measured using the method described in the 
“Optical Density Measurement” section of the Materials and Methods are below in Table 
A.1. The low %RSD indicates the very similar results from the multiple samples and all 
samples are very close to the standard measured. Since the absorbance values are 
relatively high, additional standards and a sample that clearly aggregated were compared 
to the diluted 50 mg/ml concentrations in the safflower oil and benzyl benzoate as well as 
the pure benzyl benzoate solvent using a Falcon UV transparent 96-well plate. 
Absorbance of the standard was lowered to 0.047 ± 0.005 however the sample that 
aggregated had an absorbance of 0.24, above the absorbance of any sample reported in 
table A1.1. The absorbance of the two extracted and diluted 50 mg/ml lysozyme samples 
in the safflower oil and benzyl benzoate and pure benzyl benzoate solvents were 0.052 






Table A.1 Optical Density values for the various formulations diluted to 1 mg/ml using 
standard 96-well plates measured in the μQuant spectrophotometer at 350 
nm. (Benzyl Benzoate is abbreviated BB and Lysozyme is abbreviated LYS) 
  A350 % RSD 
Standard 0.1025 0.56% 
100 mg/mL LYS in 
50/50 Safflower Oil/BB 0.106 1.16% 
200 mg/mL LYS in 
50/50 Safflower Oil/BB 0.1016 0.54% 
300 mg/mL LYS in 
50/50 Safflower Oil/BB 0.1026 0.87% 
50 mg/mL LYS in 
Water with BB 0.1032 1.06% 
50 mg/mL LYS in BB 0.105 0.80% 
100 mg/mL LYS in BB 0.1036 0.53% 
200 mg/mL LYS in BB 0.1016 1.49% 







A.1.3 Calculation for Entry Distance to Poiseuille Flow in Capillary 





where, X is the entry distance, Re is the Reynold’s Number, and d is the diameter of the 
capillary, should give the entry distance to the point where the maximum velocity in the 
tube is within 5% of the theoretical maximum.1 Assuming the viscosity and density of 
pure benzyl benzoate (μ = 8.8 cP and ρ = 1.128 g/cm3), the Reynolds number through the 
syringe (assuming constant flow to get the velocity) is 0.139. Using the equation above 
for a 25 gauge needle (ID = 0.0241 cm), the entry distance required should be 1.12*10-4 
cm, much smaller than the actual length of the needle. 
A.1.4 References 
1. Jacobson, B. O., Rheology and Elastohydrodynamic Lubrication. Elsevier 
Publishing Company: 1991; Vol. 19. 
 
A.2 SUPPLEMENTAL INFORMATION FOR CHAPTER 3 
A.2.1 Supplemental Methods 
A.2.1.1 Protein purification 
The IgG was reconstituted to 20 mg/ml in pH 7.0 phosphate buffer and further 
purified to >99% monomeric protein via FPLC size-exclusion chromatography. 
Injections of ~ 20 mg IgG were separated by a Superdex S200 Column (GE Healthcare, 




purified monomer was concentrated and the buffer was exchanged to a pH 5.5 or pH 7.0 
histidine buffer with 50,000 MWCO Amicon Ultra-15 (Millipore, Billerica, MA) 
centrifugal concentrator to yield a final IgG concentration of 20 mg/ml with a 1:1 (wt) 
ratio of α-α trehalose in histidine buffer, pH 5.5 or 7.0. 
A.2.1.2 Determination of the isoelectric point  
The pI of the IgG was determined by measuring the zeta potential of the protein in 
a 20mM histidine buffer at pHs 5.5, 6.4, and 7.4 on a Brookhaven Instruments ZetaPlus 
dynamic light scattering apparatus at a scattering angle of 90° and temperature of 25 °C. 
The average zeta potential reported is the average of 30 runs with the standard deviation 
reported as the error bars (Figure 3A). In addition, the pI of the IgG was confirmed by 
isoelectric focusing (IEF) gel electrophoresis. In a precast IEF gel (Bio-Rad product 161-
1111) with a pH range of 3-10, 5-10 μg of the purified IgG diluted in a loading buffer of 
50% glycerol with pure DI water was separated based on pI for 1 h. at 100V followed by 
2 h. at 250V using a cathode buffer containing 20mM lysine and 20mM arginine and an 
anode buffer containing 7mM% phosphoric acid. The IEF gel was stained with silver 
staining and the image captured prior to drying. 
A.2.1.3 Images of the particles before and after forming dispersions 
Samples of the dry powders after lyophilization for scanning electron microscopy 
(SEM) analysis were placed on adhesive carbon tape to fix the sample to the SEM stub. 
A drop of the final dispersion diluted to 40 mg/ml was placed on an SEM stub or lacey-
carbon transmission electron microscope (TEM) grid, blotted to remove the excess liquid 
and rapidly frozen by immersing it in liquid nitrogen. The stages were then dried using a 




12 hour ramp to +25oC and then 2 hours of secondary drying at 25oC. Each sample for 
SEM was platinum-palladium sputter coated using a Cressington 208 bench top sputter 
coater to a thickness of 10nm. Micrographs were taken using a Zeiss Supra 40 VP 
scanning electron microscope with an accelerating voltage of 5 kV. Z-contrast scanning 
transmission electron microscopy (STEM), using a high-angle annular dark field 
(HAADF) detector visualized the particles at 200 kV on a FEI Tecnai TF20 transmission 
electron microscope. 
A.2.1.4 Determination of irreversible denaturation and aggregation of IgG 
The percent of monomeric protein present in IgG samples was analyzed by 
dynamic light scattering as described above. Samples of the initial purified IgG powder, 
dissolved lyophilized particles and the dissolved particles from the dispersions were 
adjusted to ~1 mg/ml in phosphate buffer. The amount of active antibody in a sample was 
quantified using a polyclonal capture enzyme-linked immunosorbent assay (ELISA). For 
the ELISA test, high-binding ELISA plates (Costar No. 3590) were coated with 12.5 
µg/ml rabbit anti-sheep IgG (Southern Biotech No. 6150-01) and incubated at 4ºC 
overnight, then blocked with PBS-1% milk for 1 hr at room temperature. After triplicate 
washing with PBS-0.05% Tween20, sheep IgG samples were serially diluted from 100 
µg/ml using a √10 dilution scheme with PBS-milk as the diluent. After room temperature 
equilibration for 1 h and an additional wash step, peroxidase-conjugated rabbit anti-sheep 
IgG (MP Biomedical No. 55814) at 0.125 µl/ml was added. After additional equilibration 
and washing steps, substrate (tetramethylbenzidine dihydrochloride (Pierce, Rockford, 
IL)) was added and color allowed to develop for 30 seconds before quenching the 




instrument. EC50 (50% effective concentration) values were calculated from the linear 
range of the dose-response curve as the sheep antibody concentration corresponding to 
50% of the maximum absorbance. For comparison of IgG samples, relative EC50 values 
were calculated as the ratio of the treated to reference EC50. Each sample was analyzed in 
triplicate with the mean and standard deviation reported. Denatured IgG, heated to 70°C 
for 1 hr, was used as a non-binding negative control. 
A.2.1.5Determination of the dn/dc for a protein nanocluster dispersion 
The refractive index of the solvent was measured using a refractometer and 
confirmed by using optical coherence tomography. The refractive index of the solvent 














ϕ (eq. A.2.1) 
The measured value from the refractometer and by OCT differed by less than 1% due to 
the difference between measuring the phase refractive index (measured by a 
refractometer) and the group refractive index (measured by OCT).  Figure A1.2.7 shows 
the slope, indicating the dn/dc, for a BSA dispersion in 25% PEG300 and 20% Ethanol. 
Due to the amount of protein needed for this test, it was not replicated for the IgG. Since 
the absolute values corresponded with the predicted values by the Lorenz-Lorenz rule, 
and the dn/dc was the same as that for a BSA solution (0.183cm3/g 1), the calculated 
values for the solvent refractive index and reported literature values for the dn/dc of an 
IgG solution (0.185cm3/g 2, 3) were used in the calculations. 






Figure A.2.1 A) IEF analysis of sheep IgG solution, from left to right lanes are IEF 
markers (Bio-Rad), 2μg sheep IgG and 1 μg sheep IgG. B) Zeta potential 









Figure A.2.2 SEMs of dried powders frozen at 20 mg/ml IgG with a 1:1 ratio of trehalose 







Figure A.2.3 A) Concentrated DLS on a 10% solids weight polystyrene standard of 
298nm spheres. B) Correlation function for sample in A, raw data 






Figure A.2.4 Unfolding of IgG measured as maximum emission wavelength (λmax) at 






Figure A.2.5 Calibration curve for small conical vials from various solution standards  DI 
water (ηo = 1 cP), PEG200 (ηo = 50 cP), PEG300 (ηo = 70 cP), PEG400 (ηo 
= 90 cP), and benzyl benzoate (ηo = 8.8 cP). The time for the liquid level to 
be drawn from 0.4” to 0.1” in small conical vial was measured from a video 







Figure A.2.6 Static light scattering at various angles to determine porosity for A) 
Nanoclusters formed with 50 mg/ml IgG at 250 mg/ml trehalose B) 






Figure A.2.7 Group refractive index versus concentration of protein particles for a BSA 
dispersion with 25% PEG300 and 20% Ethanol. The slope of the line 
indicates the measured dn/dc used in the calculation of the B2 by SLS. The 






Table A.2.1 Material balance from actual measured powder weight and added dispersion volume and resulting volume fraction of protein and other 
crowders. To approximate the volume fraction mass density of the IgG (1.34 g/ml) was estimated from the partial molar volume of a 
native IgG4 and density of trehalose (1.64 g/ml) was estimated from the partial molar volume of trehalose5. Trehalose is included in all 






































214 mg/ml 60.2 0.100 50 mM phosphate 
buffer 
23 18 100 0 0 141 
275 mg/ml 79.3 0.090 50mM phosphate 
buffer 
30 24 90 0 0 144 
157 mg/ml – 
0.16 φP 
40.4 0.100 20%(v/v) PEG300 
in 50mM 
phosphate buffer 
15 12 80 20 0 127 
162 mg/ml – 
0.24 φP 
41.4 0.100 30%(v/v) PEG300 
in 50mM 
phosphate buffer  
15 13 70 30 0 128 
157 mg/ml – 
0.08 φP/0.16 φN 




15 12 70 10 20 127 
204 mg/ml – 
0.08 φP/0.16 φN 




21 17 70 10 20 138 
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214  - Run 1 103 9 
Run 2 68 21 
275  - Run 1 92 8 
Run 2 78 8 
Run 3 94 9 
157  0.16 φP Run 1 95 9 
Run 2 93 9 
Run 3 140 23 
162  0.24 φP Run 1 118 10 
Run 2 103 16 
157  0.08 φP  
0.16 φN 
Run 1 280 8 
Run 2 259 12 
Run 3 256 8 
Run 4 220 5 




Table A.2.3 Comparison of % monomer of 157 mg/ml IgG dispersions in pH 6.4 50mM 
phosphate buffer with 10% PEG300 and 20% N-methyl-2-pyrrolidone 
(NMP) by volume to unprocessed purified material 





157 mg/ml - 0.08 φ PEG, 0.16 φ 
NMP 




Table A.2.4 Summary of means and standard deviations for individual DLS runs for 













50 1 6.3 0.6 9 
 2 6.0 1.0 16 
 3 15.2 7.9 52 
100 1 10.9 1.0 9 
 2 9.4 0.7 8 
 3 6.1 1.5 24 
 4 11.3 1.6 15 
150 1 5.3 1.5 28 
 2 5.8 0.6 11 
 3 7.0 0.3 4 
 4 7.9 0.4 5 
 5 9.1 0.5 5 
200 1 26.5 5.8 22 
 2 27.6 6.9 25 
 3 27.3 4.1 15 
 4 19.5 7.9 41 
 5 35.7 8.6 24 
225 1 51.9 2.7 5 
 2 38.7 2.8 7 
 3 39.9 4.1 10 
240 1 67.0 4.8 7 
 2 52.1 3.0 6 
 3 50.7 2.6 5 
250 1 83.5 6.7 8 
 2 88.3 7.1 8 
 3 104.6 6.8 7 
300 1 84.4 7.8 9 
 2 129.4 6.3 5 




Table A.2.5 Values of the protein B2/B2HS and resulting ε/kT, including van der Waals 
interactions as well as short-range attraction, values for proteins of various 
molecular weights at or near the isoelectric point 









Ribonuclease A1  -0.9 13.7 1.5 -0.52 1.26 
Lysozyme2 -3.21 14.7 1.9 -1.00 1.70 
Ovalbumin3 -0.8 43.5 3.0 -0.56 1.91 
mAb4  -0.5 125.0 5.5 -0.62 1.86 
mAb3  -0.9 144.0 5.5 -1.11 2.76 
1. Tessier, PM et al. Protein: Structure, Function and Genetics 50(2), 303-311 
(2003) 
2. Tessier, PM et al. Biophy J 82 1620-1631 (2002) 
3. H Bajaj et al. Pharm Res 23(6) 1382-1394 (2006) 
4. Salinas et al. Pharm Sci 99(1) 82-93 (2010) 
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A.2.3 Supplemental Results and Discussion 
A.2.3.1 Determination of the porosity of the nanocluster dispersions  
A plot of the log of intensity versus the log of magnitude of the scattering vector 
gives a straight line with the exponent being the fractal dimension of the scattering 
particle.6 In this case, the fractal dimension was measured for two separate systems as 2.4 
and 2.6 for the concentrated sugar crowder and NMP/PEG crowders respectively (Figure 
A1.2.6). 
The fractal dimension of a floc, Df, characterizes the floc structure by relating the 
volume fraction of solid in the floc, φk to the primary particle diameter, d, and the floc 












φ    Eq. A1.2.2 
Assuming primary particles of 50nm as appear to be present under SEM, a φk for the 
NMP/PEG crowder system is estimated to be 0.53. This is consistent with the appearance 
from the SEM and STEM images in Figure 4. As the smallest primary particles would be 
the individual 11nm proteins, the calculated volume fraction of IgG within the 
nanocluster is 0.29. The sample value of 0.29 is estimated for the pure sugar crowder 
system with 85nm diameter flocs with 11nm diameter particles and a Df of 2.4. 
A.2.3.2 Formation of Aqueous Dispersions – additional comments 
Dissolution of the protein monomer in the aqueous phase is prevented with the 
addition of precipitants  typical for protein purification.8-17 Like PEG300 described in the 
text, by adding various precipitants at different ratios, it is possible to control the total 
attraction thus removes protein dependence from specific attraction. As a result since 
various proteins will have different extent of attractions, the formation of an aqueous 
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dispersion can be generalized for different proteins. PEG was chosen for these studies 
because of various polymers, PEG found to best ppt for proteins.18 For PEG, solubility 
can vary order of magnitude with > 10% increase in low MW PEG for many different 
types of molecules including monoclonal antibodies.8-14, 19 The mechanism to decrease 
the solubility of a protein by the addition of PEG is due to depletion-attraction.12-14, 20 
Solubility has been characterized by models based in statistical mechanics13 and from a 
preferential binding parameter model 14 
Ethanol precipitation is common for purification of proteins, however other 
water-soluble organic molecules can be used as well. The primary mechanism for the 
decrease of protein solubility due to an organics is the decrease dielectric constant.21 
A.2.3.3 Stability of the protein molecules in the lyophilized powder 
Lyophilized solid state protein powders are known to be stable after freezing and 
lyophilization.22 During freezing however, several studies have shown that proteins can 
have both reversible and non-reversible changes to secondary and tertiary structure in the 
frozen23 and dried22, 24 state.  The addition of a stabilizing carbohydrate such as trehalose 
22, 25, 26 or stabilizing amino acid such as histidine27 prevent the secondary structure 
changes of the protein, thus prevent an aggregation prone state from being present upon 
rehydration of the dried powder.  
A.2.4 References 
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A.3 SUPPLEMENTAL INFORMATION FOR CHAPTER 4 
 
 
Figure A.3.1 Iso-electric focusing (IEF) gel to determine the isoelectric point (pI) of mAb 
1B7. Lane  1: 5 mg/ml 1B7; 2: 2 mg/ml 1B7; 3: 1 mg/ml 1B7, 4: IEF 
standards, ranging from 4.45 to 9.6 (BioRad). 
7.0 
7.5 
1 4   
 
1 2 3 4 
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Figure A.3.2 Calibration data for the anti-pertussis toxin activity ELISA. A) Sample 
spiked serum pertussis ELISA assay analyzed using parallel line fit to a 100 
μg/ml spiked serum standard to determine EC50 in SpectraMax Pro software. 
B) Measure of the correlation between standards: natural log of the sample 
EC50 divided by the EC50 of the 100 μg/ml spiked serum standard versus the 
spiked serum concentration. For each sample, the natural log of the 







Figure A.3.3 Calibration data for the streptavidin total protein ELISA. A) Sample 
spiked serum streptavidin ELISA assay analyzed using parallel line fit to a 
100 μg/ml spiked serum standard to determine the sample EC50. B) Measure 
of the correlation between samples and standards: natural log of the EC50 





Figure A.3.4 DLS curves for two separate samples of mAb1B7 diluted in pH 7.2 50mM 
phosphate buffer. The concentration of solubilized trehalose in these 
samples will be equal to that of the protein as no addition trehalose was 




Figure A.3.5 Non-reducing western blot to detect biotinylated 1B7 in the terminal 
serum samples.  4 µg of 1B7 from serum samples were combined with non-
reducing SDS-PAGE loading buffer, boiled and applied to a 4-20% SDS-
PAGE gel. After separation and transfer to a PVDF membrane, the blot was 
blocked with 5% BSA and probed with SA-HRP to detect intact and 
fragments of mAb 1B7.  Lanes contain the following mouse samples: 1: IV 
solution, mouse #2; 2: IV solution #5; 3: SQ solution #7; 4: SQ solution 
#10; 5: SQ low dose dispersion #13; 6: SQ low dose dispersion #17; 7: SQ 
high dose dispersion #20; 8: SQ high dose dispersion #24; 9: SQ dispersion 
buffer only #18.  The amount of serum used for lane 9 corresponded to 





Figure A.3.6 Mouse anti-mAb 1B7 responses. Serum from the terminal time point was 
used to measure IgG1 antibody concentrations recognizing the mAb 1B7 
using an ELISA. A positive response was defined as a signal greater than 
twice the background. Only the positive control obtained such a response. 
 265 
 
Table A.3.1 PK analysis using total protein ELISA to measure 1B7 concentrations 
Type of injection t1/2,β (hours)  
IV solution injection 195.4 ± 15.3 
SQ solution injection 181.3 ± 10.5 
SQ dispersion 
injection  
191.6 ± 8.7 
SQ dispersion 
injection  
191.4 ± 8.5 
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Appendix B: SWIFT freezing 
B.1 METHODS 
B.1.1 Formation of SWIFT powder 
For SWIFT freezing, the direction of the rotation was changed every ~3 
revolutions resulting in a spiral towards the center of the vial. For the vials with only 1 ml 
of solution, the change in direction did not affect the rotation paper, however for larger 
volumes, the rotation patter resulted in a spiral inverting in direction every 3 rotations. 
This did not appear to affect the resulting powder or dispersion from the powder in any 
measurement and is thus, not distinguished in the manuscript. All samples, whether 
SWIFT or slow frozen were then lyophilized for 12 hours at -40°C at 100mTorr, 
followed by a 6 hour ramp to 25°C at 50 mTorr, and maintained for secondary drying at 
25°C at 50 mTorr for at least an additional 6 hours. 1 mg of powder was then weighed 
out and reconstituted at 1 mg/ml in phosphate buffer for stability analysis by size 
exclusion chromatography, SDS-PAGE gel, and enzyme-linked immunosorbant assay 
(ELISA) as described in the main text. The temperature of the freezing liquid near the 
center of the vial was measured by placing a type T 1/20” thermocouple (Omega), 
through a small hole placed in the center of the cap of the vial. The temperature was 
monitored and recorded using a NI 9211 board and NI SignalExpress software (National 
Instruments). The thickness for a single layer of the freezing protein solution was 
measured by freezing a single layer within the same 8 ml cylindrical vial, removing the 
unfrozen liquid and measuring the difference in weight from the empty vial and the vial 
with 1 layer frozen. The thickness of the annular area was then calculated based on the 
known height and inner radius of the cylindrical vial. 
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B.1.2 Determination of film thickness (t) for SWIFT freezing 
Weight of 1 annulus layer frozen on the inside of the vial was calculated from the 
difference between the weight of the vial with 1 layer frozen on the inside and the weight 
of the dried vial (Δw) 
 Eq. B.1 
Average weight from 4 trials: 0.5666 ± 0.0835 g 
Inner radius of cylindrical vial (R): 1.0 cm 
Height of inside of cylindrical vial (H) : 4.8 cm 
B.1.3 Determination of freezing time by SWIFT freezing 
As shown in Figure B.1, the plateau temperature at the freezing point of water, 
0°C, accounts for the time from the first ice nuclei to form in the solution until the entire 
contents of the vial are frozen. For 2 ml of liquid solution, the freezing time was ~15 
seconds whereas for 4ml of liquid solution, the freezing time increased to ~30 seconds. 





Figure B.1. Freezing temperature profiles of lysozyme solutions (10 mg/ml) inside vials. 
The solutions were frozen in different film thicknesses 2.6 mm and 0.6 mm 
corresponding to the total liquid volume of 4 ml and 2.6 ml in vials with 15 
mm diameter.  The coolant temperature was 80 K and the vial rotation speed 
was 30 rpm. 
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B.2 SWIFT FREEZING RESULTS AND DISCUSSION 
The rotation of the vial creates thin frozen solution films at the bottom of the vial 
in contact with liquid nitrogen. During rotation these films will freeze in a spiral towards 
the center of the vial until the full volume is frozen. The freezing time for a volume of 2 
and 4 ml in an 8 ml vial was estimated to be a total of 20 and 40 seconds respectively, in 
the same 8 ml glass vial. Thus, by this process, each ml of sample will take ~10 seconds 
to fully freeze. In comparison, upon scaling from the time to freeze 1 drop by TFF, the 
time to freeze 1 ml by TFF will be 25 seconds1, indicating both processes freeze protein 
solutions at similar rates, ~102 K/s. The submicron particle size and high stability of the 
reconstituted protein for SWIFT may be expected, as the film thickness, on the order of 
200μm for each film (one revolution) and cooling rate on the order of 102 K/s, are 
comparable to those in the similar processes, TFF and SFL, which have been analyzed in 
great detail.1, 2 A freezing film thickness of ~200nm per revolution, calculated from the 
volume of a single freezing layer inside the vial, is comparable to the 210nm thickness 
for a similar process reported previously, thin film freezing (TFF).1 In TFF, a small 
droplet (~3.6mm diameter) spreads and freezes on a cryogenically cooled surface and 
takes ~1s to freeze. To compare freezing times, the volume of the solution frozen must be 
equal, thus for a scale-up TFF disk at the same freezing rate, it would take ~5.1 s to 
freezing 1ml. For SWIFT, a comparable freezing time of ~7.5 seconds/ml of protein 
solution was measured from the total freezing time of various freezing volumes using 
temperature measurements from a thermocouple at the center of the vial (Figure B.1). As 
a result, similar morphology between TFF and SWIFT lyophilized particles frozen at the 




Figure B.2. Morphology of SWIFT powder after lyophilization by SEM
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The greater number of ice nuclei leads to the formation of many thin liquid 
channels between the frozen water domains, containing the remaining unfrozen solution. 
The rapid vitrification of the thin liquid channels then decreases the number of collisions 
between protein and sugar particles thus inhibiting growth by coagulation of particles 
relative to lyophilization which contains much larger liquid channels.1 In addition, as the 
concentrations of the protein and sugar are increased in the unfrozen liquid, the rapid 
increase in viscosity will further reduce the mobility of the growing particle nuclei. The 
formation of sub-micron particles has also been demonstrated with the extremely rapid 
(106 K/s) freezing process spray freeze drying(SFD).3 By separately studying the effects 
of the spraying, freezing, and drying steps in SFD, the large gas-liquid interface in the 
spraying step was found to be the primary cause of protein aggregation for recombinant 
human interferon-γ and lysoyzme.4, 5 The large area/volume of the gas-liquid interface of 
~6000 cm-1  in SFD for 10 µm sprayed droplets can lead to protein adsorption, 
denaturation and aggregation.1, 4, 6-8 
However, in addition to the gas-liquid interface, exposure to the ice-water 
interface has been shown to destabilize proteins at slow cooling rates (~100 C/min).9 The 
protein denaturation in that case was attributed to an increase in the number of ice nuclei 
increasing the ice-water interface area prior to complete freezing. However, the protein 
must have time to adsorb to the interface and subsequently partially unfold to form 
aggregates.4, 6, 7 As reported previously for rhIFN-γ using spray-lyophilization4, the time 
scale for freezing was faster than the time scale for diffusion, thus preventing unfolding 
of the protein on the ice-water interface. For a diffusion coefficient on the order of 10-7 
cm2/s, based on a 5 nm protein molecule in a solvent with a viscosity of 2 cp, the 
diffusion length, 2*(Dt)1/2, is on the order of 1 µm in 0.1s. Since each film layer in 
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SWIFT is on the order of 0.2 mm, the protein will only diffuse a fraction of the film 
thickness. Furthermore, the diffusion coefficient will decrease markedly as the viscosity 
increases upon freeze concentration and vitrification of the unfrozen liquid. Finally, the 
time available for adsorption of protein molecules to an ice interface will be less than 0.1 
s for each film layer formed upon a revolution of the vial. In the case for SWIFT 
freezing, the ice-water interface area was approximated as the specific surface area (SSA) 
of the final dried powder.1, 4 Given that the SEM in Figure B.2, resemble those from 
TFF1, it is reasonable to assume that our ice-water interface has an area on the order of 10 
m2/g. With this level of ice-water interfacial area, the freezing was sufficiently rapid that 
protein diffusion and adsorption at this interface did not lead to denaturation and 
aggregation, as seen by SEC, consistent with the earlier results for TFF1. Once the protein 
solution in fully frozen below the Tg’, protein stability is anticipated to be retained due to 
the decreased mobility preventing further aggregation.10 
High retention of antibody tertiary structure and activity for the SWIFT powder and for 
the protein diluted and dissolved from the aqueous dispersion, is shown in Table B.1, from a 
series of biophysical and biochemical assays including SEC HPLC, SDS-PAGE and ELISA. As 
the polyclonal sheep IgG used in these initial studies does not bind a single target, a polyclonal 
rabbit anti-sheep IgG capture ELISA was used to monitor loss of conformational epitopes due to 
denaturation.11, 12 The relative EC50 (relative to the purified never frozen IgG material) of slightly 
less than 1.0, indicates an insignificant change in activity as these values are significantly smaller 
than the >70 value measured for the heat-treated denatured IgG (30 min. at 70oC).  
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Table B.1. Relative turbidity, % monomer and relative EC50 of SWIFT frozen powders at 
different pHs at an original IgG concentration of 20 mg/ml with a 1:1 (wt) 




























5.5 dry powder 1.13 97.7 ± 0.0 97.8 ± 0.0 0.9 ± 0.3 
7.4 dry powder 1.08 98.1 ± 0.1 98.4 ± 0.1 0.8 ± 0.2 
*Relative turbidity is defined as the ratio of the absorbance at 350nm of the reconstituted 
SWIFT frozen powder to the purified solution prior to processing.  
**Relative EC50 was calculated as the difference between the EC50 of the reconstituted 




According to HPLC-SEC measurements, the change in % monomer from the original purified 
IgG solution was negligible (Table B.1). The lack of irreversible aggregates is further confirmed 
by a single band on the SDS-PAGE gel (Figure B.3) 
One practical advantage of SWIFT freezing is the ability to freeze directly in the 
final dosage vial when compared to SFL or TFF. This prevents the need for costly, solid 
transfer steps while maintaining aseptic conditions. In this case, if a dosage of 80 mg of 
the protein is required, at a concentration of 20 mg/ml, the 8 ml vial used in the study can 
serve both as the freezing vial and then the reconstitution vial following lyophilization. 
However, since the cooling rate in the case of SWIFT freezing is governed by the liquid 
cryogen used and the thickness of the glass on the vial, as well as the heat transfer 
coefficients of the materials used, the vial can easily be scaled-up or scaled-down to the 
proper size for the dosage necessary. In addition, by removing the transfer step to the 
final vial, 100% of the protein added to the vial can be recovered after lyophilization and 




Figure B.3 Size-exclusion chromatograph of purified IgG SWIFT frozen at pH 5.5, 
lyophilized powder reconstituted and the subsequent 200 mg/ml aqueous 
suspension diluted in pH 7.0 phosphate buffer as measured on FPLC. Insert 
shows the SDS-PAGE gel  of the IgG reconstituted as received (lane 2) 
followed by the purified reconstituted lyophilized powder (lane 3) and 
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